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PREAMBLE
It is important that the medical profession play a significant
role in critically evaluating the use of diagnostic procedures
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and therapies in the management or prevention of disease
states. Rigorous and expert analysis of the available data
documenting relative benefits and risks of those procedures
and therapies can produce helpful guidelines that improve
the effectiveness of care, optimize patient outcomes, and
favorably affect the overall cost of care by focusing resources
on the most effective strategies.
The American College of Cardiology (ACC) and the
American Heart Association (AHA) have jointly engaged
in the production of such guidelines in the area of cardio-
vascular disease since 1980. This effort is directed by the
ACC/AHA Task Force on Practice Guidelines, whose
charge is to develop and revise practice guidelines for
important cardiovascular diseases and procedures. Experts
in the subject under consideration are selected from both
organizations to examine subject-specific data and write
guidelines. The process includes additional representatives
from other medical practitioner and specialty groups where
appropriate. Writing groups are specifically charged to
perform a formal literature review, weigh the strength of
evidence for or against a particular treatment or procedure,
and include estimates of expected health outcomes when
data exist. Patient-specific modifiers, comorbidities, and
issues of patient preference that might influence the choice
of particular tests or therapies are considered, as well as
frequency of follow-up and cost-effectiveness.
The ACC/AHA Task Force on Practice Guidelines
makes every effort to avoid any actual or potential conflicts
of interest that might arise as a result of an outside
relationship or personal interest of a member of the writing
panel. Specifically, all members of the writing panel are
asked to provide disclosure statements of all such rela-
tionships that might be perceived as real or potential
conflicts of interest. These statements are reviewed by the
parent task force, reported orally to all members of the
writing panel at the first meeting, and updated yearly and
as changes occur.
These practice guidelines are intended to assist physicians
in clinical decision making by describing a range of generally
acceptable approaches for the diagnosis, management, or
prevention of specific diseases or conditions. These guide-
lines attempt to define practices that meet the needs of most
patients in most circumstances. The ultimate judgment
regarding care of a particular patient must be made by the
physician and patient in light of all of the circumstances
presented by that patient.
The executive summary and recommendations are pub-
lished in the September 28, 1999, issue of Circulation. The
full text is published in the October 1999 issue of the Journal
of the American College of Cardiology. Reprints of the full text
and the executive summary are available from both organi-
zations.
Raymond J. Gibbons, MD, FACC
Chair, ACC/AHA Task Force on Practice Guidelines
I. INTRODUCTION
The ACC/AHA Task Force on Practice Guidelines was
formed to make recommendations regarding the appropri-
ate use of diagnostic tests and therapies for patients with
known or suspected cardiovascular disease. Coronary artery
bypass graft (CABG) surgery is among the most common
operations performed in the world and accounts for more
resources expended in cardiovascular medicine than any
other single procedure. Since the initial guidelines for
CABG surgery were published in 1991, there has been
considerable evolution in the surgical approach to coronary
disease while at the same time there have been significant
advances in preventive, medical, and percutaneous catheter
approaches to therapy.
The current Committee was charged with revising the
guidelines published in 1991 (1). The Committee reviewed
pertinent publications, including abstracts, through a com-
puterized search of the English literature since 1989 and
performed a manual search of final articles. Special attention
was devoted to identification of randomized trials published
since the original document. A complete listing of all
publications covering coronary bypass surgery in the past 10
years is beyond the scope of this document. However,
evidence tables were developed and extensively reviewed by
an expert in meta-analysis. Inaccuracies or inconsistencies
present in the original publication were identified and
corrected when possible. Recommendations provided in this
document are based primarily on published data. Because
recent randomized trials are unavailable in many facets of
coronary artery disease (CAD) treatment, observational
studies and, in some areas, expert opinion form the basis for
recommendations that are offered. In each section of the
Indications (Section IX), the relative levels of evidence
favoring the Class I, II, and III indications were noted.
The ACC/AHA classifications I, II, and III are used to
summarize indications as follows:
Class I: Conditions for which there is evidence
and/or general agreement that a given pro-
cedure or treatment is useful and effective.
Class II: Conditions for which there is conflicting
evidence and/or a divergence of opinion
about the usefulness/or efficacy of a proce-
dure.
Class IIa: Weight of evidence/opinion is in favor of
usefulness/efficacy.
Class IIb: Usefulness/efficacy is less well established
by evidence/opinion.
Class III: Conditions for which there is evidence
and/or general agreement that the proce-
dure/treatment is not useful/effective and
in some cases may be harmful.
The Committee consists of acknowledged experts in
cardiac surgery, interventional cardiology, general cardiol-
ogy, internal medicine, and family practice. The Committee
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included representatives from the American Academy of
Family Physicians (AAFP) and the American College of
Physicians (ACP), as well as the Society for Thoracic
Surgery (STS). Both academic and private practice sectors
were represented. The document was reviewed by 3 outside
observers nominated by the ACC and 3 outside reviewers
nominated by the AHA, as well as outside reviewers
nominated by AAFP, ACP, STS, the American College of
Surgery, and the Society of Cardiovascular Anesthesiolo-
gists. This document will be reviewed annually after publi-
cation by the Task Force to determine whether a revision is
necessary. The guidelines will be considered current unless
the Task Force revises them or withdraws them from
distribution.
These guidelines overlap several previously published
ACC/AHA guidelines, including those for the manage-
ment of acute myocardial infarction (MI), for the manage-
ment of stable angina, for percutaneous transluminal coro-
nary angioplasty (PTCA), and for exercise testing. For each
of these guidelines, an analysis of overlap or contradiction
has been explored by the Committee with attempts to create
consensus in each instance. Finally, it is acknowledged that
no guideline can take into account all of the various
parameters that must be part of the individual decision to
recommend CABG for a single patient. However, this
entire report is intended to provide a framework that
doctors can use in combination with other types of knowl-
edge and patient preferences to make rational decisions
about treatment.
II. GENERAL CONSIDERATIONS AND BACKGROUND
Surgical revascularization for atherosclerotic heart disease is
one of the great success stories in medicine. Relief of angina
after revascularization, improvement in exercise tolerance,
and the realization of survival benefit have attended the
operation since the early stages of development. The evo-
lution of coronary surgery is a story of focused thought,
dedication, courage, collaboration, and serendipity.
Alexis Carrel (1872 to 1944) understood the association
between angina pectoris and coronary stenosis (2). Before
World War I, he had developed a canine model of aorto-
coronary anastomosis using carotid arteries as a conduit. For
his seminal work in the development of cardiovascular
surgical techniques, he was awarded the Nobel Prize.
Carrel’s contributions lay fallow, as he had predicted, until
a time when advances in technology would allow safe
application to humans.
Carrel and the aviator Charles Lindbergh collaborated in
the 1930s in developing a primitive heart-lung machine
intended to allow direct cardiac operation. Lindbergh was
driven to this project by the desire to save a family member
dying of valvular heart disease. The project did not produce
a clinically useful device, but it did make incremental
progress toward the ultimate goal (3). Over a professional
lifetime of intense dedication, John Gibbon developed a
clinically useful cardiopulmonary bypass (CPB) technology
and applied it successfully to a patient in 1953 (4).
With direct coronary operation awaiting advancing tech-
niques, surgical efforts to relieve angina pectoris in the
mid-20th century included suppression of metabolic stim-
ulation through thyroidectomy and augmentation of non-
coronary flow to the myocardium through creation of
pericardial or omental adhesions. Attempts to create an
artificial collateral by implantation of the internal mammary
artery (IMA) into the myocardium, the Vineberg procedure,
met with limited success (5).
Coronary surgery moved into the modern era in the
1950s. It is not entirely clear to whom credit should be given
for the first coronary bypass. The first direct surgical
approach to the coronary circulation in a patient was likely
performed by William Mustard in 1953 in Toronto, who
used a carotid-to-coronary bypass. The patient did not
survive the operation.
The first clinical use of the IMA to graft a coronary vessel
appears to have been in response to an intraoperative
misadventure. William Longmire applied the technique of
coronary endarterectomy in a series of patients in 1958. A
right coronary artery disintegrated during one of these
operations, and an IMA was placed as a direct graft to
restore flow. In retrospect, the surgeon thought it to be a
good operation (2).
Michael DeBakey and Edward Garrett had a similar
experience with a left anterior descending (LAD) coronary
endarterectomy in 1964 (6). This situation was salvaged by
an aortocoronary saphenous vein graft (SVG). The patient
did well and had a patent aortocoronary SVG when restud-
ied 8 years later. This experience was subsequently recorded
and recognized as the first successful clinical aortocoronary
SVG. An aortocoronary SVG operation by David Sabiston
at Duke in 1962, involving an anastomotic end-to-end
technique done without the use of CPB, was the first
planned saphenous vein operation but was complicated by
an early fatal outcome (7,8).
Mason Sones showed the feasibility of selective coronary
arteriography and amassed a large library of cineangiograms
that were studied in depth by Rene Favaloro (9). Sones and
Favaloro formed an innovative team that demonstrated the
efficacy and safety of SVG interposition and aortocoronary
SVGs for single-vessel, left main, and multivessel coronary
disease. An explosive growth in the application of these
techniques ensued, such that within a decade, coronary
bypass operation became the most frequent surgical proce-
dure in the United States.
Recognition of the value of the IMA (also known as the
internal thoracic artery) as a conduit came slowly. V.I.
Kolessov, working in the 1960s at the Pavlov Institute in
Leningrad, described a series of patients in whom the IMA
was used for coronary revascularization without the aid of
routine arteriography or CPB (10,11). Frank Spencer de-
veloped extensive experimental experience with the IMA to
the coronary circulation in canine models. After preliminary
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animal and cadaveric work with microscopic methods,
George Green brought this technique to successful clinical
application. Floyd Loop and colleagues at the Cleveland
Clinic incorporated the IMA into the coronary operation in
a large series of patients and subsequently published the
landmark article demonstrating the powerful survival benefit
afforded by use of the IMA for LAD coronary distribution
revascularization (12).
The 1970s, the first full decade of CABG, helped to
define its appropriate role relative to medical therapy.
Coronary bypass was found to consistently relieve angina
and improve the quality of life in symptomatic patients.
Three large, prospectively randomized, multicenter trials,
The Coronary Artery Surgery Study (CASS), The Veteran’s
Administration Coronary Artery Bypass Trial, and the
European Coronary Artery Bypass Trial, were conducted.
These trials and several smaller studies helped to define
subsets of patients likely to benefit from coronary bypass
surgery in terms of prolongation of life and specifically
identified patients with more advanced disease as those most
appropriate for application of the operation for survival
benefit. In addition to patients with triple-vessel disease and
left main disease, patients with ischemic left ventricular
(LV) dysfunction were found to benefit from the operation
relative to medical therapy. These results led to the appli-
cation of coronary bypass to progressively sicker patients in
the 1980s.
Improvements in operative techniques and new technol-
ogies have allowed increasingly difficult patients to be
approached with success. Improvements in cardiac anesthe-
sia have paralleled improvements in operative techniques.
Operation on complex patients became routine as sophisti-
cated perioperative monitoring techniques, such as Swan-
Ganz pulmonary artery catheters and intraoperative trans-
esophageal echocardiography (TEE), were applied to
specific problem situations. Anesthetic techniques, CPB
technology, and most important, methods of myocardial
protection were refined and successfully applied to specific
problem situations. Close collaboration between the sur-
geon, the anesthesiologist, the perfusionist, and the inten-
sive care team has been critically important to these ad-
vances. These refinements, discussed in Section VI, have led
to an expected 30-day mortality of ,1% in patients receiv-
ing elective coronary bypass who are ,65 years of age and
who have no severe LV dysfunction or congestive heart
failure (CHF). Even in otherwise uncomplicated patients
aged ,65 years and with an ejection fraction (EF) of 0.25 to
0.35, first-time coronary bypass has an operative risk of
,5%.
In addition to improvements in short-term outcomes,
evolving technology has contributed to improved long-term
results. The widespread use of the IMA, the use of other
arterial conduits, long-term antiplatelet therapy, and lipid
management are discussed in later sections of these guide-
lines. Progress has also been significant in the moderation of
perioperative morbidity. Central nervous system (CNS)
injury, the systemic insults of CPB, infection, and bleeding
are addressed in subsequent discussions. Finally, the appli-
cation of CABG without CPB and through limited inci-
sions has recently presented the prospect of further reduc-
tions in perioperative morbidity.
III. OUTCOMES
A. Hospital Outcomes
1. Introduction. As the clinician and the patient consider
the decision for CABG, an understanding of probable
immediate outcomes (events that occur during the imme-
diate hospitalization or within 30 days of operation) is of
paramount importance. In particular, it is important to be
able to predict the hospital mortality of the procedure and
the risk of the major complications of coronary bypass,
including cerebrovascular accidents, major wound infection,
and renal dysfunction.
2. Predicting Hospital Mortality. The risk of death with
CABG has been the focus of numerous studies in the last 2
decades. Although early reports were useful in correlating
patient factors with outcomes such as in-hospital mortality
(13), they were inadequate in their ability to risk stratify
(14,15). Subsequently, a number of large single-center and
multicenter cardiac surgical databases were established
(13,16,17). From these databases, risk stratification models
were created to better understand the variation in institu-
tional and surgeon performance and to provide a more
accurate risk prediction of mortality for patients facing
CABG. Although all datasets identified patient and disease
characteristics that consistently predicted mortality, the
inclusion or exclusion of certain variables, variations in
definitions of the same variables, and institutional and
regional differences in practice styles have made it difficult to
compare results across datasets. A review of 7 large datasets,
representing .172,000 patients who underwent surgery
between 1986 and 1994, was carried out to find the
predictive power of certain preoperative variables (18).
Seven core variables (ie, urgency of operation, age, prior
heart surgery, sex, LVEF, percent stenosis of the left main
coronary artery, and number of major coronary arteries with
.70% stenosis) were found to be predictive of mortality
after CABG in all 7 datasets. Variables relating to the
urgency of operation, age, and prior coronary bypass surgery
were found to have the greatest predictive power, while
variables describing coronary anatomy had the least predic-
tive power. Besides these 7 core variables, 13 “level 1”
variables were identified that, when added to the core
variables, had a modest influence on the predictive capability
of the model. These level 1 variables included the following:
PTCA during index admission; recent (,1 week) MI;
history of angina, ventricular arrhythmia, CHF, or mitral
regurgitation (MR); comorbidities including diabetes, cere-
brovascular disease, peripheral vascular disease (PVD),
chronic obstructive pulmonary disease (COPD), and creat-
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inine level. While the level 1 variables carry predictive
power, their addition beyond these 7 core variables has been
found to have a minimal impact on predictability (15).
While Jones and others have attempted to develop a
common risk stratification language, general application of
risk stratification models across populations must be done
with caution. Although it may be possible to generalize the
relative contribution of individual patient variables, rules
must be calibrated to regional mortality rates and should be
updated periodically to maximize accuracy (19,20). Table 1
compares the relative risk of the 7 core variables identified
by Jones et al (18) to be most predictive of mortality as
reported by 6 datasets.
Age has consistently predicted mortality after CABG
(16,26), with advancing age associated with higher mortal-
ity. Assuming that age ,65 years carries a relative risk of 1,
Tu et al (27) found that the relative risk increased to 2.07 for
patients between 65 and 74 years old and to 3.84 for those
older than 75 years. Despite this increased short-term risk of
mortality after CABG treatment, long-term results remain
encouraging. When patients ,50 years of age are compared
with those 70 years and older and are matched by age to a
population that did not undergo CABG, the older patients
experienced a longer hospitalization and higher hospital
mortality, although their long-term survival more closely
matched the general population compared with their
younger counterparts. While elderly patients face an in-
creased likelihood of morbidity after CABG and a particu-
larly high incidence of stroke when compared with the
general population (28,29), age itself should not exclude a
patient from being offered treatment with CABG, assuming
that there is no prohibitive comorbidity.
Sex also predicts early mortality after CABG, with
females facing an increased risk. Reported relative risks have
ranged from 1.5 to 2.0. Smaller body size (30), smaller
diameter of coronary arteries (31), increased age, and
comorbidity status (32) have all been suggested as explana-
tions for this increased risk. Despite the increased risk,
long-term results appear similar to those of males (33).
Having had previous open heart surgery adds consider-
able risk for patients having subsequent coronary artery
surgery. The relative risk of early mortality appears to be
’3.0 compared with first-time CABG patients (16). An
additional factor that further increases risk in this subset
appears to be whether reoperation is carried out within 1
year of the primary operation (34). Despite the significant
Table 1. Relative Mortality Risk: Core CABG Variables for 6 Datasets
NNE (21) VA (22) STS (16) NYS (23) CC (24) AGH (25)
No. of patients 3055 12 712 332 064 57 187 4918 1567
Year of publication ’92 ’92 ’97 ’94 ’97 ’96
Years included ’87–’89 ’87–’90 ’90–’94 ’89–’92 ’93–’95 ’91–’92
Type Vol reg Man nat Vol nat Man state SI SI
Database variables
Age/y 1.04 1.04 1.05 1.04 1.05 NA
Sex, F 1.2 NA 1.5 1.52 1.63 1.48
Prior heart surgery 3.6 3.2 3.0 3.73 1.72 1.39
3.5 (Mult reops)
LMD (70%) NS NA 1.3 1.43 (.90%) NA NA
No. of diseased vessels
1 1.0 NA 1.0 NA NA NA
2 1.3 NA 1.0 NA NA NA
3 1.6 NA 1.2 NA NA NA
Urgency of operation*
Elective 1.0 1.0 1.0 1.0 1.0 1.0
Urgent 2.1 2.4 1.2 1.42 (USA) NA 3.5
Emergent 4.4 3.8 2.0 3.98 5.07 7.14
Salvage NA NA 6.7 NA NA 29.9
Ejection fraction
0.60 1.0 NA . . . 1.0 (.40%) NA . . .
0.50–0.59 1.4 NA . . . . . . NA . . .
0.40–0.49 1.6 NA . . . . . . NA . . .
0.30–0.39 1.9 (,40%) NA . . . 1.63 NA 2.89 (,30%)
0.20–0.29 NA NA . . . 2.21 NA . . .
,0.20 NA NA . . . 4.06 NA . . .
NNE, Northern New England Cardiovascular Disease Study Group; VA, Veterans Affairs cardiac surgical database; STS, Society for Thoracic Surgery national cardiac surgical
database; NYS, New York State cardiac surgery reporting system; CC, Cleveland Clinic; AGH, Allegheny General Hospital; LMD, left main disease; Vol, voluntary; reg,
regional; Man, mandatory; nat, national; state, single state; SI, single institution; NA, not available; and mult reops, multiple reoperations.
The relative risk coefficient for age indicates the additional mortality risk per year of age .50 years.
*Urgent indicates patients are required to stay in hospital but may be scheduled and operated on within a normal scheduling routine; Emergent, ongoing refractory cardiac
compromise, unresponsive to other forms of therapy except for cardiac surgery; and Salvage, ongoing cardiopulmonary resuscitation en route to the operating room.
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increased risk, long-term results after reoperative CABG are
encouraging (35).
Coronary artery surgery in the presence of or immediately
after an acute MI is controversial. Despite optimistic reports
of low mortality if the operation is carried out within 6
hours of the onset of chest pain (36), most authors have
found this approach to carry excessive mortality (37–39).
Fibrinolytic therapy and/or PTCA appears to be the pref-
erable first-line therapy in the presence of an evolving MI.
CABG surgery is reserved for patients with evidence of
ongoing ischemia despite these interventions, or it may be
performed coincident with repair directed at mechanical
complications of infarction (ie, ventricular septal defect or
papillary muscle rupture).
The presence of comorbidities is also related to survival
after CABG. Though not identified by Jones et al (18) as a
core variable, treated diabetes (40), the presence of PVD
(41), renal insufficiency (42), and COPD have all been
shown to have a negative impact on outcome after CABG.
A nonoperative variable that seems to have both a
short-term and a long-term impact on survival is the use of
the IMA as a bypass conduit. Loop, Lytle, and others have
reported that use of the IMA is an independent predictor of
survival 10 to 20 years after CABG (43,44). Hospital
mortality after CABG has also been reported to be lower
when the IMA is used (45).
In summary, early mortality after CABG is associated
particularly with advancing age, poor LV function, and the
urgency of operation. Additional coronary anatomic and
comorbid conditions further influence risk. If overall risk for
an institution or region is known, then a general estimate for
the individual patient can be rendered preoperatively by
using mathematical models, as illustrated in Table 2 and
Figure 1. This application may find utility as patients and
their physicians weigh the potential benefits versus risks of
proceeding with bypass surgery.
3. Morbidity Associated With CABG: Adverse Cerebral
Outcomes. Neurological abnormalities after CABG are a
dreaded complication. The reported incidence ranges from
0.4% to nearly 80%, depending on how the deficit is defined
(46–48). Neurological derangement after CABG has been
attributed to hypoxia, emboli, hemorrhage, and metabolic
abnormalities (49,50). Despite the many advances made in
cardiac surgery, postoperative stroke remains a problem.
Postoperative neurological deficits have been divided into
2 types: type 1 deficits are those associated with major, focal
neurological deficits, stupor, and coma; type 2 deficits are
characterized by deterioration in intellectual function or
memory. Roach et al (51) reported on a multi-institutional
prospective study aimed at determining the true incidence of
both stroke (type 1 deficits) and encephalopathy (type 2
deficits) after CABG. In this study, 2108 patients operated
on at 24 institutions were observed for signs of neurological
dysfunction after CABG. Adverse cerebral outcomes oc-
curred in 129 patients (6.1%) and were evenly distributed
between type 1 (3.1%) and type 2 (3.0%) deficits. The
influence of these complications included a 21% mortality
for those with type 1 deficits and a 10% mortality for those
with type 2 deficits. In addition, patients with neurological
complications had, on average, a 2-fold increase in hospital
length of stay and a 6-fold likelihood of discharge to a
nursing home.
Independent risk factors were identified for both type 1
and type 2 deficits (51). Predictors of both types of cerebral
complications included advanced age, especially age .70
years, and a history or the presence of significant hyperten-
sion. Both of these variables have previously been reported
to be associated with adverse cerebral outcomes after CABG
(28,52).
Predictors of type 1 deficits included the presence of
proximal aortic atherosclerosis as defined by the surgeon at
the time of surgery (odds ratio [OR] 4.52), a history of prior
neurological disease (OR 3.19), use of the intra-aortic
balloon pump ([IABP] OR 2.60), diabetes (OR 2.59), a
history of hypertension (OR 2.31), a history of unstable
angina (OR 1.83), and increasing age (OR 1.75 per decade).
Perioperative hypotension and the use of ventricular venting
were also weakly associated with this type of outcome.
Proximal aortic atherosclerosis has been reported to be
the strongest predictor of stroke after CABG, supporting
the theory that liberation of atheromatous material during
manipulation of the aorta is the main cause of this compli-
cation (53). Although palpation of the aorta has tradition-
ally been used by surgeons to identify patients with ather-
omatous disease of the ascending aorta and to find “soft
spots” for cannulation or cross clamping, the use of ultra-
sound has been suggested as a more accurate means of
assessing the aorta (54). Duda et al (54) have suggested that
once aortic atherosclerosis is identified, alternative strategies
to prevent mobilization of aortic atheroma should be con-
sidered, including techniques such as groin or subclavian
placement of the aortic cannulas, fibrillatory arrest without
aortic cross-clamping, use of a single cross-clamp technique,
modifying the placement of proximal anastomoses, or all-
arterial revascularization. Other authors recommended as-
cending aortic replacement under circulatory arrest as the
best means of minimizing this complication (55,56).
A history of previous neurological abnormality or the
presence of diabetes is also a predictor of type 1 CNS
complications. These are likely markers for patients with
marginal cerebral blood flow, alterations in CNS vasomotor
autoregulatory mechanisms, or diffuse atherosclerosis. The
need for an IABP is likely correlated with a higher risk of
atheromatous emboli and is often required in patients with
systemic hypoperfusion, each of which may cause stroke
after CABG. The fact that use of an LV vent has been
associated with stroke suggests air emboli as the cause and
argues for meticulous technique when placing these devices
to prevent this complication.
Factors predictive of type 2 neurological deficits include a
history of alcohol consumption, dysrhythmia (including
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Table 2. Northern New England Cardiovascular Disease Study Group: Preoperative Estimation of Risk of Mortality, Cerebrovascular
Accident (CVA), and Mediastinitis (for Use Only in Isolated CABG Surgery)
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atrial fibrillation), hypertension, prior CABG, PVD, or
CHF. Because aortic atherosclerosis is not a predictor of
type 2 complications, encephalopathic changes may be
related to the brain’s microcirculation and are more likely to
occur after periods of hypotension or inadequate perfusion.
Individual patient counseling regarding postoperative
stroke risk represents an important opportunity to assist
patients as they weigh the risks and benefits of elective
CABG. Although postoperative stroke rates may vary
between hospitals or regions, if local rates are known, then
these may be used to assist the patient in appreciating the
general risk of this dreaded complication. Strategies to
reduce the risk of postoperative neurological complications
are discussed in depth in Section IV, A1.
4. Morbidity Associated With CABG: Mediastinitis.
Deep sternal wound infection has been reported to occur in
1% to 4% of patients after CABG and carries a mortality
rate of nearly 25% (57,58). Studies have consistently asso-
ciated obesity and reoperation with this complication, while
other risk factors such as use of 1 or both IMAs, duration
and complexity of operation, and the presence of diabetes
have been reported inconsistently. Most studies examining
deep sternal wound infection have been single-center, ret-
rospective reviews, and variation in wound surveillance
techniques and the definition of deep sternal wound infec-
tion limit comparisons.
Obesity is a strong correlate of mediastinitis after CABG
(59). In 1 report of 6,459 patients undergoing CABG at a
Figure 1. Event curves.
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single institution, Milano et al (60) found obesity to be the
strongest independent predictor of mediastinitis (OR 1.3).
In a prospective multi-institutional study, the Parisian
Mediastinitis Study Group also found obesity to carry the
greatest association with the development of postoperative
mediastinitis (OR 2.44) (61). The mechanism by which
obesity leads to this complication is poorly understood but is
likely multifactorial. Perioperative antibiotics may be poorly
distributed in adipose tissue, skin folds present a special
challenge in maintaining sterility, and large regions of
adipose tissue serve as an ideal substrate for bacteria and
represent a clinical challenge for diagnosis when early
infection occurs.
Another patient characteristic that has been associated
with postoperative mediastinitis is the presence of diabetes
(60,62), especially in patients requiring insulin (59). In
addition to the microvascular changes seen in diabetic
patients, elevated blood glucose levels may impair wound
healing. The use of a strict protocol aimed at maintaining
blood glucose levels #200 mg/dL by the continuous,
intravenous infusion of insulin has been shown to signifi-
cantly reduce the incidence of deep sternal wound infection
in diabetic patients (63,64).
Prior cardiac surgery is another factor associated with the
development of mediastinitis (60,61,65). Reoperation re-
quires additional dissection, longer perfusion times, more
bleeding, and a higher likelihood of needing transfusion,
variables that have all been linked to this complication.
Operator-dependent variables may also contribute to the
development of deep sternal wound infection. These include
the use of 1 or more IMAs for bypass conduits and excessive
use of electrocautery for hemostasis (60,66). No studies have
found the use of a single IMA to be predictive of medias-
tinitis. Two reports identified the use of both IMAs to be an
independent predictor (61,62), while several others have
shown no correlation with the development of mediastinitis
(57,60). Because the use of both IMAs may predispose to
devascularization of the sternum, it seems likely that this
technique promotes infection, especially when combined
with other risk factors such as diabetes and/or obesity.
In summary, deep sternal wound infection after CABG is
an expensive and potentially lethal complication that ap-
pears to have a multifactorial etiology. Strategies to reduce
the incidence of this complication include meticulous asep-
tic technique, keeping perfusion times to a minimum,
avoidance of unnecessary electrocautery, appropriate use of
perioperative antibiotics, and strict control of blood glucose
levels during and after operation. Each of these is discussed
in greater depth in Section IV, A4.
5. Morbidity Associated With CABG: Renal Dysfunc-
tion. The first major multicenter study of renal dysfunction
after CABG surgery has recently been published (67). This
study of 2,222 patients who underwent myocardial revascu-
larization with CPB defined postoperative renal dysfunction
(PRD) as a postoperative serum creatinine level of
$2.0 mg/dL or an increase in the serum creatinine level of
$0.7 mg/dL from preoperative to maximum postoperative
values. PRD occurred in 171 (7.7%) of the patients
studied; 30 of these (18%, or 1.4% of all study patients)
required dialysis. The mortality rates were 0.9% among
patients who did not develop PRD, 19% in patients with
PRD who did not require dialysis, and 63% among those
who required dialysis.
Several preoperative risk factors for PRD were identified,
including advanced age, a history of moderate to severe
CHF, prior CABG, type 1 diabetes mellitus, and preexist-
ing renal disease (preoperative creatinine levels between 1.4
and 2.0 mg/dL). The risk of PRD in patients ,70 years of
age nearly tripled with 1 preoperative risk factor and
increased further with 2 risk factors. A detailed analysis of
the impact of these preoperative risk factors for PRD for 3
age groups is presented in Table 3. These findings allow
identification of high-risk patients for PRD and a general
estimation of the risk for PRD for an individual patient.
The reported risk for patients with moderate renal dysfunc-
tion is consistent with previous reports from smaller, single-
center studies (68–70).
Although data from large, multicenter studies are not
available, it is reasonable to conclude that patients with
more advanced, chronic, preoperative renal failure (but
without end-stage renal disease [ESRD]) would have an
even higher incidence of PRD requiring dialysis. Because
their kidneys have a greater reduction in functioning
nephrons than those in patients with lesser degrees of renal
failure in the study cited above, they would be more
vulnerable to the maldistribution of renal blood flow, an
increase in renal vascular resistance, and the decreases in
total renal blood flow and glomerular filtration rate that
occur during CABG surgery (71–73). This conclusion has
been supported by a recent study of 31 patients who
underwent CABG with a baseline serum creatinine level
$1.6 mg/dL in the 6 months before surgery and who did
not require preoperative dialysis (74). The mean age of the
patients was 71 years, and nearly 80% were males. The
hospital mortality was 19%, and 26% of surviving patients
required chronic dialysis. Among 19 patients with a creat-
inine level $2.6 mg/dL, 42% of survivors required chronic
hemodialysis, whereas none of the surviving patients with a
creatinine level #2.6 mg/dL required chronic dialysis. This
study suggests that patients .70 years old with a creatinine
level $2.6 mg/dL are at extreme risk for dialysis depen-
dency after CABG, and alternative options for coronary
management should be strongly considered.
The importance of perioperative renal function is empha-
sized by a recent report that correlated acute renal failure
sufficient to require dialysis and operative mortality after
cardiac surgery (75). The 42,773 patients who underwent
CABG or valvular heart surgery at 43 Department of
Veterans Affairs Medical Centers between 1987 and 1994
were evaluated to determine the association between acute
renal failure sufficient to require dialysis and operative
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mortality. This degree of acute renal failure occurred in 460
(1.1%) patients. Overall, operative mortality was 63.7% in
these patients, compared with 4.3% in patients without this
complication. Acute renal failure requiring dialysis was
independently associated with early mortality after cardiac
surgery, even after adjustment for comorbidity and postop-
erative complications.
B. Posthospital Outcomes
The extensive application of CABG has been a consequence
of its effectiveness in the relief of angina and prolongation of
survival in certain subsets. The 1991 Guidelines provided
data that allow a general understanding of expectation after
CABG (1). In a heterogeneous group of patients, survival at
5 years was 92% and at 10 years was 81%. Freedom from
angina was 83% at 5 years and 63% at 10 years. The previous
guidelines provided equations for predicting patient-specific
outcomes, including freedom from unfavorable events, in a
comparison of coronary bypass surgery versus medical treat-
ment. These detailed predictive instruments remain appro-
priate for use and are not presented here. While a discussion
of the comparative benefits of CABG versus medical ther-
apy appears in Section III, C, a brief description of the
factors that influence the long-term results of the operation
is appropriate here.
The predictors of long-term survival after CABG have
been analyzed in a number of studies. In an analysis of
23,960 patients from 1977 to 1994 from Emory University,
advanced age, EF, presence of diabetes, number of diseased
vessels, and sex were significant multivariate predictors of
survival, while angina class, hypertension, history of MI,
renal dysfunction, and CHF were other important factors
identified by univariate analysis (Table 4) (76). Other
studies have identified predictors for the recurrence of
angina and for postoperative MI (Table 5). Importantly,
untoward events after coronary bypass tend to increase in
frequency between 5 and 10 years after the operation,
apparently coincident with the gradual occlusion of vein
grafts. Approximately 50% of vein grafts are closed by 10
years after operation.
The delayed return of angina and the fact that approxi-
mately half of the survivors of CABG eventually die of
cardiac-related causes identifies the “Achilles heel” of the
procedure: late vein-graft atherosclerosis and occlusion. The
most important surgical gain has been verification of excel-
lent late patency with IMA grafts (77). From this encour-
aging result with the use of a single arterial graft has sprung
Table 4. Multivariate Analysis Predictors of Late Overall and
Late Cardiac Mortality
Predictor
Risk
Ratio 95% CI P
Late overall mortality
Diabetes 2.94 1.81–4.77 , 0.001
Advancing age 1.10 1.06–1.13 , 0.001
Reduced EF 1.03 1.01–1.04 , 0.007
No IMA 1.22 0.75–1.99 0.423
Late cardiac mortality
Diabetes 1.73 2.40–9.32 , 0.001
Advancing age 1.08 1.04–1.13 , 0.001
Reduced EF 1.05 1.02–1.08 , 0.001
No IMA 1.78 0.83–3.79 0.138
CI indicates confidence; EF, rejection fraction; and IMA, internal mammary artery.
TABLE 3. Risk of Postoperative Renal Dysfunction (PRD) After Coronary Artery Bypass Graft Surgery
No. of
Risk
Factors
Combinations of Preoperative
Risk Factors for PRD
Risk of PRD in Various Clinical Strata
Depending on Risk Factors and Age
CHF Reop DM Creat >1.4 <70 y 70–79 y >80 y
0 2 2 2 2 1.9% (n5909) 7.0% (n5330) 11.8% (n568)
1 2 2 2 1 5.0% (n580) 18.4% (n576) 12.5% (n516)
2 2 1 2 5.9% (n568) 4.8% (n581) 0.0% (n51)
2 1 2 2 6.2% (n5130) 14.3% (n556) 25.0% (n54)
1 2 2 2 7.6% (n5144) 12.3% (n573) 29.4% (n517)
2 2 2 1 1 22.2% (n59) 0% (n57) 0% (n50)
2 1 2 1 20.0% (n525) 30.8% (n513) 0% (n50)
2 1 1 2 37.6% (n58) 33.3% (n53) 0% (n51)
1 2 2 1 47.4% (n519) 7.7% (n526) 44.4% (n59)
1 2 1 2 25.9% (n527) 18.2% (n511) 0% (n50)
1 1 2 2 31.6% (n519) 7.1% (n514) 100.0% (n51)
3 2 1 1 1 100% (n51) 100% (n51) 0% (n50)
1 2 1 1 8.3% (n512) 25% (n54) 0% (n51)
1 1 2 1 0.0% (n52) 33.3% (n59) 0% (n52)
1 1 1 2 33.3% (n53) 0% (n50) 0% (n50)
4 1 1 1 1 50.0% (n52) 0% (n50) 0% (n50)
CHF indicates prior congestive heart failure; Reop, redo coronary bypass operation; DM, type 1 diabetes mellitus; Creat .1.4, preoperative
serum creatinine level .1.4 mg/dL; n, observed number of patients within each clinical stratum; 2, risk factor absent; and 1, risk factor
present. Reproduced with permission from (67).
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the arterial arborization of today, with reports of multiple
and “complete” arterial grafting (78–81). This is discussed
further in Sections IV, B, and VI, B.
C. Comparison of Medical Therapies Versus Surgical
Revascularization
Since the 1991 Guidelines, relatively little clinical trial
information comparing medical with surgical treatment of
CAD has been published. However, longer follow-up of
patients enrolled in the earlier, major randomized trials has
solidified the appropriate indications for surgical treatment.
The traditional stratification of patients has been based
on the extent of CAD (ie, number of vessels with anatom-
ically significant disease and whether or not the major
epicardial obstruction is proximal) in association with the
extent of LV dysfunction (determined by a simple measure
of global LVEF). The major end point of the studies has
been survival. The major randomized trials enrolled patients
between 1972 and 1984, at which time the predominant
medical therapy was the use of b-blockers and nitrates.
There are several important limitations of the random-
ized trials in view of current practice (Table 6). In the
ensuing years, calcium channel blockers have been added,
particularly for symptomatic patients. The use of aspirin has
become more widespread in all patients with CAD. The
role of 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors and other lipid-lowering agents has now been
recognized as important in reducing recurrent ischemic
events. It is hoped that these agents will be used equally in
patients treated with medications alone and in patients after
CABG surgery, whose revascularization therapy is comple-
mented by appropriate medical treatment to reduce isch-
emic complications. The contribution of recent advances in
surgical revascularization techniques cannot be fully as-
sessed. The potential value of arterial conduits for revascu-
larization, particularly the IMA, cannot be evaluated from
these early randomized studies, yet their use is now routine
in CABG surgery. There are also no prospective, random-
ized studies comparing the more recent off-bypass or min-
imally invasive surgical approaches to medical therapy.
Finally, the randomized trials oversimplify the designation
of 1-, 2-, and 3-vessel disease. Several reports show that
prognosis is also critically related to the location of lesions
within vessels, not simply the number of vessels involved
(9,18).
1. Overview. There were 3 major randomized trials (82–
84) and several smaller ones (85–87). These studies ad-
dressed similar clinical questions and, as shown in Figures 2
and 3, had similar outcomes. Much of the primary patient
information for the 2649 patients enrolled in these random-
ized trials has been combined in a collaborative meta-
analysis, which has facilitated comparison of outcomes at 5
and 10 years’ follow-up (88) (Table 7). Extension of survival
is a useful measure to compare different treatment strategies
and can be adjusted for patient characteristics (Figure 4).
Across all patients, the improvement in survival with
CABG compared with medical treatment is 4.3 months at
10-year follow-up. In patients with left main disease, the
survival benefit is 19.3 months. Subset analyses for other
subgroups show statistical benefit for those with 3-vessel
disease, and in those with 1- or 2-vessel disease including
LAD CAD. Relative risk reductions were similar with
abnormal or normal LV function. However, a similar
relative risk reduction is associated with a greater absolute
Table 5. Multivariate Analysis Predictors for Anginal
Recurrence, Late MI, and Any Cardiac Event
Predictor
Risk
Ratio 95% CI P
Angina recurrence
Female sex 1.81 1.22–2.69 0.003
Obesity 1.69 1.21–2.19 0.002
Preoperative hypertension 1.54 1.87–2.19 0.015
No IMA 2.47 1.49–4.10 , 0.001
Late MI
Diabetes 3.39 1.81–6.34 0.001
Single IMA 2.31 1.15–4.67 0.019
Any cardiac event
No IMA 2.88 1.48–5.15 , 0.001
MI indicates myocardial infarction; CI, confidence interval; and IMA, internal
mammary artery.
Table 6. Limitations of Randomized Trials in View of Current Practice
Patient Selection Surgical Factors
Medical/Nonsurgical
Therapy
Patients #65 years of age Only 1 trial used arterial grafts
(CASS) (in only 14% of patients)
Lipid-lowering therapy not
used or standard
Only 1 trial included
women (CASS)
Newer modalities of cardioprotection
not used
Aspirin not widely used
Predominantly low-risk,
stable patients
Minimally invasive, off-bypass
techniques not used
b-Blockers used in only
half of patients
Aspirin not routinely given early
postoperatively
ACE inhibitors not used
Coronary angioplasty not
widespread
CASS indicates Coronary Artery Surgery Study; ACE, angiotensin-converting enzyme.
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survival benefit in the high-risk population with depressed
LV function. The survival benefit of CABG surgery for
individuals with 1- and 2-vessel disease without LAD
involvement is small, particularly in the setting of normal
LV function. A higher clinical risk score, more severe
angina, and a positive exercise test are associated with a
greater prolongation of survival after CABG surgery than
with medical therapy at 5 and 10 years (Table 7) (88). Two
clinical scoring systems had been used. The Veterans
Administration trial used the clinical variables of angina
class, history of hypertension, and MI as well as the degree
of ST-segment depression at rest. The Coronary Artery
Bypass Graft Surgery Trialists Collaboration (88) developed
a stepwise logistic regression analysis-based risk score
that included clinical and angiographic variables as well
as EF (Tables 7 through 9). Patients can be stratified
according to these clinical criteria and by using these
scoring systems. There was little survival benefit in those
with a low risk (1% annual mortality) but increasingly
significant survival extension in those at moderate (an-
nual mortality of 2.5%) or high (annual mortality of 5%)
(Tables 7 through 9) risk.
The randomized trials provide robust results for the
populations studied. However, there are important limita-
tions in generalizing the results of these studies to most
patients with coronary disease because of the way patients
were selected for the randomized studies (Tables 7 through
9). Specifically, the mean age of randomized patients was
50.8 years, there were very few patients .65 years, 96.8%
were male, and only 19.7% had an LVEF ,0.50 (88). The
challenge of choosing a therapeutic option in patients with
CAD is that the clinical course is highly variable, and the
“average” patient does not fit perfectly into 1 of the groups
studied. The large registries (89–91) and other studies
(92–94) provide useful confirmatory information in support
of the clinical trials and, if interpreted with appropriate
caution, can help in the subsets not well studied in the
randomized trials. The following discussion combines in-
formation from randomized and nonrandomized trials in
which the directional trends are consistent with the ran-
domized information.
Figure 2. Survival curves of the three large studies and the four
small studies combined. Reproduced with permission from (88).
Figure 3. Cumulative total mortality. Reproduced with permission from (88).
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2. Location and Severity of Stenoses.
a. Left Main Disease
The benefit of surgery over medical treatment for patients
with significant left main stenosis is little argued. All of the
trials define significant left main stenosis as being .50% as
judged by contrast angiography. The median survival for
surgically treated patients is 13.3 years versus 6.6 years in
medically treated patients (95,96).
Left main equivalent disease, defined as severe ($70%)
proximal LAD and proximal left circumflex disease, appears
to behave similarly to true left main disease. Median survival
for surgical patients is 13.1 years versus 6.2 years for
medically assigned patients (95). However, there are few
randomized or randomizable patients with this anatomy. By
15 years, there is less survival benefit for patients assigned to
surgery. It is estimated that if all medical patients survived
15 years, 65% would eventually have surgery (88). At 15
years, cumulative survival in the CASS registry for patients
with left main equivalent disease was 44% for surgical
patients and 31% for the medical group (95,97,98).
b. Three-Vessel Disease
Significant CAD is defined variably in the major studies.
CASS originally reported results with significant stenosis
defined as $70%. The Veterans Administration and Euro-
pean studies used 50% as the cutoff for significant stenosis,
and when the studies were combined for the meta-analysis
(88), the 50% criterion defined significant disease for all
vessels.
The outcome of patients with 3-vessel CAD assigned to
surgical or medical treatment is similar at the 10-year
follow-up to that reported earlier in randomized trials. The
more severe the symptoms, the more proximal the LAD
CAD, and the worse the LV function, the greater is the
benefit from surgery (84,88,99–103). In patients with
3-vessel disease, the relative risk reduction for surgery at 5
years is 42% and at 10 years is 24%, with an increase in
survival of 5.7 months at 10-year follow-up (88).
c. Proximal LAD Disease
Proximal LAD CAD (.50% stenosis) is an important
contributor to outcome. In patients with proximal LAD
disease, the relative risk reduction of CABG at 5 years is
42% and at 10 years, 22%. In LAD disease without proximal
involvement, the relative risk reduction at 5 years is 34% and
at 10 years, 10%. In the presence of depressed LV function,
the absolute benefit of surgery is greater because of the risk
of this population (84,104).
TABLE 7. Total Mortality at 5 and 10 Years
Trial
No. of Patients
Randomized 5-Year Mortality 10-Year Mortality
CABG
Medical
Treatment CABG
Medical
Treatment
Odds Ratio
(95% CI) CABG
Medical
Treatment
Odds Ratio
(95% CI)
VA (82) 332 354 58 79 0.74 (0.50–1.08) 118 141 0.83 (0.61–1.14)
European (84) 394 373 30 63 0.40 (0.26–0.64) 91 109 0.72 (0.52–0.99)
CASS (83) 390 390 20 32 0.60 (0.34–1.08) 72 83 0.84 (0.59–1.19)
Texas 56 60 10 13 0.79 (0.31–1.97) 23 25 0.97 (0.46–2.04)
Oregon 51 49 4 8 0.44 (0.12–1.56) 14 14 0.94 (0.39–2.26)
New Zealand 51 49 5 7 0.65 (0.19–2.20) 15 16 0.94 (0.38–2.31)
New Zealand 50 50 8 8 1.00 (0.34–2.91) 17 16 1.15 (0.50–2.65)
Total 1324 1325 135 210 0.61 (0.48–0.77) 350 404 0.83 (0.70–0.98)
(10.2%) (15.8%) P,0.0001 (26.4%) (30.5%) P50.03
CABG indicates coronary artery bypass graft; CI, confidence interval; VA, Veterans Administration; and CASS, Coronary Artery Surgery Study.
P values for heterogeneity across studies were 0.49, 0.84, and 0.95 at 5, 7, and 10 years, respectively. Reproduced with permission from (88).
Figure 4. Extension of survival after 10 years of follow up in
various subgroups from a meta-analysis of 7 randomized studies.
Reproduced with permission from (88).
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d. LV Function
LV systolic function remains an important predictor of
which patients are likely to benefit from surgery (100–
102,105). In patients with a normal EF, surgical revascu-
larization provides little survival benefit. In patients with
mild to moderately depressed function, the poorer the LV
function, the greater is the potential benefit of surgery
(100–102,106,107). The relative benefit is similar, but there
is greater absolute benefit because of the high-risk profile of
these patients. It is important to note that the randomized
trials did not include patients with an LVEF ,0.35. Thus,
TABLE 8. Subgroup Results at 5 Years
Subgroup
Overall
Numbers
Mortality Rates,
%
Odds Ratio
(95% CI)
P for CABG Surgery
vs
Medical TherapyDeaths Patients Surgical Medical
No. of diseased
vessels
1 21 271 5.4 9.9 0.54 (0.22–1.33) 0.18*
2 92 859 9.7 11.7 0.84 (0.54–1.32) 0.45*
3 189 1341 10.7 17.6 0.58 (0.42–0.80) ,0.001*
Left main artery 39 150 15.8 36.5 0.32 (0.15–0.70) 0.004*
No LAD disease
1 or 2 Vessels 50 606 8.3 8.3 1.05 (0.58–1.90) 0.88
3 Vessels 46 410 7.7 14.5 0.47 (0.25–0.89) 0.02
Left main artery 16 51 18.5 45.8 0.27 (0.08–0.90) 0.03†
Overall 112 1067 8.6 12.3 0.66 (0.44–1.00) 0.05
LAD disease present
1 or 2 Vessels 63 524 9.2 14.6 0.58 (0.34–1.01) 0.05
3 Vessels 143 929 12.0 19.1 0.61 (0.42–0.88) 0.009
Left main artery 22 96 12.8 32.7 0.30 (0.11–0.84) 0.02‡
Overall 228 1549 11.2 18.3 0.58 (0.43–0.77) 0.001
LV function
Normal 228 2095 8.5 13.3 0.61 (0.46–0.81) ,0.001
Abnormal 115 549 16.5 25.2 0.59 (0.39–0.91) 0.02§
Exercise test status
Missing 102 664 13.1 17.4 0.69 (0.45–1.07) 0.10
Normal 60 585 9.0 11.6 0.78 (0.45–1.35) 0.38
Abnormal 183 1400 9.4 16.8 0.52 (0.37–0.72) ,0.001
Severity of angina
Class I, II 178 1716 8.3 12.5 0.63 (0.46–0.87) 0.005
Class III, IV 167 924 13.8 22.4 0.57 (0.40–0.81) 0.001
CI indicates confidence interval; CABG, coronary artery bypass graft; LAD, left anterior descending coronary artery; and LV, left ventricular.
*Includes only (82–83). †Excludes (84). ‡Excludes (84–87). §Excludes (83). Reproduced with permission from (88).
TABLE 9. Subgroup Analysis of 5-Year Mortality by Risk Stratum
Deaths,
n
Patients,
n
Medical
Treatment
Mortality Rate, %
Odds Ratio
(95% CI)
P for CABG vs
Medical
Treatment
Risk strata derived by risk score*
Lowest tertile 23 406 5.5 1.18 (0.51–2.71) 0.70
Middle tertile 90 930 11.5 0.63 (0.39–1.01) 0.05
Highest tertile 153 849 23.0 0.50 (0.35–0.72) 0.001
Risk strata by stepwise risk score†
Lowest tertile 52 783 6.3 1.17 (0.66–2.07) 0.60
Middle tertile 85 784 13.9 0.55 (0.34–0.88) 0.01
Highest tertile 157 783 25.2 0.54 (0.37–0.77) 0.001
CI indicates confidence interval; CABG, coronary artery bypass graft. Modified with permission from (88).
*Veterans Administration–type risk score 5 (0.70 3 presence of class III/IV angina) 1 (0.37 3 history of hypertension) 1 (0.83 3 ST-segment depression at rest) 1 (0.39
3 history of myocardial infarction). †Stepwise risk score 5 (0.015 3 age) 1 (0.56 3 presence of class III/IV angina) 1 (0.35 3 history of myocardial infarction) 1 (0.62 3
abnormal ejection fraction) 1 (0.53 3 proximal lesion of .50% in the left anterior descending coronary artery) 1 (0.29 3 right coronary artery lesion .50%) 1 (0.43 3 history
of diabetes) 1 (0.37 3 history of hypertension).
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many of the patients operated on today were not well
represented in the randomized trials.
A major growth in our understanding of the potential
reversibility of chronic systolic dysfunction among patients
with CAD has occurred in the past few years. Systolic
dysfunction that is a result of chronic hypoperfusion (“hi-
bernating”) and not a result of infarction can now be
identified noninvasively by positron emission tomographic
scanning, radioisotope imaging, or dobutamine echocardi-
ography. Patients with large areas of myocardial viability
may benefit from revascularization. Small, observational
studies of patients with hibernating myocardium who are
undergoing coronary revascularization have shown func-
tional and perhaps survival benefit, especially when LV
function is particularly poor. This is discussed further in
Section V, I.
There are few data regarding optimal choices for women.
The higher early surgical mortality needs to be weighed
against the lessons derived from the predominantly male
subjects (108), and this as well as other subsets will be
discussed in Section V.
e. Symptoms/Quality of Life
More attention has been paid recently to improvement in
symptoms and quality of life measurements. The findings
from randomized trials for these outcomes parallel those of
the survival data. Apart from its effect on survival, CABG is
potentially indicated for 2 symptom-based indications: to
alleviate symptoms of angina pectoris over and above
medical therapy and to reduce the incidence of nonfatal
outcomes such as MI, CHF, and hospitalization. CABG is
considered to improve or to relieve angina pectoris in a
much broader group of patients than the subgroups in
which it has been found to improve survival. Registry
studies have suggested a favorable impact on late MI among
highest-risk subsets, such as patients with 3-vessel disease
and severe angina pectoris. However, in the pooled data
from the randomized trials (88), no overall beneficial impact
of CABG on subsequent MI could be demonstrated. This
likely reflects an early increase in MI perioperatively in
patients undergoing CABG surgery balanced by fewer MIs
in the long term.
At 5 years, patients treated surgically used less antianginal
medicines, with 63% of patients completely symptom-free
compared with 38% of medically assigned patients (99). At
10 years, however, these differences were no longer signif-
icant. Patients treated surgically and medically used similar
amounts of long-acting nitrates and b-blockers, with 47%
of surgical patients asymptomatic compared with 42% of
medical patients. Recreational status, employment, fre-
quency of CHF, use of other medicines, and hospitalization
frequency were also similar between the groups (109–116).
At 10 years, the frequency of angina and other quality-
of-life measurements were similar between surgically and
medically treated groups. Those who have multivessel dis-
ease and who receive complete revascularization are less
symptomatic, and symptom benefit is most apparent in
patients with severe angina and LV dysfunction (EF ,0.35)
(109,111–117). Perhaps because of the symptomatic relief
associated with surgical revascularization, the “crossover”
from medical treatment to surgery may be of greater
significance in improving quality of life. Medically assigned
patients who had persistent angina despite medical therapy
were able to undergo surgical revascularization and thus
obtain relief of symptoms.
f. Loss of Benefit of Surgery
The meta-analysis based on individual patient data from
all of the available randomized trials indicates a gradually
increasing reduction in mortality over the first 5 to 7 years
when coronary surgery is compared with medical therapy.
After this period, at about the 10- to 12-year follow-up,
there is a tendency of the survival curves to converge. This
decreased long-term benefit has been shown in the individ-
ual studies as well and is likely due to a combination of
factors. First, it is inevitable in studies with long-term
follow-up that survival curves of various treatment groups
will eventually merge. This result has to do with the reduced
life expectancy of patients with coronary disease, regardless
of treatment.
Second, there is an increased event rate in late follow-up
of surgically assigned patients because of the progression of
native and graft disease, with a disproportionate increase in
late surgical mortality. Finally, crossover to surgery of
medically assigned patients is important. Thus, high-risk,
medically assigned patients may gain the “benefit” of surgery
even when assigned to medical therapy. The crossover rate
at 10 years is between 37% and 50%, and this may
contribute to the better survival and improved quality of life
in such “medically assigned” patients.
g. Summary
CABG improves long-term survival in a broad spectrum
of patients at moderate to high risk with medical therapy.
Although a relative risk reduction of ’40% can be expected
overall in comparison with medical therapy, absolute bene-
fits are proportional to the expected risk with medical
therapy. As such, absolute benefit is greatest among those at
highest risk with medical therapy (5-year mortality .20%).
Clinical and angiographic markers of risk, including severity
of CAD, LV dysfunction, and myocardial ischemia, can
identify patients in various risk strata.
D. Comparison With Percutaneous Techniques
Although PTCA was initially used only for the treatment of
single-vessel CAD, advances in technique, equipment, and
experience have resulted in its expanded use for patients
with multivessel disease. In general, PTCA is less invasive
and requires a shorter hospitalization and recovery time than
does bypass surgery. However, the disadvantages of PTCA
as initial therapy for coronary disease include restenosis of
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treated lesions and, compared with CABG, a lesser ability
to revascularize all lesions in patients with multivessel
disease. Recent clinical trials comparing PTCA and CABG
have further defined the relative advantages and disadvan-
tages of these treatments.
1. Overview of Randomized Trials. Nine randomized,
clinical trials comparing PTCA and CABG have been
published (Table 10). Before discussing the results of these
trials, it is important to consider what we can expect to learn
from them. A comparative trial must be large enough to
have sufficient statistical power to detect a difference in
survival, the usual primary end point. If no difference is
observed between CABG and PTCA, it can be concluded
that the treatments are equivalent only if trials are large
enough to reliably detect or exclude relative differences in
mortality of ’20% and include a large number of patients in
whom CABG has been shown to improve prognosis.
Because ’600 deaths would be needed in the “control”
group to exclude a relative risk difference of 20% with 90%
power, trials with ’4,000 moderate- to high-risk patients
per treatment arm would be needed. However, if a 30% risk
difference is considered the smallest clinically important
difference, trials of ’2,000 patients in each group are
required. Unfortunately, all of these trials excluded patients
in whom survival had already been shown to be better with
CABG when compared with medical therapy. Second,
follow-up must be long enough (generally 4 to 5 years) to
detect a survival advantage with either approach. Third, to
reliably compare the 2 treatments, there must be a high rate
of compliance with the original treatment allocation; if a
substantial proportion of patients “cross over” (30% to 40%
by 5 years), the ability to detect differences in survival
decreases markedly. Finally, the patients enrolled in the trial
must be similar to those not enrolled to allow generalization
of the findings. All of the randomized trials fall short of 1 or
more of these criteria. However, the largest of the 9
randomized trials, the Bypass Angioplasty Revascularization
Investigation (BARI), comes closest to fulfilling these cri-
teria and will be discussed in detail (118).
In this trial, 1792 patients with multivessel disease were
randomized at 18 centers to PTCA or CABG. The primary
end point was all-cause mortality at 5 years, and predefined
subgroup analyses were performed for the severity of angina,
the number of diseased vessels, LV function, and lesion
complexity. In addition, a separate analysis of diabetic
patients was added partway through the trial. Baseline
characteristics of the BARI study population included a
mean age of 61 years, mean LVEF of 0.57, a 41%
prevalence of 3-vessel disease, and 26% women; there were
no significant differences between treatment groups. Revas-
cularization was accomplished by PTCA in a mean of 2.4
lesions per patient, with a success rate of 88% for at least 1
lesion, and by CABG with a mean of 2.8 grafts per patient
(82% with an IMA). Stents were not routinely employed
(118). The average postprocedure length of stay was shorter
with PTCA (3 versus 7 days). The rate of in-hospital
Q-wave MI was higher for CABG than for PTCA (4.6%
versus 2.1%, P , 0.05), and 6.3% of PTCA patients
required urgent CABG. At a mean follow-up of 5.4 years,
there was no statistically significant difference in long-term
survival or freedom from MI, but patients initially random-
ized to PTCA had more hospitalizations and required more
repeated revascularization procedures (Table 10). Thirty-
one percent of patients initially assigned to PTCA under-
went CABG during the trial (118). Compared with the
other randomized comparisons, overall mortality in BARI
was higher owing to the inclusion of older patients, more
women, and more patients with multivessel disease and
other comorbidities. This difference underscores the impor-
tance of comparing the methodology of these trials before
discussing their conclusions.
The most important limitation of all of the randomized
trials relates to the generalizability of the conclusions. The
findings are not applicable to all patients with multivessel
coronary disease for 2 reasons. First, only ’5% of screened
patients with multivessel disease were enrolled in the trials
(119,120). In the BARI trial, .25,000 patients with mul-
tivessel coronary disease by diagnostic angiography were
screened for eligibility. About 50% of these patients were
ineligible because of left main disease, insufficient symp-
toms, or other reasons. One third of the remaining 4110
patients had multivessel disease suitable for both PTCA and
CABG, and only half of these (7% of those screened) were
enrolled in the randomized trial (121). Second, examination
of the Emory Angioplasty versus Surgery Trial (EAST)
registry suggests that physician judgment may be an impor-
tant determinant of outcome that is eliminated by a ran-
domized design. In this registry of 450 eligible patients who
refused randomization, survival was slightly better than in
the 392 randomized patients despite similar baseline fea-
tures (122). This may reflect physician judgment, as CABG
was utilized more often in patients with 3-vessel disease and
PTCA more often in patients with 2-vessel disease (122).
The age range (mean age varied from 56 to 61 years) and
sex distribution (’20% female) were similar in most trials,
although the Medicine, Angioplasty, or Surgery Study
(MASS) trial had 42% women (123). All of the randomized
trials excluded patients with low EFs and those for whom
CABG was known to provide a survival advantage. Six trials
included only patients with multivessel disease and 2, only
single-vessel disease (MASS, Lausanne); the Randomized
Intervention Treatment of Angina (RITA) trial included
both (Table 10). Several trials were conducted in single
centers, whereas RITA, the German Angioplasty Bypass-
surgery Investigation (GABI), the Coronary Angioplasty
versus Bypass Vascularization Investigation (CABRI), and
BARI were multicenter. The CABRI and EAST trials
permitted incomplete revascularization, whereas the others
had a goal of complete revascularization. CABRI and RITA
included vessels with total occlusion, accounting for the
lower success rate of PTCA; the success rate for these
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vessels in RITA was only 48%. Asymptomatic patients were
excluded from GABI, and the extent of coronary disease
also varied widely. Three-vessel disease was present in only
12% and 18% of RITA and GABI subjects, respectively,
and present in .40% of BARI and Estudio Randomizado
Argentino de Angioplastia vs Cirugia (ERACI) patients.
The incidence of diabetes mellitus varied from 10% to 12%
(Toulouse, Goy, ERACI, GABI, and CABRI) to .20%
(EAST and BARI).
Finally, the trials used different primary end points and
follow-up periods. Neither CABG nor PTCA has been
shown to reduce the risk of subsequent nonfatal MI, and
therefore inclusion of such an end point would dilute
relative differences and decrease the likelihood of detecting
differences. End points included survival (BARI), freedom
from angina (GABI and Toulouse), freedom from death
and MI (RITA), and other combinations including symp-
toms, stress thallium defects, and repeated revascularization
(Table 10). Most required Q waves and a clinical event to
define an MI, but EAST included “silent” MIs as well.
Follow-up ranged from 1 to 5 years, and only MASS
required angiography in all patients (123). Overall, all of the
trials except BARI were underpowered and lacked sufficient
follow-up.
2. Results of Randomized Trials
a. Acute Outcome
Despite the differences in design and follow-up, the
results of randomized trials comparing PTCA and CABG
have been similar. Procedural complications including death
(1% to 2%) and Q-wave MI (up to 10%) were low for both
procedures but tended to be higher with CABG (Table 10).
A statistically significant increase in MI rate was present
only in GABI and EAST and in two meta-analyses includ-
ing many of the trials (119,124). For patients initially
randomized to PTCA, CABG was needed during the initial
hospitalization for ’6% (range 1.5% to 10%) and was
performed in close to 20% by 1 year (124).
The cost and length of stay were lower for PTCA than
for CABG. In BARI, the cost of PTCA was ’50% of that
for CABG (125,126). The lengths of stay in RITA were 4
and 12 days for PTCA and CABG, respectively (127).
Patients having PTCA returned to work sooner and were
able to exercise more at 1 month (128). The extent of
revascularization achieved with CABG was higher than
with PTCA (118,120). In the EAST trial, the percentage of
revascularizable segments successfully treated was 99% for
CABG versus 75% for PTCA (120). When the comparison
was limited to severe and physiologically important lesions,
the extent of early revascularization was similar, although
this analysis includes the patients who crossed over from
PTCA to CABG (120,129).
b. Long-Term Outcome
There was no significant difference in survival in any of
the nine randomized trials that compared PTCA and
CABG at follow-up periods ranging from 1 to 5 years
(Table 10). BARI was the largest trial with the longest
follow-up. Survival was 89.3% after CABG and 86.3% after
PTCA (118). Although this 2.9% absolute difference was
not statistically significant, the 95% confidence interval was
wide (20.2% to 6.0%), and this study did not establish with
certainty the equivalence of these strategies (130). In fact,
the results are consistent with the level of clinically impor-
tant difference in mortality stated in the protocol (.2.5%
absolute difference) in favor of CABG. A secondary analysis
of 5-year cardiac mortality demonstrated a significant sur-
vival advantage with CABG (95.1% versus 92% in patients
assigned to PTCA), but this difference was not apparent in
nondiabetics (131). The combined end point of cardiac
mortality and MI was similar at 5 years with both treat-
ments (131).
Similarly, none of the trials or meta-analyses were able to
demonstrate a difference in Q-wave MI or the combined
end point of death and MI (Table 10) (119,124). Most trials
found that CABG resulted in greater freedom from angina,
and the difference from PTCA was statistically significant in
EAST, Toulouse, RITA (Figure 5), and CABRI. Exercise
time at 2.5 years was assessed in RITA and favored patients
initially treated by PTCA (191 versus 171 minutes) (127).
Large thallium defects (assessed in EAST) were slightly
more common in PTCA patients at 3 years (120). The
relative risk for angina with PTCA tended to be higher early
but decreased with longer follow-up (124) (Figure 5).
The most striking difference between the treatments was
in the need for subsequent procedures. The rate was four- to
tenfold higher for PTCA in every trial (Table 10). Three
trials (Lausanne, MASS, and ERACI) that included re-
peated revascularization as part of the primary, composite
end point demonstrated a statistically significant reduction
in events with CABG (123,132,133). Eight percent of
CABG patients required additional revascularization within
5 years in BARI, compared with 54% of PTCA patients
(118). Additional procedures were needed earlier in PTCA
patients and included PTCA only (23.2%), CABG only
(20.5%), or both (10.8%) (118).
Several studies have compared quality of life and cost
(125,128,134,135). In RITA, physical activity and employ-
ment were similar for both procedures after 3 years (128). A
BARI substudy including 52% of enrollees found that
functional status assessed by the Duke Activity Index
improved more with CABG early on but was equivalent by
5 years (125). Emotional health and employment were also
similar in this study and others (125,128,134). The early
cost benefit of PTCA decreased during follow-up owing to
the more frequent need for repeated procedures and hospi-
talization approaching the cost of CABG (124,125,134,135).
There appeared to be a greater cost benefit to PTCA in
patients with 2-vessel disease (125). In BARI, it was
estimated that the slight survival advantage of CABG would
cost $26,117/y of added life (125).
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c. Special Subsets
The BARI trial prespecified 4 subsets for analysis. The
primary end point of survival did not differ in these
subgroups based on severity of angina, extent of disease, LV
function, and lesion complexity (118). However, 3-year
cardiac mortality was higher with PTCA in several high-
risk groups (in unstable angina and non–Q wave MI, PTCA
8.8% versus CABG 4.9%; in CHF, PTCA 27.7% versus
16.4% with CABG) (131). The ERACI trial included a
high proportion (83%) of patients with unstable angina, and
there was no difference in survival at 1 year (132).
Data from thrombolytic trials suggesting an adverse effect
of diabetes mellitus on PTCA outcome prompted the
addition of treated diabetes mellitus as a subgroup for
analysis partway through BARI (118,136). This subgroup of
353 patients (19% of total) were more likely to be women or
members of minorities and belong to a lower socioeconomic
class. They also had more severe heart disease and comor-
bidities, but their in-hospital complications were similar to
those in nondiabetics and were also higher for CABG than
for PTCA (136).
All-cause mortality and cardiac mortality were both
higher in diabetics treated with PTCA (34.7% versus 19.1%
and 20.6% versus 5.8%, respectively) (136) (Figure 6). This
benefit of CABG was confined to patients receiving IMA
grafts, which may reflect a selection bias or the low numbers
of patients not receiving IMA grafts. A similar result with
regard to diabetic patients was found in a post hoc analysis
of 122 diabetic patients in CABRI (137), but no difference
was found for diabetics in EAST (120).
Figure 5. Freedom from angina in the Randomized Intervention Treatment of Angina (RITA) trial. Reproduced with permission from (127).
Figure 6. Improved survival with CABG versus PTCA in diabetes
mellitus. Results from the Bypass Angioplasty Revascularization
Investigation (BARI) showing that patients with multivessel cor-
onary disease who were being treated for diabetes at baseline had
a significantly better survival after coronary revascularization with
coronary artery bypass graft (solid curve) than with percutaneous
transluminal coronary angioplasty (dashed curve) (P 5 0.003).
Modified with permission from (136).
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A separate meta-analysis of the randomized trials for
single-vessel disease has also been performed (124). As
expected, the overall risk for events is less than in patients
with multivessel disease. Although the risk of death and MI
was lower with CABG, this finding should be interpreted
with caution, since no such difference was found for mul-
tivessel disease. The need for late CABG was lower in
patients with single-vessel disease, and there was less dif-
ference in angina frequency (124).
d. Results From Nonrandomized Trials and Registries
Much of the debate relating to the finding for a survival
advantage of CABG in treated diabetic patients is based on
the results of nonrandomized trials and registries. Treated
diabetics in the BARI registry who refused randomization
and selected their form of revascularization did not fare
worse with PTCA (138). In a retrospective cohort study
comparing PTCA and CABG for diabetic patients with
multivessel disease and similar age, sex, EF, and severity of
angina, there was also no difference in survival after 6 years
(139). However, in one comparison of CABG and PTCA
in a nonrandomized, observational database, insulin-
requiring diabetics had a lower long-term survival after
treatment with multivessel PTCA (140). Limitations of this
conclusion include the unknown adequacy of glucose con-
trol and the absence of a survival advantage for CABG
when patients in the randomized trials are pooled and in
other, nonrandomized registries (141).
The majority of patients in the randomized trials had
angina. A small trial that demonstrated improved outcomes
with revascularization compared with medical therapy in
patients with asymptomatic ischemia also examined the
relative benefits of the type of revascularization (142). In
this nonrandomized trial, CABG provided superior relief of
exercise-induced as well as ambulatory ischemia compared
with PTCA (143).
A more compelling report was recently published by
Hannan et al (144), which described a 3-year survival
analysis of the ’30,000 patients enrolled in the New York
State PTCA registry compared with that of ’30,000
patients in the CABG registry from 1993 to 1995. As
opposed to the randomized trials, this large experience
showed survival benefit for patients receiving CABG when
proximal LAD stenosis was .70%, regardless of whether
1-, 2-, or 3-vessel disease was present (Figures 7A and 7B
and Table 11). Patients with 3-vessel disease not involving
the proximal LAD also fared better with CABG than with
PTCA. Patients with 1-vessel disease without severe prox-
imal LAD stenosis had better survival with PTCA. Several
potential limitations of this experience deserve comment.
Unmeasured differences in patient severity not accounted
for in the risk-adjustment method could have affected the
conclusions. Similarly, physicians’ choice of treatment may
have been based on unmeasured patient factors. Finally,
coronary stents were utilized in just 11.8% of PTCA
patients.
e. Conclusions
For patients included in the randomized trials, CABG
provided better relief of angina with a lower need for
subsequent procedures. Initial complications are higher with
CABG, as is the cost and length of hospitalization. Patients
may return to work sooner after PTCA but are subsequently
hospitalized more often, thus generating similar, overall,
long-term costs. Randomized trials do not show any differ-
ence in late death or rate of MI, except possibly in patients
with treated diabetes mellitus, for whom CABG may be
superior. Contrariwise, data from large registries, particu-
larly that of New York State, suggest that patients with
severe, proximal LAD stenosis and/or 3-vessel disease may
achieve improved survival with CABG. Patients with
1-vessel disease not involving severe, proximal LAD disease
may do better with PTCA.
Several important caveats and limitations to these con-
clusions must be discussed. Since completion of the trials,
the influence of new technology, particularly on PTCA, has
been considerable. Intracoronary stents are now used in 50%
or more of percutaneous coronary interventions and have
reduced the need for both urgent CABG and subsequent
procedures by as much as 50% (145). Continuing advances
in PTCA and stent designs, including the use of brachy-
therapy (local radiation), will likely further reduce the need
for repeated procedures. Medical management of athero-
sclerosis, both before and after revascularization, has con-
tinued to evolve, with greater use of b-blockers and
angiotensin-converting enzyme inhibitors after MI and the
introduction of statins and other lipid-lowering agents. The
recent ability to select patients for revascularization proce-
dures by using a methodology that can separate scarred from
viable myocardial segments will undoubtedly alter the out-
comes from these procedures. Other recent changes in
patient management that may influence these conclusions
include the use of platelet glycoprotein IIb/IIIa inhibitors
during percutaneous interventions, the more frequent use of
IMA grafts, and the emergence of less-invasive surgical
approaches.
It is likely that during the progress of their disease, many
patients will benefit from a combined application of percu-
taneous and surgical techniques, taking advantage of the low
morbidity of percutaneous methods and the established
long-term benefit of surgical revascularization with arterial
conduits.
IV. MANAGEMENT STRATEGIES
A. Reduction of Perioperative Mortality and Morbidity
One of every $10 spent on surgical treatment of coronary
disease is related to a complication: a sum of 1 billion dollars
annually in the United States (148). Careful evaluation of
patient characteristics should lead to proper risk stratifica-
tion and the identification of areas for risk neutralization.
Some risk factors that at first appear immutable may in fact
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Figure 7. A, 95% Confidence interval for ln (adjusted hazard ratio)
of PTCA patient death: CABG patient death within a three-year
period (excluding patients with myocardial infarction [MI] ,24 h
before the procedure). For sample size within each anatomic
cohort, see Table 10. (Reprinted with permission from [144].) B,
Differences in adjusted percent survival at 3 years: percent CABG
survival minus percent PTCA survival. Solid bars show statistically
significant differences.
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be markers or surrogates for conditions that can be modi-
fied. The incremental incorporation of new advances can
lead to coronary bypass results that are superior to those of
the past. The following discussion formalizes this mind-set
of risk neutralization to maximize the margin of safety for
coronary bypass.
1. Reducing the Risk of Brain Dysfunction After Coro-
nary Bypass. As discussed in Section IV, A, one of the
most devastating complications of coronary bypass surgery is
perioperative stroke. In addition to patient morbidity and
mortality, there are indirect costs through lost productivity;
the direct economic cost of a stroke ranges from $90,000 to
$228,000 over a patient’s life span (149–151). Postoperative
stroke is the second most common cause of operative
mortality (after low cardiac output state) (152). The inci-
dence of stroke after coronary operation is related to
increased age (Figure 8A) (153), which parallels the accel-
erated involvement of the aorta and great vessels with
atherosclerotic plaque (Figure 8B) (152). Age per se is less
important than atherosclerosis, which plays a role in at least
two thirds of adverse events after coronary bypass.
As discussed in Section III, A3, post-CABG neurological
events can be classified into type 1 injuries, which are
predominantly focal stroke, transient ischemic attack, and
fatal cerebral injuries, and type 2 events, which reflect a
more global/diffuse injury, with disorientation or immediate
(and usually reversible) intellectual decline.
a. Type 1 Neurological Injury
Type 1 injury occurs in 3.1% of patients, is responsible for
a 21% post-coronary bypass mortality rate, 11 days in the
intensive care unit, 25 days in hospital, at least an additional
$10,266 in hospital boarding charges, and a cost of 5 to 10
times the in-hospital charge for rehabilitative and outpatient
support (51,148).
(1) Aortic Atherosclerosis and Macroembolic Stroke
The surgeon’s identification of an atherosclerotic ascend-
ing aorta is the single, most significant marker for an adverse
cerebral outcome after coronary bypass operations (OR 4.5,
P , 0.05) (51), reflecting the role of aortic atheroembolism
as the cause of ischemic stroke (157–161). Since the early
days of the operation, atheroemboli and calcific debris have
been detected in the cerebral circulation in patients dying
after coronary bypass surgery (162). Since the average age of
patients having coronary bypass is increasing, perioperative
atheroembolism from aortic arch plaque is also increasing
and is likely responsible for ’1 in 3 strokes after coronary
bypass (163). This risk is particularly increased in patients
beyond 75 to 80 years old (53) (Figures 8B and 8C). Most
perioperative cerebral atheroembolization likely arises intra-
operatively from manipulation of the ascending or trans-
verse aorta during cannulation, clamping, or placement of
proximal anastomoses or from the blast effect of the flow
from the aortic cannula (156,164). Preoperative, noninva-
sive testing for detection of the high-risk patient has limited
sensitivity. Computed tomography identifies most severely
involved aortas but underestimates mild to moderate in-
volvement compared with echocardiography (159,165).
TEE is useful for aortic arch examination, but evaluation of
the ascending aorta is somewhat limited by the intervening
trachea (166). The intraoperative assessment of ascending
aortic atheroma by epiaortic imaging (in which the imaging
TABLE 11. Three-Year Survival by Treatment in Each Anatomic Subgroup
Coronary Anatomy Group
Patients,
n
Survival
P
Observed,
%
Adjusted,
%
1-Vessel, no LAD CABG 507 89.2 92.4 0.003
PTCA 11 233 95.4 95.3
1-Vessel, nonproximal LAD CABG 153 95.8 96.0 0.857
PTCA 4130 95.7 95.7
1-Vessel, proximal LAD CABG 1917 95.8 96.6 0.010
PTCA 5868 95.5 95.2
2-Vessel, no LAD CABG 1120 91.0 93.0 0.664
PTCA 2729 93.4 92.6
2-Vessel, nonproximal LAD CABG 850 91.3 92.3 0.438
PTCA 2300 93.3 93.1
2-Vessel, proximal LAD CABG 7242 93.5 93.8 ,0.001
PTCA 2376 92.8 91.7
3-Vessel, nonproximal LAD CABG 1984 90.1 90.3 0.002
PTCA 660 86.7 86.0
3-Vessel, proximal LAD CABG 15 873 90.1 90.3 ,0.001
PTCA 634 88.2 86.1
LAD indicates left anterior descending coronary artery; CABG, coronary artery bypass graft; and PTCA, percutaneous
transluminal coronary angioplasty. Comparative observed and adjusted 3-year survival of patients treated with PTCA or CABG
in various anatomic subgroups. Reprinted with permission from New York State registry as published in (144).
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probe is placed directly on the aorta) is superior to both
TEE and direct palpation (166).
Nevertheless, TEE identification of a mobile arch ather-
oma in coronary bypass patients was associated with a 33%
stroke rate versus 2.7% in patients with nonmobile plaque
(P 5 0.01) (167). Intraoperative palpation is notorious for
its underestimation of the high-risk aorta (166). Palpation
detected only one third of atherosclerotic lesions identified
by epivascular echocardiography (165). The aortic pattern
with the highest risk is the protruding or mobile aortic arch
plaque, and this eludes intraoperative palpation in 80% of
cases (168). Intraoperative epivascular echocardiography
represents an important advance and is now used in many
centers for intraoperative diagnosis and stroke risk reduction
(165,169). The technique is highly sensitive and specific for
identification of the high-risk aorta.
An aggressive approach to managing patients with se-
verely atherosclerotic ascending aortas identified by intra-
operative echocardiographic imaging appears to reduce the
risk of postoperative stroke (56,170). Twelve hundred of
1,334 consecutive open heart patients (88% with coronary
disease) underwent screening intraoperative epivascular
echocardiography. These findings led to a change in intra-
operative technique in 19.3% of patients. In patients with
#3-mm wall thickening, standard techniques were used.
When the aorta demonstrated a .3-mm thickening, the
cannulation, clamp, or proximal sites were changed, or a
no-clamp fibrillatory arrest strategy (171) was used. For
high-risk patients with multiple or circumferentially in-
volved areas or those with extensive mid-ascending aortic
involvement, the ascending aorta was replaced under hypother-
mic circulatory arrest. The 27 high-risk patients had no strokes
and a mortality rate of just 3%. Among patients with a
moderately to severely involved aorta treated with the less-
radical approaches, the incidence of stroke was 6.3%. When
epivascular echocardiography showed no or mild atheroscle-
rotic disease, the stroke incidence was low, 1.1% (56,171).
In a smaller study of epivascular echo-directed manage-
ment, 195 consecutive coronary bypass patients were com-
pared with a control group of the previous consecutive 165
Figure 8. A, Incidence of permanent, focal, central nervous system injury after coronary bypass is strongly correlated with increasing age
(56,153–155). B, Ascending aortic atherosclerosis is a powerful marker of increased risk for perioperative stroke in the coronary bypass
population and increases directly with age. C, Strong correlation between perioperative atheroembolism and the degree of atherosclerotic
involvement of the ascending aorta. The solid line represents severe atherosclerotic involvement and the interrupted line, lesser
involvement. D, Extracranial cerebrovascular disease is a significant contributor to stroke after coronary bypass and is strongly correlated
with age, suggesting a population for aggressive preoperative screening (184,202,203). Reproduced with permission from (156).
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patients for whom only the surgeon’s palpation was used to
evaluate the aorta. Ten percent of the epivascular group had
the intraoperative technique modified versus 3% of the
control group. The most common change in operative
approach was use of a no-clamp, cold fibrillatory arrest
technique. Three percent of the control group had strokes
compared with none of the epivascular echo-managed group
(P , 0.02) (54).
With a no-clamp technique, the surgeon may completely
revascularize the heart with standard in situ IMA and
aortically based SVGs, typically constructing a single, prox-
imal anastomosis during a brief period of total circulatory
arrest on a safe area of the aorta. Alternatively, the surgeon
may use an all-in situ arterial revascularization approach, or
SVGs may be grafted onto the in situ IMA by using an
end-vein to side-artery anastomosis (163,172).
Preoperative risk assessment may identify a small popu-
lation of patients with such extensive aortic atherosclerosis
and poor outlook that benefit from coronary bypass would
appear to be very small. This population is difficult to define,
but a starting point may include patients with aortic plaques
$4 mm or with certain morphologies that are associated
with only a 20% chance at 4 years of freedom from
peripheral embolism, MI, recurrent stroke, or death (161).
This risk, along with an extremely high perioperative risk,
would argue for nonoperative treatment. However, if the
cardiac risk of medical therapy is high (5-year mortality
.20%), alternative forms of revascularization should be
considered. These include off-bypass surgery; minimally
invasive direct CABG (MID-CAB) without CPB, with or
without concomitant PTCA; and exclusive percutaneous
revascularization. These techniques may provide the benefit
of revascularization in such high-risk patients while mini-
mizing the perioperative risk of stroke.
(2) Atrial Fibrillation and Postoperative Stroke
Chronic atrial fibrillation is a hazard for perioperative
stroke as a result of cardioarterial thromboembolism. Intra-
operative surgical manipulation or spontaneous resumption
of sinus rhythm early in the postoperative period may be
associated with embolism of a left atrial clot. One potential
approach to reduce atrial fibrillation-associated embolism is
the performance of preoperative TEE. Absence of a left
atrial clot would suggest that the operation may proceed
with acceptable risk. If a left atrial clot is identified, 3 to 4
weeks of anticoagulation, restudy, and then subsequent
operation is a rational approach if the clinical situation
allows this. Unfortunately, few clinical trial data are avail-
able to assist physicians in the best management for this
situation.
New-onset postoperative atrial fibrillation occurs in ’30%
of patients undergoing CABG (173–175), with the peak
incidence on the second to third postoperative day (176). It
is associated with a 2- to 3-fold increase in postoperative
risk for stroke (177,178). Patients at risk for postoperative
atrial fibrillation have been identified and include those with
COPD, proximal right CAD, prolonged cross-clamp time,
atrial ischemia, advanced age, and withdrawal of b-blockers.
Identifying at-risk patients and directing treatment to these
patients (see Section IV, A5) appears to be effective in
reducing the incidence of post-CABG atrial fibrillation and
thus, the morbid complication of postoperative strokes
associated with this arrhythmia. Minimally invasive proce-
dures may also reduce the incidence of postoperative atrial
fibrillation (179).
The role of anticoagulation in patients who develop
post-CABG atrial fibrillation is unclear. In general, an
aggressive anticoagulation and cardioversion philosophy
may reduce the neurological complications associated with
this arrhythmia. Early (within 24 hours of onset of atrial
fibrillation) attempts at cardioversion can probably be safely
performed without anticoagulation. However, if the ar-
rhythmia persists beyond this time, it may be advisable to
use intravenous heparin while cardioversion is attempted. If
the atrial fibrillation persists, anticoagulation with Couma-
din on an outpatient basis may be necessary, with further
attempts at cardioversion determined by the individual
patient profile.
(3) Recent Anterior MI, LV Mural Thrombus, and
Stroke Risk
The patient with a recent, anterior MI and residual
wall-motion abnormality is at increased risk for develop-
ment of an LV mural thrombus and its potential for
embolization. Keren et al (180) identified LV thrombus in
38 of 124 anterior-infarct patients (31%) and in none of 74
patients with inferior infarcts (P , 0.001). Early thrombo-
lytic therapy was not uniformly protective against LV
thrombus, and 30% occurred after discharge. Such patients
are at risk for perioperative mechanical dislodgement and
systemic embolization of the LV clot. Preoperative screen-
ing with echocardiography may demonstrate the clot and
allow delay of the operation for long-term anticoagulation
and reevaluation by echocardiography to ensure resolution
or organization of the thrombus before operation. Also,
long-term (3 to 6 months) anticoagulation appears prudent
for the patient with persistent anterior wall-motion abnor-
malities after coronary bypass. LV thrombus may recur in
patients receiving short-term (2 months) anticoagulation.
Apical akinesis at 10 days after infarction was a strong
predictor for subsequent thrombus formation, which con-
ferred an increased risk for subsequent stroke (181).
(4) Recent Antecedent Cerebrovascular Accident
A recent, preoperative cerebrovascular accident presents
another situation in which delaying the operation may
reduce the perioperative neurological risk. Evidence of a
hemorrhagic component to the cerebrovascular accident,
based on the results of a computed tomography scan,
identifies those patients at particular risk for extension of the
neurological damage due to cardiopulmonary bypass (182).
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It is generally believed that a delay of 4 weeks or more is
prudent if coronary anatomy and symptoms permit.
(5) CPB Time and Neurological Risk
Increased time on CPB is closely correlated with adverse
neurological outcome, emphasizing the need for an orga-
nized, expeditious operation. On average, patients without
postoperative neurological events have shorter pump times
than those who develop postoperative stroke (183).
(6) Carotid Disease and Neurological Risk Reduction
The problem, rationale, and strategy for concurrent
treatment. Carotid disease is significantly associated with a
type 1 neurological outcome (P 5 0.001) (51). Hemody-
namically significant carotid stenoses are associated with as
many as 30% of early postoperative coronary bypass strokes
(154). Strokes caused by carotid disease are particularly
devastating, since they often occur on the second to ninth
postoperative day in the midst of an apparently smooth
recovery (155). The trend for coronary surgery to be
performed in an ever-increasingly elderly population under-
scores the importance of the issue (Figure 8D). The
prevalence of significant carotid disease in the current
cardiac surgical population reflects the diffuse nature of the
atherosclerotic process: 17% to 22% of patients have $50%
carotid stenosis, and 6% to 12% have $80% carotid stenosis
(184,185). Perioperative stroke risk is #2% when carotid
stenoses are ,50%, 10% when stenoses are 50% to 80%, and
11% to 18.8% in patients with stenoses .80% (56,186).
Although the patient with untreated, bilateral, high-grade
stenoses or an occluded carotid artery and contralateral
high-grade stenosis is rare, such patients have a 20% chance
of stroke (187,188).
Conversely, the leading cause of short- and long-term
risk for patients having surgical treatment of carotid disease
is the associated coronary disease (189–192). Coronary
bypass is the most effective treatment for many of these
patients. In the proper hands, prophylactic carotid endar-
terectomy is superior to conservative therapy for prevention
of stroke in symptomatic or asymptomatic patients with
high-grade carotid stenoses (193–195).
With proper teamwork, carotid endarterectomy for high-
grade stenosis preceding or coincident with a coronary
operation can be associated with a low risk for short- and
long-term neurological sequelae (155,187,189,196) (Figure
9). Carotid endarterectomy done before or concomitant
with coronary bypass carries a low mortality (3.5%), reduces
early postoperative stroke risk to ,4%, and confers a
10-year freedom from stroke of 88% to 96% (187,196,197).
Special interest in this problem among caregivers and
careful collaboration between the carotid and coronary
surgical teams are keys to success. Also, stroke and mortality
rates after carotid endarterectomy are inversely related to
institutional volume (198,199).
Who should undergo carotid screening? The absence of
symptoms referable to carotid disease is not reassuring: a
carotid stenosis of $75% in an asymptomatic patient is an
independent predictor of stroke risk immediately after
coronary bypass (OR of 9.87, P , 0.005) (154,155). The
presence or absence of a cervical bruit is poorly predictive of
a high-grade stenosis even in the setting of known symp-
tomatic carotid disease (sensitivity 63%, specificity 61%)
(200).
A prospective examination of preoperative carotid duplex
scans in 1087 open heart–surgical patients aged 65 or older
defined the markers associated with important ($80%)
carotid stenosis: female sex, PVD, previous transient isch-
emic attack or stroke, smoking history, or left main disease
(P , 0.05) (184). If all patients with at least one of these
risk factors were screened, 95% of those with an 80%
stenosis would be detected and 91% of those with a 50%
stenosis would be detected. Unfortunately, this would lead
to screening in 85% of patients aged 65 years or older. This
example illustrates the correlation of carotid stenosis with
age and suggests that the lower limit of age at which carotid
screening will be cost-effective is not yet known. For safety
and simplicity, many centers screen all of those aged 65 or
older. The strong association between left main disease and
carotid stenosis argues that left main patients should be
screened at any age. Similarly, those with a previous
transient ischemic attack or stroke should receive carotid
screening independent of age. Preoperative CNS symptoms
suggestive of vertebrobasilar artery insufficiency should lead
to evaluation by magnetic resonance angiography.
Surgical tactics to reduce the risk for concurrent carotid/
coronary disease. When surgical treatment of concurrent
carotid and coronary disease is planned, the procedures may
Figure 9. Contemporaneous surgical treatment of carotid and
coronary disease is associated with an excellent long-term out-
come. The graph shows freedom from stroke, myocardial infarc-
tion, and death over time. Reproduced with permission from
(196).
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be done in either a combined (same operative setting, carotid
to precede coronary revascularization) or staged fashion. The
staged approach is most commonly used, particularly in
patients with noncritical coronary anatomy. Postoperative
care is rendered in a telemetry setting, with special attention
to prevent postoperative myocardial ischemia. Coronary
bypass follows in 1 to 5 days with the use of standard
techniques. The superiority of the combined versus staged
approach has not been established by prospective trials.
Thus, current tactics are best left to local team policies and
preferences based on careful examination of team outcomes.
An individualized, patient-specific, selective approach with
the decision based on symptoms and the relative severity of
extracranial cerebrovascular disease and coronary disease
appears prudent and is used in many institutions. The
results of these approaches in a collation (196) of 7 pub-
lished series, each with $100 patients, published from the
mid-1980s to the mid-1990s had an overall mortality of 4%
and permanent neurological deficit in 3.4% of patients.
Some observational series have suggested that combined
carotid/coronary operations carry a higher risk for in-
hospital stroke and mortality compared with patients in the
same institution having a staged procedure (201). These
studies may be confounded by selection bias toward recom-
mending combined operations in patients with more ad-
vanced carotid and coronary disease. Contrariwise, a recent,
single-center series in which a combined operation for all
patients with concurrent carotid and coronary disease was
used suggested this approach to be safe and to have low
overall resource requirements (196).
Stroke risk appears to be increased when the so-called
reverse-staged procedure is used. In this strategy, the coro-
nary bypass precedes the carotid endarterectomy by $1 day
during the same hospitalization. A prospective, randomized
trial that evaluated this approach demonstrated a stroke risk
of 14% when carotid operation followed rather than pre-
ceded (2.8%, P , 0.05) coronary bypass, whereas mortality
rates were similar (204). It is generally accepted that cerebral
revascularization should precede coronary revascularization
when significant carotid disease is known, except in the
uncommon situation of the truly emergency coronary bypass
patient in whom carotid endarterectomy should then closely
follow the heart operation.
Most workers in the field have focused on in-hospital
neurological outcomes for treatment of combined carotid
and coronary disease. Recent multicenter trials have shown
an advantage of surgical over medical management for
significant carotid stenosis in either symptomatic or asymp-
tomatic patients (193,205–207). These data argue for an
aggressive surgical approach in this population and demand
a longer-range vision. The long-term outlook for combined
treatment of carotid and coronary disease is shown in Figure
9. The above-suggested strategy for carotid disease manage-
ment in the setting of coronary bypass is in concordance
with Guidelines for Carotid Endarterectomy: A Multidisci-
plinary Consensus Statement From the Ad Hoc Committee,
American Heart Association [Special Report] (208). The suc-
cess of this long-term strategy is predicated on assembling a
team that can achieve excellent near-term carotid and
coronary surgical results (198,199,209–211).
Summary. Epivascular echocardiographic detection of
ascending or transverse aortic atherosclerosis and modifica-
tion of operative technique hold great promise for signifi-
cant stroke risk reduction. In the current era, important
concurrent carotid and coronary disease should be sus-
pected, sought by screening, and, when found, managed
surgically (Table 14). This strategy neutralizes the short-
term risk of treatment of either disease alone and enhances
long-term quality and length of life for the patient with
generalized atherosclerosis.
b. Type 2 Neurological Injury
Type 2 neurological complications occur in 3.0% of
patients and are correlated with a 10% post-coronary bypass
mortality rate, an average of 7 days in the intensive care unit
and 20 days in hospital, and at least an additional $6150 of
in-hospital charges. Forty percent of these patients incur
additional costs as a result of the need for transitional care
after hospital discharge (51,148).
Abnormal neurocognitive function is frequently present
preoperatively in the coronary bypass population (212).
There is a further decline in neurocognitive function after
any major operation in this population, but this decline is
likely worse and more persistent after operations employing
CPB (46). This deficit usually improves over time, such that
by 2 months’ follow-up, there is little to no difference
between patients having undergone major operations with-
out extracorporeal circulation compared with coronary by-
pass patients with extracorporeal circulation. Both groups
frequently show subtle neurological and neuropsychological
impairment (213–216).
(1) Reducing the Risk of Microembolization
Microembolization is a major contributor to postopera-
tive cerebral dysfunction after coronary bypass (217,218).
Transcranial Doppler examination of the middle cerebral
artery of patients on extracorporeal circulation suggests that
most emboli occur during surgical manipulation (clamping,
cannulation) of the ascending aorta (217,219,220). Many of
these emboli appear to be gaseous, either derived from the
oxygenator or entrained directly from the ambient atmo-
sphere. Postmortem examination of the brains of patients
dying soon after CPB has shown diffuse, small, capillary-
arteriolar dilatations (221). These vacuolated vascular ab-
normalities have also been seen after catheter manipulation
of the ascending aorta, suggesting an atheroembolic etiol-
ogy. Small gaseous or lipid emboli could also be responsible
for the findings. Neuroanatomists have postulated that these
could impair circulation and lead to the neurocognitive
decline seen after CPB.
The number of microemboli delivered during CPB is
correlated with the postoperative neurocognitive decline
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seen immediately and 8 weeks after CPB (222). The use of
a 40-mm arterial-line filter in the heart-lung machine circuit
appears to be protective. Type 2 neurological outcomes may
be further reduced by routine use of the membrane oxygen-
ator rather than the less-expensive bubble oxygenator,
which is still used selectively in the United States
(183,223,224).
(2) Cerebral Hypoperfusion and Neurological Outcome
Intraoperative electroencephalographic monitoring can
detect electrical patterns suggestive of cerebral hypoperfu-
sion and allow real-time intraoperative correction. De-
creases from 29% to 44% to 4% to 5% in postoperative
neurocognitive and neuropsychological dysfunction (type 2)
have been demonstrated by intraoperative electroencepha-
lographic monitoring (225,226). However, the level of
training necessary for interpretation of the electroencepha-
logram and the poor suitability of current technology for the
operating room currently preclude its general clinical use for
detection of hypoperfusion. Also, the electrical changes
associated with microembolization and macroembolization
are at the limits of resolution. The limitations cited rein-
force the importance of strategies to prevent embolization.
Cerebral blood flow during CPB is kept relatively con-
stant over a wide range of systemic arterial pressures with
the alpha-stat extracorporeal circulation acid-base manage-
ment technique. The incidence of persistent, postoperative
neurocognitive deficits at 2 months with the use of this
technique is significantly less compared with the alternative
(pH-stat) technique (27% of patients versus 44%, P 5
0.047) (227).
(3) Potentiators of Adverse Neurological Outcome
If neuroprotective mechanisms fail, there are strategies to
minimize damage to the marginally perfused cerebral tissue,
which has the potential for recovery. Cerebral hyperthermia
potentiates the damage of an acute neurological injury. In
the recent evolution of warm-heart surgery, some centers
used techniques that had the potential for intraoperative
cerebral hyperthermia. Techniques that have the patient
“drift” on CPB toward ambient temperatures (34°C to 35°C
or lower) rather than immediate warming (to maintain strict
normothermia) allow an improved margin of neurological
safety (228–231). Hyperglycemia may also amplify the
impairment caused by an acute neurological event, empha-
sizing the importance of meticulous perioperative glucose
monitoring and control (231).
Cerebral edema that may be present in patients immedi-
ately after extracorporeal circulation (232) may also poten-
tiate CNS damage. Efforts to reduce the potential for brain
swelling include maintenance of an unobstructed pathway
for venous drainage to the CPB reservoir while on the
pump. Anti-inflammatory strategies for CPB may reduce
interstitial edema and are discussed subsequently, but pul-
satile perfusion does not appear to be protective (233–235).
2. Reducing the Risk of Perioperative Myocardial Dys-
function. Most modern myocardial protection techniques
allow the coronary bypass patient to leave the operating
room without a significant perioperative decrement in
myocardial performance. Ideally, the surgeon is familiar
with the broad range of myocardial protection principles
that allow the adaptation of technique to accommodate
varying patient presentations (236,237). There is no substi-
tute for a well-orchestrated, technically sound, expeditious
operation to minimize risk.
a. Myocardial Protection for the Patient With Satisfactory
Preoperative Cardiac Function
The wide latitude of techniques associated with excellent
results for the majority of coronary bypass patients is
testimony to the fact that there is no “ideal” or universally
applicable myocardial protection technique (238). The
greater the myocardial functional reserve in the patient
population studied, the more difficult it is to demonstrate
differences in myoprotective techniques. A variety of stud-
ies, including prospective trials, confirm the safety of many
variations of cardioplegic arrest, which is the most widely
used method for intraoperative myocardial protection. A
single-center trial of cold crystalloid versus warm blood
cardioplegia in 1001 elective coronary bypass patients dem-
onstrated a low, perioperative MI rate (1.4% warm versus
0.8% cold, NS), IABP use (warm 1.4% versus cold, 2.0%,
NS), and mortality (1.0% warm versus 1.6% cold, NS) with
either technique (236). Advances in the understanding of
myocardial and endothelial metabolism, temperature man-
agement, chemical/electrolyte composition, sanguineous or
asanguineous delivery media, substrate enhancement, con-
trol of conditions of reperfusion, and delivery route have all
led to important incremental advances in patient outcome
(239–242). Certain techniques, however, offer a wider
margin of safety for special patient subsets.
b. Myocardial Protection for Acutely Depressed Cardiac
Function
In contrast to the patient with normal myocardial func-
tion, it is easier to demonstrate benefit from specialized
protocols (243,244) in the patient with an acutely injured
ventricle. One multicenter study of emergency coronary
bypass for patients with acute coronary occlusion (some with
cardiogenic shock) demonstrated that controlled, surgical
reperfusion with prompt, vented CPB and substrate-
enhanced sanguineous cardioplegic technique led to a 96.1%
survival, which approaches that seen in low-risk, elective
coronary bypass series (245). Preoperative regional wall-
motion abnormalities improved after bypass in 87% of these
patients despite an average of .6 hours from infarct to
revascularization.
Another observational study compared consecutive pa-
tients receiving cold crystalloid cardioplegia with a warm
blood technique that did not include substrate enhancement
in emergency coronary bypass after failed angioplasty. There
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was a significant reduction in MI with the sanguineous
technique (65% infarcts with crystalloid versus 26% for
blood, P , 0.007) (246). Multivariate analysis confirmed
normothermic blood cardioplegia as an independent predic-
tor of freedom from infarct in this study (P , 0.005).
Prospective, randomized trials have shown a survival benefit
for patients treated with blood cardioplegia compared with
crystalloid cardioplegia in the setting of urgent revascular-
ization for unstable angina. In one trial, the operative
mortality (0% versus 5%), incidence of MI (4% versus
13.5%), and low-output syndrome (10% versus 19%) were
favorably reduced in patients receiving blood cardioplegia
versus crystalloid (247). Multivariate analysis confirmed that
crystalloid cardioplegia (P 5 0.008) was a significant,
independent predictor of postoperative morbidity when
compared with warm blood cardioplegia (248).
c. Protection for Chronically Dysfunctional Myocardium
Severe LV dysfunction is an important risk factor for
patients undergoing coronary bypass (249). Efforts to doc-
ument reduction of risk in this cohort are confounded by
incomplete data on the prevalence of reversibly ischemic
systolic dysfunction (hibernating myocardium) and the con-
tribution of improved function from revascularization of
myocardium as opposed to myocardial protection strategies
(250). There is an emerging consensus, however, that for
the chronically impaired ventricle, there is an added margin
of safety provided by blood cardioplegic techniques (250–
252). Its theoretical advantages include superior buffering
capacity, rheological considerations at the capillary level,
and free-radical control when compared with crystalloid
cardioplegia.
d. Adjuncts to Myocardial Protection
The use of prophylactic IABP as an adjunct to myocardial
protection may decrease mortality and overall resource
utilization in certain high-risk patients. A retrospective
evaluation of 163 consecutive patients with an LVEF of
#0.25 demonstrated a 4-fold reduction in 30-day mortality
in patients treated with IABP. Thirty-day mortality was
2.7% in patients who received a prophylactic IABP placed
preoperatively versus 11.9% for patients not receiving a
balloon (P , 0.005). IABP use was also associated with a
shorter hospital stay and lower hospital charges (253). A
recent, randomized trial confirmed the benefit of preoper-
ative IABP support in high-risk patients. Placement of the
IABP immediately before operation afforded similar protec-
tion to that accompanying placement the day before bypass
surgery (254,255).
Appreciation of the role of the activated leukocyte in the
genesis and exacerbation of myocardial reperfusion injury
has led to strategies to remove leukocytes from the coronary
blood flow. Clinical studies of leukocyte depletion have
shown significant benefit to myocardial performance in the
hypertrophied LV and in those with acute or chronic
ischemia (256–260). However, leukocyte depletion as an
adjunct to myocardial protection/reperfusion strategies has
yet to achieve widespread recognition and use among
surgeons; therefore, no consensus statement is appropriate
at this point.
The long-term survival benefit afforded by use of the
IMA is well recognized (12,261). Less appreciated is the
reduction in immediate, operative mortality associated with
the use of the mammary artery as opposed to saphenous
revascularization. Its use may thus be considered an adjunct
to myocardial protection. Its use should be encouraged in
the elderly (262,263), the emergent/acutely ischemic patient
(264), and other subgroups that previously were thought not
to receive its immediate and long-term benefit. The large,
coronary bypass database available to the STS (265) was
analyzed for the influence of use of the IMA on operative
mortality. Use of the IMA was associated with reduced
operative mortality in all subgroups analyzed with regard to
age (P , 0.005), sex (P , 0.005), priority of operation (P ,
0.005), normal (P , 0.01) or reduced (P , 0.005) LV
function, diabetics (P , 0.005), obese patients (P , 0.005),
history of previous infarct (P , 0.005), previous PTCA
(P , 0.001), and any pattern of coronary anatomy (P ,
0.005). Multivariate analysis also confirmed use of the IMA
as an independent predictor of operative survival (P ,
0.0025). When risk factors were combined, the only groups
found to have similar operative mortality between use/
nonuse of the IMA were elective and nonelective reoperative
patients .70 years of age.
e. Reoperative Patients
For patients undergoing repeated CABG surgery who
previously have had a left IMA-to-LAD graft, a concern
has been the inadvertent transection of the graft during
sternotomy. However, one report from a high-volume
center showed that experienced surgeons rarely encountered
this complication (,3%) (266). The risk of death or serious
myocardial dysfunction related to atheroembolism from
patent, diseased SVGs is low in the current era and is
attributable to recognition of the problem and careful
operative techniques by experienced surgeons who encoun-
ter an increasing percentage of reoperative candidates in
their practices (266). A risk-neutralizing strategy in this
situation is the use of retrograde delivery of cardioplegia.
This procedure allows early exclusion of atherosclerotic
SVGs from the coronary circulation, as they are no longer
needed to deliver cardioplegia.
f. Inferior Infarct With Right Ventricular Involvement
Right ventricular (RV) failure secondary to an ischemic
RV (either infarction or stunning) presents a particularly
hazardous situation (267). The prototypical patient has an
occluded right coronary artery proximal to the major RV
branches and presents with an inferior MI with or without
recognized RV failure (268–272). Angiography may dem-
onstrate that the coronary anatomy is best treated surgically,
but the opportunity for maximal benefit of an emergency
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operation (initial 4 to 6 hours) has often passed. There is
substantial risk in operating after this small window of
opportunity but before the recovery of RV function, which
usually occurs at 4 weeks after injury (273). During this
postinfarct month, the RV is at great risk for severe
postoperative dysfunction, which often requires extraordi-
nary levels of perioperative pharmacological and mechanical
support and has a very high mortality. The nonsurgical
postinfarction patient can most often be supported with
pacing, volume loading, and judicious inotropic administra-
tion (274). In the surgical setting, the RV takes on different
characteristics. There is loss of the pericardial constraint
immediately on exposing the heart, which results in acute
dilatation of the dysfunctional RV. The RV often fails to
recover in this setting, even when state-of-the-art myocar-
dial protection schemes and revascularization are employed
(275). The parallel effects of RV dilatation and dysfunction
on LV diastolic and systolic function are magnified and may
be associated with the need for high levels of support,
inability to close the chest owing to cardiac dilation, need
for ventricular-assist devices, prolonged convalescence,
transplantation, or death (276).
The best defense is an index of suspicion and recognition
of the RV dysfunction by physical examination (277,278),
electrocardiography (right precordial leads), echocardiogra-
phy, or radionuclide-gated blood pool study (273,278–280).
If early PTCA of the right coronary artery is indicated, this
should be performed. It is best to delay surgery for $4
weeks to allow recovery of RV function.
3. Attenuation of the Systemic Sequelae of CPB. Extra-
corporeal circulation elicits a diffuse inflammatory response
that is attended by a transient, multisystem organ dysfunc-
tion that may prolong convalescence (281,282). Numerous
strategies have been shown to blunt this counterproductive
immune response (281). Preoperative corticosteroid admin-
istration is inexpensive and appears to be efficacious. Cor-
ticosteroid administration has favorable effects on the sys-
temic inflammatory response associated with extracorporeal
circulation. Glucocorticoid, when given before CPB, re-
duces complement activation and the levels of proinflam-
matory cytokines (283–287). Compared with placebo,
patients receiving glucocorticoid are less febrile postopera-
tively, have higher cardiac indexes, require less inotropic and
volume support, and spend less time in the intensive care
unit (288–292). Although there is no demonstration of an
increased risk for infection in studies to date, it may be
prudent to avoid the use of steroid in diabetic patients (291).
The proper timing and duration of administration in this
application are incompletely resolved; there is evidence that
steroid delivery more in advance of an insult is more
efficacious (293). Preoperative corticosteroid administration
is inexpensive and appears to reduce the systemic inflam-
matory response associated with CPB with little downside
risk. Current understanding supports liberal prophylactic
use in patients undergoing extracorporeal circulation (283).
Aprotinin, a serine protease inhibitor known for its
hemostatic characteristics, also attenuates complement ac-
tivation and cytokine release during extracorporeal circula-
tion. There appears to be an emerging role for its prophy-
lactic use as an anti-inflammatory agent in patients
undergoing CPB. There was a significant reduction in
length of stay and hospital charges when aprotinin therapy
was applied to a high-risk cardiac surgical population (281).
However, there are insufficient data at present to make a
strong recommendation for the routine use of this relatively
expensive drug (283) (Table 14) (287,294).
Perioperative leukocyte depletion through hematologic
filtration may benefit patients by improving pulmonary
function. One study suggested that low-risk patients benefit
from a strategy of leukocyte depletion during CPB in
conjunction with leukoreduction of homologous blood
products (281,295–297). Although the literature does sup-
port the routine use of arterial-line filters to minimize
microembolization in extracorporeal circulation, there is no
current consensus on the value of selective leukocyte filtra-
tion for the CPB circuit. Although blood-surface interface
modifications for the CPB circuit have also been shown to
decrease markers of inflammation, translation into clinical
benefit in terms of reduced morbidity, mortality, or resource
utilization has been equivocal. The concern over thrombotic
complications tempered enthusiasm among cardiac sur-
geons (281,298 –302). Surface modification such as
heparin-bonded circuitry for extracorporeal circulation
holds promise for reduction of the systemic inflammatory
response to CPB, but at present the evidence is sufficiently
conflicting that firm guidelines are not at hand.
4. Reducing the Risk of Perioperative Infection. Multi-
ple opportunities exist for infection risk neutralization in
coronary bypass patients. Interval reporting to individual
surgeons of their respective wound infection rates leads to
risk reduction through discipline in adherence to sterile
operative techniques. Skin and nasopharyngeal Gram-
positive organisms are the leading cause of the most
threatening complication: deep sternal wound infection or
mediastinitis. Skin preparation with topical antiseptics
(303,304), clipping rather than shaving the skin (305–308),
avoidance of hair removal (61), reduction of operating room
traffic, laminar-flow ventilation, shorter operations, minimal
electrocautery (66), avoidance of bone wax (309), use of
double-gloving barrier techniques for the operating team
(310–314), and routine use of an easily constructed pleuro-
pericardial flap (315) have all been shown to be of value in
reducing postoperative infection (63).
Several newer strategies that are easily integrated into
practice deserve consideration. Diabetes mellitus afflicts 1 of
5 coronary bypass patients and is an independent risk factor
for wound infection (316). The risk for deep sternal wound
infection is halved by aggressive perioperative glucose con-
trol by using a continuous, intravenous, insulin infusion
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(0.9% deep sternal wound infection) versus intermittent
subcutaneous insulin treatment (1.9%, P 5 0.04) (63).
Homologous blood transfusions after coronary bypass are
correlated in a dose-related fashion to increased risk for viral
and bacterial infections, increased length of stay, antimicro-
bial use, and mortality through transfusion-related immu-
nomodulation (317,318). A retrospective study of 238
coronary bypass patients demonstrated this immunosup-
pressive effect of transfusion. Wound and remote infections
occurred in 4% of patients who received #2 U of red blood
cells, in 7% of those transfused with 3 to 5 U, and in 22%
in those having received $6 U (317). Leukodepletion
strategies have been shown to blunt the immunosuppressive
effect of blood transfusion in surgical patients (318). The
dose-related effect of blood transfusion on increased infec-
tion risk has been known for general surgical and orthopedic
operations and is thought to be caused by the accompanying
leukocytes in the red blood cell transfusion (319). A single-
center prospective trial of 3 transfusion protocols in 914
cardiac surgical patients showed a significant reduction for
patients receiving leukocyte-depleted blood (17.9%) as op-
posed to nonfiltered blood (23.5%, P 5 0.04) for all
infections (respiratory, urinary tract, bacteremia, and
wound) (318). Most striking was the reduction in 60-day
mortality in transfused patients having received filtered
blood: transfused/nonfiltered patient mortality was 7.8%;
transfused/filtered at the time of donation, 3.6%; and
transfused/filtered at the time of transfusion, 3.3% (P 5
0.019) (318). The reduction in the postoperative rate of
noncardiac causes of death (ie, multisystem failure) in
leukocyte-depleted/transfused patients compared with pa-
tients receiving nonfiltered blood was highly significant
(P 5 0.001) (318). Leukodepletion can be accomplished by
regional blood banks at the time of donation or at the
bedside at time of transfusion by using a relatively inexpen-
sive in-line transfusion filter.
Preoperative antibiotic administration reduces the risk of
postoperative infection 5-fold (320). Prophylactic antimi-
crobial efficacy is dependent on adequate drug tissue levels
before microbial exposure (321,322). Multi-institutional
studies suggest that many centers, including those with
training programs in cardiothoracic surgery, are not consis-
tent in delivering or teaching effective use of perioperative
antibiotics.
The cephalosporin class of antimicrobials is currently the
agent of choice for prophylaxis of infection for coronary
operations. There is a trend toward superior efficacy with
cefuroxime compared with the other cephalosporins, but
this difference does not reach statistical significance (Table
12) (323). Institution- or surgeon-specific selection is ap-
propriate within this class (323). Data suggest that a 1-day
course of intravenous antimicrobials is as efficacious as the
traditional 48-hour (or longer) regimens (324–327). There
is little evidence that prolonging ($2 days) the antimicro-
bial prophylaxis even in high-risk patients provides any
benefit (328). A 1-day course of antimicrobial prophylaxis is
TABLE 12. Prophylactic Antimicrobials for Coronary Artery Bypass Graft Surgery (322, 421–423)
Cephalosporins
Equivalent Efficacy
IV Dosing Regimens
Dose and Interval
Cost per
Dose Comments
Cefuroxime 1.5 g preoperatively
1.5 g after CPB
1.5 g Q12348
$6.33/1.5 g First-line agents; low
toxicity; pharmacokinetics
vary; shorter prophylaxis
duration ,24 h may be
equally efficacious for
cefuroxime
Cefamandole, cefazolin 1 g preoperatively $6.27/g
1 g at sternotomy $0.90/g
1 g after CPB
1 g Q6348 (Initial dose to be given 30–
60 minutes before skin incision)
Vancomycin 1 g Q12/h/until lines/tubes out
At least 2 doses
$5.77/g Reserved for penicillin-
allergic; justified
(During 30–60-minute infusion timed to
end before skin incision)
in periods of methicillin-
resistant Staphylococcus
species outbreaks;
vancomycin-resistant
Enterococcus problem is on
horizon; more likely to
require vasopressor agent
perioperatively
CPB indicates cardiopulmonary bypass.
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safe and effective (329). There are insufficient data to
suggest that aminoglycosides add substantial benefit to the
antimicrobial prophylactic regimen (323). Usual cephalo-
sporin pharmacokinetics mandates administration within 30
minutes of incision and redosing if the operation exceeds 3
hours (321,330).
Antimicrobial selection is a moot point if the agent is not
delivered during the optimal 30- to 60-minute window just
before incision. The beneficial effect is negated if the drug is
given after incision. This is a major issue. A recent multi-
institutional study, including those with cardiothoracic
training programs, confirmed the suboptimal use of prophy-
lactic antimicrobials. In 1994, only 23% of the institutions
studied had a system that assured proper administration of
prophylactic antimicrobials in the generous 2-hour period
just before incision for coronary bypass patients. One year
later, compliance was even worse at 20% (331). A practical,
fail-safe guideline to assure proper timing is the adminis-
tration of the cephalosporin by the anesthesiologist after
induction but before skin incision. Then the surgeon con-
firms administration before the scalpel is in hand (322,332).
Surgeons should be familiar with the pharmacokinetics of
their preferred cephalosporin to modify initial and subse-
quent dosing based on patient size and duration of opera-
tion. This knowledge can favorably influence plasma, ster-
nal, and soft-tissue bacteriocidal activity for the individual
patient.
If preventive strategies fail, prompt recognition of deep
sternal wound infection or mediastinitis is critical. Morbid-
ity and mortality for deep sternal wound infection or
mediastinitis have decreased over the past 20 years for
several reasons. Aggressive surgical debridement and early
vascularized muscle flap coverage are key to reducing the
cost, length of stay, and death (333,334). A recent prospec-
tive trial has lessened debate on proper management of the
deeply infected sternotomy incision. Treatment by wound
exploration, sternal rewiring, and drainage failed in 88.2%
of patients compared with high success in patients treated
initially with muscle flap closure (335).
5. Prevention of Postoperative Dysrhythmias. Postoper-
ative atrial fibrillation increases the length of stay up to 5
days (336), increases the charges by as much as $10,055
(336), and is associated with a 2- to 3-fold increase in
postoperative stroke (177,178).
The causal and temporal relationship among atrial fibril-
lation after coronary bypass, the incidence of new left atrial
thrombus, and the potential for cardioarterial embolus and
stroke remains ill-defined. However, if atrial fibrillation
after coronary bypass persists into a second day, warfarin
anticoagulation with a goal international normalized ratio of
2.0 should be considered (337).
Withdrawal of b-blockers in the perioperative period
doubles the incidence of postoperative atrial fibrillation after
coronary bypass. One series showed that 40 of 105 patients
who had withdrawal of b-blockers developed postoperative
atrial fibrillation compared with 18 of 105 patients who had
early postoperative reinstitution of b-blocker (P 5 0.02).
Virtually every study of b-blockers administered for the
purpose of reducing postoperative atrial fibrillation has
shown benefit. Most trials have examined the initiation of
prophylaxis in the postoperative period. There appears to be
an even greater benefit if b-blockers are begun before
operation. For example, in 1 controlled trial, atenolol started
3 days before operation led to a reduction of atrial fibrilla-
tion from 37% in the control group to 3% in the atenolol
group (P 5 0.001) (338) (Table 13) (339).
A recent, prospective study of propafenone versus ateno-
lol for prevention of postcardiotomy supraventricular tachy-
arrhythmias showed no significant difference between the 2
drugs (339). Both groups had a low incidence of postop-
eration atrial fibrillation (12% for propafenone versus 11%
for atenolol, P 5 0.89). This result identifies a less nega-
tively inotropic drug (propafenone) as an alternative to
b-blockers in patients in whom underlying LV dysfunction
is an important concern (340) or for patients whose active
bronchospasm makes b-blocker use less attractive.
Low-dose sotalol also appears to be effective for reduction
of atrial fibrillation after coronary bypass. In a prospective,
double-blind, randomized, placebo-controlled study, the
placebo group had an incidence of supraventricular arrhyth-
mias of 43% compared with 26% for sotalol (P 5 0.0012, or
a 43% reduction) (341).
Amiodarone administered beginning 1 week preopera-
tively halves the incidence of postcardiotomy atrial fibrilla-
tion (53% placebo to 25%, P 5 0.003), reduces hospital
costs ($26,000 to $18,000, P 5 0.03), and shortens the
length of stay (8 to 6.5 days, P 5 0.04) (342). This
represents another option for elective surgical patients who
have contraindications to b-blocker therapy.
Digoxin and calcium channel blockers (verapamil has
been the most extensively studied) have no consistent
benefit for prophylaxis of supraventricular arrhythmias after
coronary bypass operation (Table 13) (341). Currently,
preoperative or early postoperative administration of
b-blockers is considered standard therapy to prevent atrial
fibrillation after coronary bypass surgery.
6. Strategies to Reduce Perioperative Bleeding and
Transfusion. Despite the increasing safety of homologous
blood transfusion, patients and their families are often far
more concerned about transfusion risk than MI, stroke, or
death after coronary bypass. Well-publicized cases of trans-
mission of viral illness with transfusion after cardiac oper-
ation in the early 1980s have sensitized the North American
population. A study of donors who passed current blood
donor screens but subsequently seroconverted suggests a
current risk for donation of blood during an infectious
period of 1/493,000 for human immunodeficiency virus,
1/641,000 for human T-cell lymphotrophic virus,
1/103,000 for hepatitis C virus, and 1/63,000 for hepatitis B
virus (343).
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Cardiac surgical patients account for 10% of blood
transfusions in the United States (344). Twenty percent of
patients having cardiac operations use 80% of the blood
products attributed to cardiac surgical use. Several of the
short-term, deleterious effects of transfusion were discussed
in the section on reducing infection (345). Predisposing risk
factors for transfusion after coronary bypass include advanc-
ing age, lower preoperative red blood cell volume, preoper-
ative aspirin therapy, priority of operation, duration of CPB,
recent thrombolytic therapy, reoperative coronary bypass,
and differences in heparin management (346–352). Institu-
tional protocols with thresholds for transfusion lead to an
overall reduction in the number of units transfused and the
percentage of patients receiving any blood (353).
Aspirin, a very common preoperative medication in
coronary bypass patients, decreases platelet aggregation and
increases postoperative blood loss. The magnitude of this
effect has been confirmed in prospective, controlled trials
(354). Preoperative aspirin is associated with increased risk
for transfusion, prolonged wound closure time, and a 4-fold
increase in early reoperation for bleeding (355). The value of
aspirin in the treatment of acute coronary syndromes will
often outweigh the increased risk for perioperative bleeding
should coronary bypass be indicated early in the course of
the acute event. In certain patients in an appropriate clinical
setting, including chronic stable angina, low-risk plaque
morphology, and others, cessation of aspirin and other
platelet inhibitors 7 to 10 days before elective cardiac
operation appears prudent to decrease the risk of postoper-
ative bleeding and transfusion.
Aprotinin, a serine protease inhibitor with antifibrinolytic
activity, significantly decreases postoperative blood loss and
transfusion requirements (both units and number of pa-
tients) in high-risk, primary coronary bypass patients, those
on aspirin, and in particular the reoperative bypass popula-
tion (356,357). Aprotinin does not appear to decrease early
graft patency after coronary bypass despite its benefit in
reducing postoperative bleeding and need for blood trans-
fusion (358,359). Mechanical strategies to reduce the need
for homologous blood have been only marginally successful.
Both «-aminocaproic acid and an analogue, tranexamic
acid, have antifibrinolytic activity. Both have been demon-
strated to decrease mediastinal drainage after cardiac oper-
ation (360–363). Demonstration of a reduction in transfu-
sion requirements has been inconsistent, however (361).
Although these agents are relatively inexpensive, the data
are insufficient to recommend their routine use. In contra-
distinction to aprotinin, the safety regarding the thrombotic
potential including graft patency issues is unresolved
(359,364). The concept of risk stratification for transfusion
requirements has been validated (365) and suggests more
rational approaches of risk reduction strategies to minimize
blood requirements (365).
Efforts to synthesize multiple blood-conservation meth-
ods have proven successful in reducing transfusion (366).
The most fully evolved protocol using multiple mechanical
and pharmacological means achieved a remarkable series of
100 consecutive, selected coronary bypass patients without
transfusion (367). Intrinsic to this strategy was the concept
of varying risk for transfusion and an individualized,
algorithm-driven approach for the elective coronary bypass
patient. Models for prediction of the need for transfusion
postoperatively allow shepherding of resources and applica-
tion of risk-neutralizing strategies to those more likely to
benefit (25). Comparison was made with a consecutive
series of concurrent patients with the same transfusion
criteria. The multimodality conservation patients had no
transfusion compared with 38% of the concurrent control
group who received an average of 2.2 6 6.7 U of blood.
Mediastinal drainage for the conservation group was half
that of the control group (370 6 180 versus 660 6 270 mL,
P 5 0.001) (367). Costs were similar between groups. The
liberal use of aprotinin (69% of patients), exclusion of
anemia patients, and minimal hemodilution appear to be
the keys to these results.
Prehospitalization autologous blood donation can be
effective. If a patient has no exclusionary criteria (hemoglo-
bin ,12, heart failure, unstable angina, left main disease, or
symptoms on the proposed day of donation) and can achieve
1 to 3 U of donated blood over 30 days before operation, the
risk of homologous transfusion is significantly lowered
(12.6% versus 46% in a non-preadmission donor control
group, P 5 0.001). An alternative or additional method of
pre-CPB blood “donation” is the removal of blood from the
patient in the operating room immediately before CPB.
This blood is then set aside, not exposed to the CPB
circuitry, and then reinfused into the patient after the
patient is disconnected from CPB. This donation immedi-
ately before CPB yielded a significantly higher platelet and
hemoglobin count in 1 study (P , 0.01) compared with
similar postoperative levels in patients who did not undergo
harvesting of blood immediately before CPB. In this study,
this technique translated into a 6-fold decrease in the
percentage of patients requiring transfusion (10% transfu-
sion rate in pre-CPB donors versus a 65% transfusion rate in
non-pre-CPB donors, P , 0.01) (368).
A multicenter, prospective study of recombinant human
erythropoietin given over a 5-day course failed to demon-
strate a significant reduction in transfusion requirement,
although a significant rise in preoperative hemoglobin (P ,
0.05) was noted (369).
A randomized, placebo-controlled trial demonstrated no
advantage of iron supplementation for restoration of red
blood cell mass after coronary bypass, but the patients
receiving iron did have significantly more gastrointestinal
complaints (364,368).
Autotransfusion has had a generally favorable effect on
decreasing allogeneic blood use, but concerns about stimu-
lation of fibrinolysis with reinfusion of shed mediastinal
blood prevent unequivocal recommendations on its use,
particularly in routine low-risk patients (370).
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7. General Management Considerations. Acuity of oper-
ation is an important determinant of operative morbidity
and mortality. The need for an emergent or even urgent
operation can often be forestalled by appropriate pharma-
cological therapy, placement of an IABP, or even percuta-
neous revascularization of “culprit” stenoses. In each in-
stance, the benefit of temporizing therapy must be weighed
against the risk of waiting and the risk of the therapy used
to achieve delay. A discussion of this strategy as applied to
the acute coronary syndrome is presented in Section V, K.
Smoking cessation and improvement of chronic bronchitis
before elective coronary operation lessen the risk for peri-
operative pulmonary complications (281). Preoperative pul-
monary edema is a particularly hazardous situation, as
extracorporeal circulation will worsen the lung water and
predispose the patient to prolonged, postoperative mechan-
ical ventilatory support. Ideally, the operation is deferred
until resolution of the edema is accomplished. Obesity is an
independent risk factor for perioperative respiratory failure,
sternal and leg wound complications, perioperative MI, and
arrhythmias (371). If the patient’s coronary anatomy and
clinical course permit, a concerted effort at weight reduction
is appropriate and operation is deferred.
B. Maximizing Postoperative Benefit
1. Antiplatelet Therapy for SVG Patency. Aspirin signif-
icantly reduces vein graft closure through the first postop-
erative year. A demonstrable effect on arterial graft patency
has not been demonstrated. Aspirin administration before
operation offers no improvement in subsequent vein graft
patency compared with early postoperative initiation (355).
Fail-safe mechanisms should exist to ensure prompt post-
operative initiation of aspirin therapy. Prospective con-
trolled trials have demonstrated a graft patency benefit when
aspirin was started 1, 7, or 24 hours after operation
(372–374). The benefit of postoperative aspirin on SVG
patency is lost when started .48 hours after surgery (375).
Dosing regimens ranging from 100 mg once per day to
325 mg 3 times daily appear to be efficacious. As the graft
recipient coronary artery luminal diameter increases, SVG
patency rates improve and the advantage of aspirin over
placebo is reduced (376).
Ticlopidine is efficacious (377) but offers no advantage
over aspirin except as an alternative in the truly aspirin-
allergic patient. Life-threatening neutropenia is a rare but
recognized side effect. When ticlopidine is used, white
blood cell count should be periodically monitored in the
early months after initiating treatment. Clopidogrel offers
the potential for fewer side effects compared with ticlopi-
dine as an alternative to aspirin for platelet inhibition. The
incidence of severe leukopenia was rare and similar to that of
aspirin in a recent controlled trial (378). Indobufen is a
reversible inhibitor of platelet cyclooxygenase, in contradis-
tinction to aspirin, so platelets recover function within 24
hours of cessation of the drug. It appears to be as effective as
aspirin for saphenous graft patency over the first postoper-
ative year but with fewer gastrointestinal side effects (379).
Current evidence suggests that dipyridamole adds noth-
ing to the aspirin effect for saphenous graft patency (355).
Warfarin has shown no consistent benefit in maintaining
saphenous graft patency (380) and may be associated with
an increased risk for bleeding compared with antiplatelet
therapy for this application (381).
In summary, aspirin is the drug of choice for prophylaxis
against early saphenous graft thrombotic closure and should
be considered a standard of care for the first postoperative
year (Table 14). In general, patients are continued on aspirin
indefinitely, given its benefit in the secondary prevention of
acute MI.
2. Pharmacological Management of Hyperlipidemia.
The Cholesterol Lowering Atherosclerosis Study was the
first angiographic study to provide clear evidence of a
treatment effect on human atherosclerotic lesions (382).
This study was conducted with 162 middle-aged, nonsmok-
ing men who had recently undergone coronary bypass and
were treated with placebo or combined colestipol hydro-
chloride and niacin therapy. Serial angiograms demon-
strated a significant reduction of progression of atheroscle-
rosis (P , 0.001) in the treated group. Specifically, there
was a reduction in the number of new native coronary (P ,
0.03) and graft (P , 0.04) lesions and the slowed progres-
sion of existing native coronary (P , 0.04) and graft (P ,
0.03) stenoses in the treatment group.
The efficacy of statin treatment in the postbypass patient
has been demonstrated by the Post Coronary Artery Bypass
Graft Trial Investigators. Angiographic progression of ath-
erosclerotic vein-graft disease was significantly retarded by
lovastatin (with the occasional addition of cholestyramine to
achieve the individualized lipid-lowering goal). Patients
having aggressive cholesterol lowering (achieved low density
lipoprotein ,100 mg/dL) had disease progression in 29% of
saphenous grafts over an average 4-year follow-up compared
with 39% in the moderate treatment group (achieved low
density lipoprotein ,140 mg/dL) (P , 0.001; Post CABG
Trial 1997). The aggressively treated group had a lower
repeated revascularization rate over the course of the study
compared with the moderate treatment cohort: 6.5% versus
9.2% (29% lower, P 5 0.03). These results, along with those
from a number of both primary and secondary prevention
trials, strongly support aggressive attempts to screen for and
treat elevated low density lipoprotein cholesterol levels in
patients receiving coronary bypass surgery. Patients already
taking 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors preoperatively should have them resumed post-
operatively. Patients with unknown lipid levels should be
screened and treated if low density lipoprotein .100.
Hyperhomocystinemia, recognized as an independent
risk factor for coronary disease, is reduced by the adminis-
tration of oral folic acid along with vitamins B6 and B12. In
the sole study of its relationship to coronary bypass grafting,
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there was no association with early graft attrition found, but
the angiographic follow-up was only through 1 year (383).
In summary, all patients should be considered candidates
for pharmacological low density lipoprotein reduction after
CABG if their low density lipoprotein level exceeds 100
(Table 14).
3. Hormonal Manipulation. More than 30 observational
studies have shown a reduced mortality for coronary disease
in postmenopausal women on hormone replacement ther-
apy. The American Heart Association and the American
Fertility Society have reached a consensus that hormone
replacement therapy lowers mortality in women with mod-
erate or severe coronary disease (384). The one long-term
observational study that focused on hormone replacement
therapy in postmenopausal women after coronary bypass
demonstrated a marked reduction in all-cause mortality
(385). A stepwise proportional-hazards analysis confirmed a
significant reduction in relative risk with hormone replace-
ment therapy. Eighty-one percent of women using hormone
replacement therapy were alive 10 years after coronary
bypass compared with only 65% who were not on hormone
replacement therapy (P 5 0.0001). Benefit was realized
even when hormone replacement therapy began after coro-
nary bypass.
The recently completed Heart and Estrogen/progestin
Replacement Study trial (386), a randomized comparison of
placebo and estrogen plus progestin, examined hormonal
manipulation for the secondary prevention of coronary
disease in postmenopausal women. Treatment had a bene-
ficial effect on low density lipoprotein cholesterol level, with
an 11% reduction (P # 0.001), and a 10% increase in high
density lipoprotein cholesterol level (P # 0.001). However,
there was no beneficial effect on the overall rate of coronary
heart disease events. The question remains open as to
whether unopposed (without progestin) estrogen replace-
ment therapy in this patient population is beneficial. This
study included patients having had coronary bypass, but a
subgroup analysis for this subset was not reported.
In summary, hormone replacement therapy should be
considered in postmenopausal women after CABG when,
in the physician’s judgment, the potential coronary benefit is
not offset by a perceived risk for uterine and/or breast
cancer.
4. Smoking Cessation. Smoking is the single, most im-
portant cause of preventable premature mortality in the
United States (387). There is strong evidence from the
CASS that smoking cessation after coronary bypass is
rewarded by less recurrent angina, improved function, fewer
hospital admissions, maintenance of employment, and im-
proved survival (84% survival for quitters versus 68% for
persistent smokers at 10 years for those randomized to
operation) (P 5 0.018) (388). Cessation of smoking after
coronary bypass improves the postoperative survival of
successful quitters to that of postbypass patients who have
TABLE 14. Proven Management Strategies to Reduce Perioperative and Late Morbidity and Mortality
Timing
Class
Indication Intervention Comments
Preoperative
Carotid screening I Carotid duplex ultrasound
in defined population
Carotid endarterectomy if stenosis
$80%
Perioperative
Antimicrobials I Prophylactic antimicrobials Table 12
Antifibrinolytics IIa Aprotinin in selected groups Significant reduction in blood
transfusion requirement
Antiarrhythmics I b-Blockers to prevent
postoperative atrial
fibrillation
Propafenone or amiodarone are
alternatives if contraindication to b-
blocker (Table 13)
Anti-inflammatory drugs IIa Minimize diffuse
inflammatory response to
cardiopulmonary bypass
Postoperative
Antiplatelet agents I Aspirin to prevent early
vein-graft attrition
Ticlopidine or clopidogrel are
alternatives if contraindications to
aspirin
Lipid-lowering therapy I Cholesterol-lowering agent
plus low-fat diet if low-
density lipoprotein choles-
terol .100 mg/dL
3-Hydroxy-3-methylglutaryl/coenzyme
A reductase inhibitors preferred if
elevated low-density lipoprotein is
major aberration
Smoking cessation I Smoking cessation
education, and offer
counseling and
pharmacotherapies
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never smoked; persistent smokers have significantly more
MIs and reoperations (389). As expected, smoking leads to
angiographically detected deterioration over time: only 39%
of smokers’ saphenous grafts are disease-free at 5 years
compared with 52% of nonsmokers’ (390).
Failure to attempt cessation and recidivism are the
difficult issues. Treatment individualized to the patient is
crucial. Smoking is an addictive disorder and should be
treated as such and not as an indication of self-
destructiveness or weak willpower (391).
Depression is an important complicating factor in smok-
ing and may account for a significant number of cessation
failures (392,393). Behavioral treatments alone are not as
effective as drug therapy (394).
The nicotine transdermal patch is effective in smoking
cessation treatment. The average cost per year of life saved
ranges from $965 to $2360 (387). A transdermal nicotine
patch in conjunction with a behavioral modification pro-
gram sustained continuous abstinence for 20% of patients
receiving the patch versus 9% for those receiving behavioral
modification alone (395). Nicotine gum added to transcu-
taneous patch therapy significantly increased abstinence
rates above that of the active patch alone at 52 weeks (396).
A sustained-release form of bupropion, an antidepressant
similar to the selective serotonin reuptake inhibitors, is
effective for smoking cessation in a dose-related fashion.
The agent reduces the nicotine craving and anxiety of
smokers who quit. Three hundred milligrams per day led to
a 44% smoke-free rate at 7 weeks and 23% at 1 year, double
that of the placebo group (P , 0.001) (393). The results at 1
year parallel those seen with nicotine replacement strategies.
In summary, all smokers should receive educational coun-
seling and be offered smoking cessation therapy after coro-
nary bypass. Pharmacological therapy including nicotine
replacement and bupropion should be offered to patients
indicating a willingness to quit.
5. Cardiac Rehabilitation. Cardiac rehabilitation includ-
ing early ambulation during hospitalization, outpatient pre-
scriptive exercise training, family education (397), and
sexual counseling (398) have been shown to reduce mortal-
ity (399,400). Cardiac rehabilitation beginning 4 to 8 weeks
after coronary bypass and consisting of 3-times-weekly
educational and exercise sessions for 3 months is associated
with a 35% increase in exercise tolerance (P 5 0.0001), a
slight (2%) but significant (P 5 0.05) increase in high
density lipoprotein cholesterol, and a 6% reduction in body
fat (P 5 0.002) (401). Exercise training is a valuable adjunct
to dietary modification of fat and total caloric intake in
maximizing the reduction of body fat while minimizing the
reduction of lean body mass (402). A significant hurdle
appears to be initiation of rehabilitation. In a prospective
study of recruitment for a comprehensive, cardiac rehabili-
tation program for patients having just undergone coronary
bypass, only 52 of 393 elected to participate. Participation
was lower for women (26% of nonparticipants versus 12% of
enrolled, P 5 0.02), unemployed patients (63% of those
declining versus 45% of the participants, P 5 0.02), those
with a lower income and educational level (both P 5 0.001),
and those with a greater functional impairment (P 5 0.001)
(403). If the barriers to enrollment can be overcome,
benefits seem to accrue to all special groups studied. The
benefits of cardiac rehabilitation extend to the elderly and to
women (404,405). Despite the fact women have a generally
higher risk profile and a relatively lower functional capacity
than men at initiation of a rehabilitation period (406), there
were similar compliance and completion rates, and women
achieved a similar or greater improvement in functional
capacity (women increased peak metabolic equivalents by
30%, men by 16%, P , 0.001) (407). Medically indigent
patients appear to have rehabilitation compliance and ben-
efit rates on par with insured/private-pay patients if reha-
bilitation is initiated and appropriately structured (408).
In a long-range trial focused exclusively on a coronary
bypass population, postoperative patients were randomized
to standard posthospital care (n 5 109) or standard care plus
rehabilitation (n 5 119). At 5 years, the groups were similar
on measures of symptoms, medication use, exercise capacity,
and depression scores. However, rehabilitated patients re-
ported more freedom of physical mobility (Nottingham
Health Profile, P 5 0.005), perceived better health (P 5
0.03), and a perceived better overall life situation (P 5
0.02). A larger proportion of the rehabilitated patients were
working at 3 years (P 5 0.02). This difference disappeared
with longer follow-up (409). Patients who sustained an
infarct followed by coronary bypass had greater improve-
ment in exercise tolerance after rehabilitation (change in
exercise capacity 2.8 6 1.4 metabolic equivalents) than did
those having infarct alone (0.8 6 2, P , 0.02). Improve-
ment was sustained to 2 years (410).
In addition to benefiting a sense of well-being, there is an
economic benefit that accrues from participation in cardiac
rehabilitation programs. During a 3-year follow-up (mean
of 21 months) after coronary events (58% of events were
coronary bypass operations), per capita hospitalization
charges were $739 lower for rehabilitated patients compared
with nonparticipants ($1197 6 3911 versus $1936 6 5459,
P 5 0.022) (411).
The coronary bypass patient is more likely to resume
sexual activity and to a greater degree than is the postinfarct
patient. Anticipatory and proactive advice by the physician
or surgeon on the safety of resumption of sexual activity as
the patient reengages in other daily activities is beneficial
(412).
In summary, cardiac rehabilitation should be offered to all
eligible patients after coronary bypass surgery.
6. Emotional Dysfunction and Psychosocial Consider-
ations. The 2 most important independent psychosocial
predictors of death in a multivariate analysis of elderly
postoperative coronary bypass patients are a lack of social
participation and religious strength (413). Social isolation is
1299JACC Vol. 34, No. 4, 1999 Eagle and Guyton et al.
October 1999:1262–347 ACC/AHA Guidelines for CABG Surgery
associated with increased mortality and coronary disease
(414), and successful treatment may improve outcome
(415). Depression is generally poorly recognized by the
cardiac specialist (401). Mood for up to 1 year after coronary
bypass is correlated most strongly with mood before coro-
nary bypass. The prevalent opinion that depression is a
common result of coronary bypass is challenged by several
reports (416). Half of patients who were depressed before
operation were not depressed afterward, and only 9% of
patients experienced new depression postoperatively. The
overall prevalence of depression at 1 month and 1 year was
33%, which was similar to that in reports of patients
undergoing other major operations. Some have argued that
preoperative screening simply sensitizes the healthcare team
and family to postoperative mood problems, rather than
there being a more direct pathophysiological association of
coronary bypass per se and depression. Coronary disease and
psychiatric disorders are highly prevalent and frequently
concurrent. Anxiety and depression are often encountered
around the time of coronary bypass operation. Anxiety may
intensify the autonomic manifestations of coronary disease
and complicate patient care. Realization of one’s mortality,
physical limitations, limitations of sexual activity, survival
guilt after successful operation, and development of nihilism
regarding modification of risk factors play a role in recovery.
Denial has adaptive value during hospitalization and can
enhance care, but its persistence in the early home conva-
lescence may be counterproductive. Clinical depression is
correlated with subsequent mortality (417).
Eighteen percent of patients are depressed after major
cardiac events, including coronary bypass (401). Cardiac
rehabilitation has a highly beneficial effect on these patients,
whether moderately or severely depressed. In a prospective
but uncontrolled study of 3 months of rehabilitation on
measures of depression, anxiety, hostility, somatization,
mental health, energy, general health, bodily pain, func-
tional status, well-being, and a total quality of life score,
patients were improved from 20% to 57% (P value for the
scores ranged from 0.001 to 0.004) (401).
7. Rapid Sustained Recovery After Operation. Rapid
recovery and early discharge, the “fast-track” approach, for
the coronary bypass patient should become the standard goal
of care. The shortest postoperative stays in the hospital are
followed by the fewest rehospitalizations (418). There is
very little evidence of a rise in morbidity, mortality, or
readmission rates in systems employing fast-track protocols.
Longer initial hospitalizations generally are recognized not
to prevent rehospitalizations. Prevention or prompt correc-
tion of noncardiac disorders allows rapid recovery after
coronary operations. Important components of the fast-
track system are patient selection, patient and family edu-
cation, short-acting narcotic or inhalational anesthetic
agents allowing early extubation and transfer from the
intensive care setting, prophylactic antiarrhythmic therapy,
dietary considerations, early ambulation, early outpatient
follow-up by telephone, and a dedicated fast-track coordi-
nator (419,420).
8. Communication Between Caregivers. A primary care
physician frequently refers patients who undergo CABG to
a cardiologist and/or surgeon. Maintaining appropriate and
timely communication between treating physicians regard-
ing care of the patient is crucial. The primary care physi-
cian’s request for referral may well be verbal but should also
be documented in writing and accompanied by relevant
medical information. Ideally, the primary care physician
follows the patient with the other treating physicians during
the perioperative course in the hospital if circumstances and
geography permit. The referral physician(s) needs to provide
written reports of findings and recommendations to the
primary care physician, including a copy of the discharge
summary from the hospital. Discharge medications that are
likely to be required for the long term should be clearly
identified. The decision about the degree of responsibility
for postoperative care and prevention strategies needs to be
made by mutual agreement among the patient, the primary
care physician, the cardiologist, and the surgeon in each
individual case. The primary care physician can emphasize
and continue to implement secondary prevention strategies,
frequently begun by the cardiologist and surgeon, since most
of these strategies involve lifestyle changes or pharmacolog-
ical therapies over an extended period of time.
V. SPECIAL PATIENT SUBSETS
A. CABG in the Elderly: Age 70 and Older
The evolution in surgical techniques and changing de-
mographics and patient selection for CABG surgery have
led to its application in older and sicker patients with more
complex disease (447). Nearly all reports during the past 10
years define “elderly” in the context of coronary surgery as
age 70 years or older. However, the definition of elderly in
the literature has gradually increased from 65 years or older
to 80 years or older. The greatest increase in numbers has
occurred in the oldest group, persons 85 years or older
(448). This group has a higher incidence of left main
disease, multivessel disease, LV dysfunction, and reopera-
tion as the indication for surgery, and for many, concomi-
tant valvular surgery. These patients generally have more
comorbid conditions, including diabetes, hypertension,
COPD, PVD, and renal disease. This combination of more
advanced coronary disease and worse comorbidity leads to
increased fatal and nonfatal complications. Higher rates of
intraoperative or postoperative MI, low-output syndrome,
stroke, gastrointestinal complications, wound infection, re-
nal failure, and use of an IABP may occur (449,450). In
Figure 10, operative mortality (%) is shown as a function of
age. A near-linear slope changes abruptly at age 75. Simi-
larly, in Figure 11 the OR for operative mortality is shown
as a function of age (26). The effects of these factors on
patient outcomes and institutional resources have significant
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implications for peer review, quality assurance screening,
institutional reporting to external sources, and reimburse-
ment (449).
Operative mortality in the elderly has ranged from 5% to
20% during the past 20 years for isolated CABG, averaging
8.9%. In a large study from Ontario, Canada, Ivanov et al
(448) found a 34% reduction in risk-adjusted operative
mortality (1982 to 1996) while confirming a time-related
increase in the prevalence of older patients and an increase
in the preoperative risk profile in these patients. They
reported an overall mortality of ,5% for elderly patients,
with a 3% mortality for low- and medium-risk patients.
Preoperative predictors of hospital mortality and morbid-
ity (30 days) in elderly patients include a near-linear relation
to New York Heart Association (NYHA) class and/or
reduced LVEF (particularly if ,0.20). Other correlates of
increased risk include increasing age; recent MI (,30 days),
especially in the presence of unstable angina, left main
disease, or 3-vessel disease; emergent or urgent coronary
bypass; reoperation; reduced renal function; cerebrovascular
disease; COPD; a smoking history; obesity; and female sex
(37,451–458). A higher operative mortality occurs for all
identified risk factors in patients aged 75 years or older than
for those ,65 years old. However, in particular, emergency
surgery confers up to a 10-fold increase in risk (3.5% to
35%), urgent surgery a 3-fold increase (3.5% to 15%),
hemodynamic instability a 3- to 10-fold increase, and an
LVEF ,0.20 up to a 10-fold increase (26,459,460). Pre-
dictors of postoperative low cardiac output syndrome are, in
descending order of importance, LVEF ,0.20, repeated
operation, emergency operation, female sex, diabetes melli-
tus, age .70 years, left main disease, recent MI, and/or
3-vessel disease (461). The greatest risk is in the acutely ill,
elderly patient for whom the CABG operation may be the
best of several high-risk options (462).
Operative factors that have been reported to adversely
influence hospital mortality in the elderly include the use of
bilateral IMA grafts, prolonged pump time and/or cross-
clamp time, an increased number of grafts required, right
IMA grafting, and any postoperative complication
(262,454,455,463). Obesity has been identified as a risk
factor for infection in patients receiving bilateral IMA grafts
(464). Contrariwise, improved hospital mortality and long-
term survival have been reported when the left IMA is used
along with 1 or more vein grafts as opposed to vein grafting
alone. Thus, use of the left IMA as a conduit appears to be
a predictor of improved early and late survival
(45,263,265,465). CABG without cardiopulmonary pump
assistance may be advantageous in high-risk patients, par-
ticularly those with an LVEF ,0.35 (466,467).
Postoperative atrial fibrillation is a particular problem in
elderly patients undergoing CABG. Correlates of postop-
erative atrial fibrillation include age .70 (especially age
.80), male sex, postoperative pulmonary complications,
ventilation time .24 hours, return to the intensive care
unit, and use of the IABP. Atrial fibrillation contributes to
a substantially prolonged hospital stay (9.3 6 19 versus
15.3 6 28 days) (336). Patients with preoperative chronic
renal failure are at a particular risk, as they tend to be older
and have additional comorbidity (74). Interventions to
prevent atrial fibrillation are discussed in Section IV.
It should be emphasized that long-term survival and
functional improvement can be achieved in the elderly
patient despite severe cardiovascular disease and an urgent
indication for surgery (468). The 5-year survival of such
patients who recover from surgery is comparable to that of
the general population matched for age, sex, and race
Figure 10. Operative mortality (%) for CABG in various age
cohorts (26).
Figure 11. Operative mortality odds ratio (26).
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(469–471). Preoperative variables that are correlated with
poor long-term survival in elderly patients include the
presence of atrial fibrillation, smoking, PVD, and poor renal
function (low creatinine clearance). An unsatisfactory func-
tional outcome has been influenced by hypertension, cere-
brovascular insufficiency, and poor renal function (low
creatinine clearance) (472).
Peterson et al (473) analyzed the Medicare database to
assess long-term survival in patients 80 years and older and
found it comparable to the general population of octoge-
narians. This group was hospitalized significantly longer
than those aged 70 or younger (14.3 versus 21.4 days) and
had a higher hospital mortality (11.5% versus 4.4%) and
higher 3-year mortality (28.8% versus 18.1%). Hospital
costs and charges were also higher. Similar findings are
reported by others, with actuarial survival including hospital
death at 80 months of 32.8% versus 37.6% for age-, sex-,
and race-matched populations. These authors concluded
that advanced age alone should not be a contraindication to
CABG if it had been determined that long-term benefits
outweighed the procedural risk (471,473,474). Although
hospitalization may be longer for elderly patients, physio-
logical, psychological, and social recovery patterns through
the first 6 weeks postoperatively have been reported to be
similar to those of a younger age group (475). Age 70 and
older is an independent risk factor for stroke after CABG,
adversely affecting hospital mortality, prolonging the hospi-
tal stay, and negatively impacting late death (476).
In operations combining valve surgery and CABG, inde-
pendent predictors for late survival included NYHA Class
IV, age .70 years, male sex, decreased LVEF, extent of
CAD and use of a small prosthetic valve, but not necessarily
the presence of CAD per se (477–480).
In summary, the patient aged 70 years or older who may
be a candidate for CABG surgery has, on average, a higher
risk for mortality and morbidity from the operative proce-
dure in a direct relation to age, LV function, extent of coronary
disease, comorbid conditions, and whether or not the proce-
dure is emergent, urgent, or a reoperation. Nonetheless, func-
tional recovery and sustained improvement and quality of life
may be achieved in the large majority of such patients.
The patient and physician together should explore the
potential benefits of improved quality of life with the
attendant risks of the procedure versus alternative therapy,
taking into account baseline functional capacities and pa-
tient preferences. Age alone should not be a contraindica-
tion to CABG surgery if it is thought that long-term
benefits outweigh the procedural risk (454,481–483).
B. CABG in Women
Early studies provided evidence that female sex was an
independent risk factor for higher in-hospital mortality and
morbidity than in males, but that long-term survival and
functional recovery were similar to those in males undergo-
ing CABG surgery (33,484–487). More recent studies have
suggested that on average, women have a disadvantageous
preoperative clinical profile that may account for much of
this perceived difference. This includes the fact that women
present for treatment at an older age, with poorer LV
function, more frequently with unstable angina pectoris,
NYHA Class IV heart failure, 3-vessel and left main
disease, and more comorbid conditions including hypothy-
roidism, renal disease, diabetes mellitus, hypertension, and
PVD (486,488–497). Based on these differences, it has
been inferred that women may be under-referred or referred
late for treatment and/or coronary angiography. These
findings are not universal, as significant differences exist in
clinical practice between institutions (487,488).
A variety of factors may account for the perception that
female sex is an independent risk factor for in-hospital
mortality and morbidity after CABG surgery. For example,
Israeli women were reported to have a 3.2-fold higher
hospital mortality than men, but women also received a
higher number of SVGs, suggesting more diffuse disease.
When this consideration was adjusted for, mortality was
found to be similar (498). Others have argued that smaller
coronary arteries in women may contribute to higher risk
(31). IMA grafts have been reported to be used less often in
women, possibly contributing to a higher mortality
(492,494). Kurlansky et al (81) reported favorable results in
327 women with bilateral IMA grafts plus supplemental
vein grafts, with a hospital mortality of 3% to 4%, low
postoperative morbidity, excellent functional improvement,
and enhanced long-term survival. Five-year survival of
90.5% and of 65.6% at 10 years was achieved, with 94% of
patients reaching NYHA Class I and 4.5% NYHA Class II.
Hammar et al (486) reported that when age and body
surface area were taken into account, the relative operative
risk between men and women became similar. Others have
also found no differences in operative mortality, total post-
operative morbidity, and intensive care unit length of stay
(499,500). Comparable findings were reported for coronary
bypass surgery in black male and female patients (501).
However, analysis from the CASS found a higher oper-
ative mortality for women (OR 2) (501) as did Jaglal et al
(502), even when comorbidities were adjusted for appropri-
ately. They suggested that the excessive mortality was due to
late treatment (502). Farrer et al (503) found that women
had more severe symptoms with a similar severity of
coronary disease as defined by angiography when compared
with men, suggesting a referral bias with referral occurring
later in the course of the disease. Whether these perceived
biases are real and whether they are practitioner or patient
related or have a biological explanation is not known. They
serve as a challenge for future investigation (504).
Postoperative complications in women mirror those seen
in all patients undergoing CABG surgery. These include
MI, stroke, reoperation for bleeding, pulmonary insuffi-
ciency, renal insufficiency, sternal wound infection (perhaps
related to obesity), CHF, rhythm other than normal sinus
rhythm, and low cardiac output syndrome (81,494,498).
Women appear particularly vulnerable to postoperative
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CHF, low cardiac output syndrome (33,488,494), and blood
loss (491). Although postoperative depression is common in
women and men, its occurrence in women has been re-
ported to be more common (’60%) and more commonly
unrecognized (103). Nonetheless, at 6 months postopera-
tively, men and women report similar psychosocial recovery
(490) (see Section IV).
In the CASS, although a higher operative mortality for
women was found, the subsequent 15-year postoperative
survival and benefits were similar to those for men. Greater
absolute benefit was achieved in those with the highest risk
in both male and female groups. For women, independent
risk factors for poorer long-term survival included older age,
prior MI, prior CABG, and diabetes mellitus (505).
Over time, changes in the clinical characteristics of
women undergoing coronary bypass surgery mirror those of
the changing characteristics of the general population. One
study compared female patients operated on between 1974
and 1979 to a group receiving surgery between 1988 and
1999 and showed that operative mortality had increased
from 1.3% to 5.8%. This rise was attributed to an older
cohort of women, more emergent or urgent operations, an
increased incidence of depressed LV function, diabetes
mellitus, and more 3-vessel and left main disease, all
suggesting that the female population undergoing coronary
bypass surgery had changed (497). In another report,
women aged 70 or older were found to be at no greater risk
for operative mortality and postoperative complications than
men of similar age (506).
In conclusion, it appears that in-hospital mortality and
morbidity and long-term survival are related more to risk
factors and patient characteristics than is sex. Coronary
bypass surgery should therefore not be delayed or denied to
women who have the appropriate indications for revascu-
larization.
C. CABG in Patients With Diabetes
Coronary heart disease is the leading cause of death
among adult diabetics and accounts for ’3 times as many
deaths among diabetics as among nondiabetics (507). Not
only is the frequency of acute MI increased in diabetic
patients (508,509) but also its treatment is more compli-
cated than in the nondiabetic patient. Diabetic patients with
acute MI, regardless of the level of control of their diabetes
before hospital admission, exhibit significantly higher mor-
tality and morbidity, with fatality rates as high as 25% in the
first year after infarction in some series. Several factors
contribute to this increase in mortality. The size of the
infarct tends to be greater, and diabetics have a greater
frequency of CHF, shock, arrhythmias, and recurrent MI
than do nondiabetics. Similarly, diabetic patients with
unstable angina have a higher mortality than do nondiabetic
patients. A recent prospective study indicated a 3-month
mortality of 8.6% and 1-year mortality of 16.7% in diabetics
versus 2.5% and 8.6%, respectively, in nondiabetics (510).
CABG surgery in elderly diabetics (age 65 or greater) has
been reported to result in a reduction in mortality of 44% in
CASS. The relative survival benefit of CABG versus med-
ical therapy was comparable in diabetic and nondiabetic
patients (511). Nevertheless, a recent study from Sweden
has indicated that diabetic patients of all ages have a
mortality rate during the 2-year period after CABG that is
about twice that of nondiabetic patients. Thirty-day mor-
tality after CABG was 6.7% in diabetic patients, and
subsequent mortality between day 30 and 2 years was 7.8%
compared with 3% and 3.6%, respectively, in nondiabetic
patients (512).
Despite increased morbidity and mortality after coronary
revascularization, results from the BARI trial showed that
patients with multivessel coronary disease who were being
treated for diabetes at baseline had a significantly better
survival after coronary revascularization with CABG than
with PTCA (Figure 6) (118). In this study, patients were
followed up for an average of 5.4 years. Better survival with
CABG was due to reduced cardiac mortality (5.8% versus
20.6%, P 5 0.0003), which was confined to those patients
receiving at least one IMA graft. Thus, although mortality
after CABG surgery may be increased in diabetics, CABG
surgery when indicated appears to provide a better chance
for survival than does medical therapy or PTCA.
Diabetic patients who are candidates for renal transplan-
tation may have a particularly strong indication for CABG
surgery. Approximately 20% to 30% of these patients have
significant CAD, which may be asymptomatic or unassoci-
ated with conventional cardiovascular risk factors (374,513).
One study assessed the incidence of coronary disease via
angiography (which was performed independently of the
presence of risk factors or suggestive symptoms) in 105
consecutive dialysis patients with diabetes (374). Angio-
graphic evidence of significant coronary disease was found
in 38 (36%) patients, only 9 of whom experienced prior
symptoms of angina. The degree of hypercholesterolemia,
hypertension, and smoking history did not differ between those
with and without documented coronary disease. Thus, nonin-
vasive testing and, if indicated, cardiac catheterization should
be performed before renal transplantation, because conven-
tional clinical predictors of disease are unreliable and active
intervention may improve patient outcomes (374,514). This
approach is supported by a study that randomized 26 patients
with .75% stenosis in at least one coronary artery and
relatively normal LV function to either revascularization or
medical therapy with aspirin and a calcium channel blocker
(513). Both the incidence of cardiovascular end points (2 of 13
versus 10 of 13) and mortality rate (0 of 13 versus 4 of 13) were
lower in the revascularized patients.
D. CABG in Patients With Pulmonary Disease, COPD,
or Respiratory Insufficiency
For many years, it has been recognized that patients
undergoing cardiac surgery develop variable degrees of
respiratory insufficiency postoperatively. In these patients,
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higher concentrations of oxygen are required to achieve
adequate arterial oxygen tension, primarily as a consequence
of intrapulmonary shunting. Scattered regions of atelectasis
and alveolar collapse may occur, resulting in some air spaces
receiving pulmonary blood flow that are not being venti-
lated. Other contributing factors may occur. Impaired
capillary endothelial integrity may be followed by an in-
crease in interstitial fluid and alveolar edema. Anesthetic
agents may affect pulmonary vasoconstriction. Other causes
of gas exchange abnormalities after cardiac surgery include
central effects from anesthesia and narcotics as well as CNS
embolization of air or blood clots. Impairment of carbon
dioxide elimination may develop from a rise in alveolar dead
space secondary to decreased ventilatory drive from the
effects of general anesthesia and/or narcotics. Inadequate
tidal volume from neuromuscular weakness may occur.
Changes in the mechanics of breathing may occur postop-
eratively as a result of inhalation anesthetics and/or muscle-
paralyzing agents. Pain from the chest incision and thoracic
or mediastinal chest tubes may result in diminished excur-
sion of the chest and diaphragm. Obesity and rare phrenic
nerve injury may also play a role (515). Postoperatively, early
extubation is desirable, appears safe, and does not increase
postoperative cardiac or pulmonary morbidity, especially if
the total bypass time is ,100 minutes (516,517). However,
longer periods of mechanical ventilatory support postoper-
atively may be necessary in patients who develop acute adult
respiratory distress syndrome or who have evidence of severe
pulmonary insufficiency postoperatively.
Preoperatively, it is important to identify patients with
significant restrictive or obstructive pulmonary disease. The
former includes patients with pulmonary venous congestion,
large pleural effusions, and a large, dilated heart compress-
ing the lungs, all of which may result in a reduction of lung
compliance. Restrictive lung disease is also found in patients
with interstitial lung disease including pulmonary fibrosis,
sarcoidosis, pneumoconiosis, and collagen vascular diseases.
The most common cause of preoperative pulmonary dys-
function, however, is COPD. Patients with mild COPD
and few or mild symptoms generally do well through cardiac
surgery. However, patients with moderate to severe obstruc-
tive pulmonary disease who are undergoing coronary bypass
grafting, especially those in an older age group, are at an
increased risk for operative mortality and postoperative
complications in a near-direct relation to the severity of the
degree of pulmonary dysfunction (451,518–520). Identifi-
cation of these higher-risk patients is important because
preoperative measures to improve respiratory function may
diminish postoperative complications. These measures in-
clude the use of antibiotic therapy for lung infections,
bronchodilator therapy, cessation of smoking, preoperative
incentive spirometry, deep-breathing exercises, and chest
physiotherapy. Such measures frequently permit patients
with obstructive pulmonary disease to safely undergo cardiac
surgery (518).
The parameter most commonly reported by authors in
estimating the degree of pulmonary dysfunction is the
forced expiratory volume per second (FEV1). There is little
consistency in the literature defining the level of abnormal-
ity for moderate to severe COPD. Values for FEV1 range
from ,70% to ,50% of the normal predicted value and/or
an FEV1 of ,1.5 L. Others measure arterial oxygen tension
and carbon dioxide tension. Any degree of hypercapnia
above a normal range places the patient at least in a
moderate-risk category (515,518,519), as does the need for
oxygen at home before surgery. FEV1 levels as low as 1.0 L
would not necessarily disqualify a candidate for CABG
surgery. Clinical evaluation of lung function is likely as
important as most spirometric studies. This sentiment is
reflected by Cohen et al (519), who compared 37 patients
with COPD who were undergoing CABG surgery to 37
matched control patients without COPD. They defined
COPD in clinical terms (ie, age, smoking history, presence
of preoperative arrhythmias, history of hospitalization for
shortness of breath, and evidence of COPD on x-ray film).
Those with COPD had lower values for FEV1 (1.36 6
0.032 versus 2.33 6 0.49 L [,60% of control value]) and a
lower arterial oxygen tension. This group had a significantly
higher rate of preoperative atrial and ventricular arrhyth-
mias. Postoperatively, they remained in the intensive care
unit longer, had a longer intubation period and more
frequent reintubations, had more postoperative atrial and
ventricular arrhythmias and complications, and remained in
the hospital twice as long. By 16 months postoperatively, 5
of the COPD patients had died, with deaths related to
arrhythmias. None was functionally improved after coronary
bypass surgery. These investigators concluded that clinical
COPD is a significant factor for morbidity and mortality, in
large part due to more frequent postoperative arrhythmias.
Subsequent long-term clinical benefits were significantly
reduced (519). Kroenke et al (518) reported the results of
107 operations in 89 patients with severe COPD, defined as
an FEV1 ,50% of predicted and an FEV1 to forced vital
capacity ratio of ,70%. In this diverse group, 10 patients
underwent CABG surgery. Pulmonary complications oc-
curred postoperatively in 29% of all patients and were
significantly related to the type and duration of surgery.
Mortality clustered primarily around the time of CABG (5
of 10 patients) compared with only 1 death in 97 noncoro-
nary operations. In this study, noncardiac surgery (as op-
posed to CABG) was accompanied by an acceptable oper-
ative risk in patients, even in the presence of severe COPD
(518).
Severe, reversible, restrictive pulmonary function abnor-
malities, which appear not to be caused by advanced age or
preexisting COPD, have been reported to follow coronary
bypass surgery in the early postoperative period. In the early
postoperative period, these changes may delay ventilator
weaning in the first 72 hours, but full recovery is expected
(521). Wahl et al (521) compared pulmonary function in a
group of patients older than age 70 with a group with
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COPD, defined as a ratio of FEV1 to forced vital capacity
of ,70% and total lung capacity ,80% of predicted, and a
normal group in the preoperative and postoperative periods.
All 3 groups demonstrated comparable decreases in FEV1,
total lung capacity, and forced vital capacity postoperatively.
Partial recovery occurred by day 7 and returned to preop-
erative levels by 3 months (521). Similar findings were
reported by Goyal et al (522) after CABG with saphenous
veins, IMAs, or a combination. Others have reported more
severe abnormalities of pulmonary gas exchange and pul-
monary function through 72 hours postoperatively in pa-
tients receiving left IMA grafts, with normality returning by
hospital discharge (523,524).
A history of COPD and .2 days on a mechanical
ventilator postoperatively have been reported as risk factors
for nosocomial pneumonia in postoperative coronary bypass
patients (525) and have been documented as a risk factor for
mediastinitis (526,527). Moderate to severe degrees of
obstructive pulmonary disease preoperatively, whether de-
fined by clinical or laboratory parameters, represent a
significant risk factor for early mortality and/or postopera-
tive morbidity in patients undergoing CABG. However,
with careful preoperative assessment and treatment of the
underlying pulmonary abnormality, many patients may be
successfully carried through the operative procedure.
E. CABG in Patients With End-Stage Renal Disease
The latest available data indicate that during 1995,
.257,000 Americans were treated for ESRD, with substan-
tial associated morbidity and mortality (528). Data from the
US Renal Data System (USRDS) have established that the
mortality rate of dialysis patients in the United States is high
compared with that of other industrialized nations (528).
The basis for this difference is not well understood, but case
mix appears to be of great importance, with a major factor
being cardiovascular disease (529). Previous data from the
USRDS have indicated a 41% prevalence of cardiovascular
disease among dialysis patients, with the mortality risk for
these patients being 22% greater than for those free of
disease (530). MI and other cardiac disorders constitute the
leading causes of death in the ESRD population, and death
rates due to cardiac disease increase dramatically with age in
these patients. With growing numbers of older patients
undergoing renal replacement therapy, the number of pa-
tients with ESRD who present with CAD amenable to
surgical revascularization is likely to increase.
Cardiovascular disease is the single best predictor of
mortality in patients with ESRD, as it accounts for almost
54% of deaths (528). The high rate of cardiac morbidity and
mortality is occurring at a time when the prevalence of
coronary disease is declining in the general population and
is related in part to the changing nature of new patients
being started on dialysis. At present, more than one third of
such patients have diabetes mellitus, and the average patient
age at initiation of dialysis is .60 years. In addition to the
foregoing, patients with ESRD have a number of other risk
factors for cardiovascular mortality, including hypertension,
LV hypertrophy, myocardial dysfunction, abnormal lipid
metabolism, anemia, and increased plasma homocystine
levels.
When indicated, dialysis patients can be treated with
either PTCA or CABG. The indications for these proce-
dures are similar to those in non-ESRD subjects with
coronary disease. Coronary revascularization with surgery or
PTCA is associated with better survival than is standard
medical therapy in several specific settings. These include
patients with a modest decrease in LV function, significant
left main coronary disease, 3-vessel disease, and unstable
angina (531). Although these patients also are at increased
risk for operative morbidity and mortality, they are at even
higher risk when treated with conservative medical manage-
ment.
It should be noted that patients with chronic renal failure
clearly differ in several respects from other patients who
undergo surgical coronary revascularization. Patients with
ESRD often have multiple comorbid disorders, including
hypertension and diabetes mellitus, each with its own
complications and associated impact on both short- and
long-term survival (532). In addition, infection and sepsis
have been identified as significant causes of morbidity and
mortality in patients with ESRD undergoing cardiac surgi-
cal procedures (532). As a result of these factors and others
such as perioperative volume and electrolyte disturbances,
patients with chronic renal failure are at increased risk for
complications after coronary bypass grafting.
Both the mortality with CABG and the complication rate
with PTCA appear to be increased in patients with ESRD
(533,534). An additional problem is that the success rate
with PTCA is less satisfactory in this setting. In one small
series, for example, the angina recurrence rate was 75% and
the restenosis rate was 81%, and subsequent restenosis
occurred in 11 of 12 vessels after repeated PTCA (none of
these patients had stents) (535). There also is evidence that
the risk of cardiac events in dialysis patients is higher after
PTCA than after CABG (533,536). Thus, CABG is the
preferred approach in the treatment of severe coronary
disease in patients with ESRD, as confirmed in a more
recent study indicating that dialysis patients undergoing
PTCA have a higher risk of subsequent angina, MI, and
cardiovascular death than do those undergoing CABG
(537).
In one recent large series, CABG was associated with
significant improvement in cardiac symptoms and overall
functional status in patients with ESRD on dialysis (538).
In fact, the patients in this series represent a subgroup of
patients with severely debilitating symptoms of coronary
disease along with many associated risk factors other than
renal failure. Nevertheless, overall 30-day mortality for the
group was 9%, and the reduction in cardiac symptoms was
excellent, both at discharge and during follow-up. Thus,
CABG in dialysis patients may be associated with an
acceptable mortality, with a significant increase in the
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quality of life for long-term survivors. Each of the 19
hospital survivors in this series returned to routine mainte-
nance dialysis therapy and enjoyed symptomatic improve-
ment. However, because this retrospective study lacked the
matched control groups of prospective randomized studies,
this study cannot definitively compare coronary bypass
grafting with other therapies for patients with ESRD and
coronary disease.
Thus, the primary question remaining to be answered is
whether freedom from cardiac-related events is improved by
surgical revascularization in dialysis patients. Unfortunately,
alternatives to revascularization often are limited in patients
with severe coronary symptoms refractory to medical ther-
apy, and long-term results of PTCA have been relatively
poor in ESRD patients (537). More definitive demonstra-
tion of the relative costs and benefits of CABG in this
patient population awaits future studies, particularly in
patients who present for elective revascularization.
In summary, coronary bypass grafting may be performed
for selected patients with ESRD who are dialysis depen-
dent, with increased but acceptable risks of perioperative
morbidity and mortality. Early after revascularization, pa-
tients may expect relief from coronary symptoms with
coincident improvement in overall functional status. How-
ever, long-term survival remains relatively limited in this
patient population, suggesting a need for further investiga-
tions to establish the relative costs and benefits of revascu-
larization in patients with dialysis-dependent ESRD.
F. Valve Disease
The coexistence of CAD and valvular disease will vary
throughout the population, dependent on which disease
initiates the patient’s symptoms, their age, sex, and clinical
risk factors. The incidence of aortic valve disease in patients
undergoing CABG is much less than the incidence of CAD
in patients undergoing valve replacement. In general, the
incidence of CAD in patients with typical angina who are
undergoing aortic valve replacement (AVR) is 40% to 50%
and drops to ’25% in patients with atypical chest pain and
to ’20% in those without chest pain (539–546). The
incidence of CAD is generally less in patients with aortic
regurgitation than aortic stenosis owing to the younger
patient population presenting with aortic regurgitation
(539–546). The incidence of CAD in patients with mitral
stenosis is small, owing to the fact that this lesion is more
frequently seen in middle-aged women.
There is a distinctive relationship between MR and
CAD, especially when the mitral valve is structurally normal
but functionally regurgitant. This MR is usually caused by
ischemia. The quandary this presents is when the MR
requires correction at the time of CABG. The question is
easily answered if there are structural abnormalities in the
mitral apparatus. Mitral repair is indicated in the majority of
such circumstances, although occasional patients require
valve replacement. The structurally normal mitral valve may
be regurgitant due to reversible ischemia involving the
papillary muscles, and the dilemma is when it is necessary to
inspect the mitral valve for correction. Intraoperative TEE
has brought dramatic refinement to this question by pro-
viding a functional and quantitative assessment before and
after CPB. When the MR is grade 1 to 2, this may decrease
during anesthesia induction and/or with complete revascu-
larization, thus eliminating the need to inspect the valve
during cross-clamping of the aorta. An added finding by
echocardiography or direct inspection at the time of oper-
ation is the presence of an enlarged left atrium, which
generally signifies chronicity to the MR and adds justifica-
tion to the consideration of mitral valve repair. This strategy
is further assessed by a final post-CPB TEE in the operat-
ing room. If, under this rare circumstance, the MR is
unacceptable, reinstitution of CPB can be performed and
the MR corrected. For instance, if the MR is grade 3 to 4,
it is necessary to inspect the valve and correct the mechan-
ical lesion. It is important to stress that in this situation, it
is imperative that an intraoperative TEE be performed to
see whether the MR is grade 3 to 4, to assess the reparability
of the valve, and to assess success of the repair.
For situations in which patients are undergoing mitral
valve surgery and have “incidental” CAD and nonischemic
mitral valve disease, the approach has been to perform
CABG on vessels with .50% stenosis at the same opera-
tion. There are far fewer data on this topic than that of AVR
and CAD, but conventional wisdom has promoted this
policy, and there have not been reports of significant
increases in operative mortality.
The discussion of combined procedures revolves around
overall operative risk, which is dependent on several vari-
ables. The most notable of these are age .70 years, female
sex, advanced NYHA class, poor LV function, and multiple
valve procedures (547). There is also a difference in early and
late mortality when the valve lesion is aortic versus mitral
and when the mitral lesion is ischemic. The simple addition
of MR to a coronary bypass without valve correction
increases the operative mortality to 3% to 5%. The operative
mortality of rheumatic mitral valve disease and CAD varies
from 3% to 20% (548).
The results of combined aortic valve and coronary disease
have led to the recommendation to graft significantly
obstructed vessels ($50%) when an AVR is performed. The
operative mortality for patients undergoing AVR who have
ungrafted CAD approaches 10%, while those patients
having AVR and concomitant CABG for CAD have an
operative mortality approaching that of AVR alone (549). It
is generally accepted that the risk of adding CABG to a
valve replacement or repair will increase the operative
mortality over that of an isolated valve procedure. The
additional variables of age .70 or 80 years and poor LVEF
will further increase this risk.
Another aspect of this combined condition is the patient
with prior CABG who now requires a valve replacement or
repair. There is inconclusive evidence whether or not the
reoperative risk of late AVR after previous CABG is
1306 Eagle and Guyton et al. JACC Vol. 34, No. 4, 1999
ACC/AHA Guidelines for CABG Surgery October 1999:1262–347
significantly increased. Sundt et al (550) stated that the
operative risk for AVR alone was 6.3%, whereas the risk of
AVR after previous CABG was 7.4%. Odell et al (551)
found the risk of reoperative AVR with prior CABG to be
12%. A report from the same institution identified an
operative risk of 3.7% (11 of 297) for isolated AVR (552).
The discrepancy may be due to sample size, in that the
article by Sundt et al reviewed 52 patients, whereas Odell et
al reported on 145 patients undergoing reoperation for AVR
with prior CABG.
G. Reoperation
Reoperation for CAD is responsible for as many as 15%
to 18% of all CABGs in some centers. The STS National
Database, which has collected data since 1987, reports an
incidence of 8.6% to 10.4% with a total patient enrollment
of 594,059. At least 2 factors explain this discrepancy. First,
enrollment in the STS National Database is voluntary. This
means that not all cases are required to be sent to the data
center. It simply reports the incidence of reoperations of
those patients enrolled. To the extent that centers may only
be enrolling first-CABG cases, the data may underestimate
the true incidence. Second, nationwide the incidence of
reoperations varies among centers, with tertiary care centers
receiving reoperation referrals that were not deemed appro-
priate at primary (or community) centers. As has been well
documented in the early years of CABG, the predominant
reason that reoperation is necessary is the development of
vein-graft atherosclerosis. Although there is disease pro-
gression in native vessels and the development of new
disease in previously ungrafted coronary arteries, these do
not approach the frequency and clinical importance of late
SVG disease.
The operative mortality of reoperations for CABG is
distinctly higher than the mortality of first-time operations.
Reoperative mortality increases with the urgency or severity
of symptoms, age .65 years, ,1 year between first and
second operations, and low EF (34) (Table 15) (553–555).
The highest risk seems to be associated with a short time
interval between the first operation and the subsequent need
for reoperation. Christenson et al (34) reported a reoperative
mortality risk of 18% in a group of patients who underwent
reoperation ,1 year after their first CABG. This figure was
compared with an 8% mortality in those patients who had
an operation-free time of .1 year. The presence of diabetes
was greater in the group undergoing operation in ,1 year.
Third- and fourth-time coronary bypass operations are
becoming more frequent with longer follow-up. Occlusion
or stenosis of prior placed grafts was the principal reason for
reoperation in .90% of the patients. It was also noted that
the risk of left main disease and/or triple-vessel disease was
more prevalent in the multiple-reoperation patient group
(555). Second- or third-time reoperations for CABG are
associated with a higher incidence of perioperative compli-
cations, including reoperation for bleeding, perioperative
MI, and neurological and pulmonary problems (Table 15).
The 5- and 10-year survival after reoperation for CAD is
reported at 77% and 48%, respectively (554,555). These late
results provide significant reason to recommend patients for
reoperation provided that the severity of symptoms and
anticipated benefit justify the risk. It has been argued that
once the patient’s symptoms present, it is better to proceed
with prompt revascularization rather than delay the proce-
dure, during which time the condition may progress and
lead to an emergency operation, which carries a much
higher perioperative risk (554,556).
One intriguing aspect of the reoperation question is what
effect arterial grafts will have on the incidence and risks of
reoperation. One recent report (555), comparing the effect
Table 15. Risk for First, Second, and Third Reoperation for CABG
CASS, % Portland, %
Mayo,
Secondary, %
Cleveland Clinic,
Secondary, %
Mayo,
Tertiary, %
Cleveland Clinic,
Tertiary, %
Hospital mortality 3.1 2.0 2.8 3.4 11.9 7.0 (0–14)
Perioperative MI 5.8 4.2 7.5 7.2 8.9
Reoperation/bleeding 2.9 4.6 4.7 6.8 6.0
Wound infection 1.9 0.6 1.9 1.6 3.0
Neurological complication 0.8 1.2 0.9 2.1 4.5
Overall survival, %
5 Years 95 90 94 90 75 84
10 Years 89 75 89 75 48 66
Event-free survival, %
5 Years 78 63 76 74
10 Years 50 26 48
Angina-free survival, %
5 Years 28 52
10 Years 64
CABG indicates coronary artery bypass graft; CASS, Coronary Artery Surgery Study; and MI, myocardial infarction.
References for each study are as follows: CASS (557,558); Portland (559); Mayo—secondary (560); Mayo—tertiary (555); Cleveland Clinic—secondary (561); and Cleveland
Clinic—tertiary (554).
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on late events of single versus bilateral IMAs used for
coronary revascularization, demonstrated a reduction in late
events, including reoperation, with the use of both IMAs.
This finding, however, was not independent of the presence
of diabetes. This implies that patients with diabetes were
unlikely to have had bilateral IMAs used, presumably owing
to the fear of increased incidence of sternal wound infection
with the use of both IMAs. Also, the incidence of reopera-
tion is increased when an IMA is not used at the first
operation. The future of coronary artery surgery is being
rewritten in light of arterial coronary grafting. To date,
there are sparse data to guide recommendations advocating
multiple arterial grafting, though advocated by many. How-
ever, it is accepted that superior results occur with use of the
left MA, especially when grafted to the LAD.
H. Concomitant PVD
The coexistence of CAD and PVD is well known. It is
estimated that the prevalence of serious, angiographic CAD
ranges from 37% to 78% in patients undergoing operation
for PVD (562). CAD is the leading cause of both early and
late mortality in patients undergoing peripheral vascular
reconstruction (563). MI is responsible for about half of all
postoperative deaths in patients undergoing abdominal
aortic aneurysm resection (564,565), extracranial revascular-
ization (190,566), or lower-extremity revascularization
(565,567). Long-term survival after successful vascular re-
construction is limited by the high incidence of subsequent
cardiac death (568). On the other hand, the presence of
PVD is a strong, independent predictor of long-term
mortality in patients with stable chronic angina (569). After
successful myocardial revascularization, patients with PVD
are at substantially increased risk for in-hospital (570) and
long-term (41) mortality.
The importance of preoperative cardiac evaluation was
demonstrated by Hertzer et al (563) in a study of 1,000
patients with PVD: abdominal aortic aneurysm, cerebrovas-
cular disease, or lower-extremity ischemia. All 1,000 pa-
tients underwent coronary angiography. Severe, surgically
correctable CAD was found in 25% of the patients; 34% of
the patients suspected to have CAD on clinical grounds
were found to have severe, surgically correctable CAD; 14%
of the patients not suspected to have CAD were found to
have severe, surgically correctable CAD. The early postop-
erative mortality rate after the peripheral vascular proce-
dures was lower in patients who had preliminary CABG
compared with those who did not. The long-term beneficial
effect of preliminary CABG in patients undergoing periph-
eral vascular reconstruction was reported by Eagle et al
(569) in their retrospective cohort analysis of 1834 patients
with combined CAD and PVD. Nine hundred eighty-six
patients received CABG and 848 patients were treated
medically. In a mean follow-up of 10.4 years, 1100 deaths
occurred and 80% were due to cardiovascular causes. The
group treated with surgical coronary revascularization had
significant survival benefits at 4, 8, 12, and 16 years
compared with patients treated with medical therapy alone.
Subgroup analysis suggested that the long-term survival
benefits of surgical coronary revascularization were particu-
larly seen in patients with 3-vessel CAD and depressed
LVEFs.
The predictive value of PVD for short- and long-term
clinical outcomes of patients receiving CABG was also
examined by the Northern New England Cardiovascular
Disease Study Group (41,570). In-hospital mortality rates
with CABG in patients with PVDs were 7.7%, a 2.4-fold
higher incidence than in patients without PVD (3.2%).
After adjusting for higher comorbidity scores associated
with patients with PVD, patients with PVD were 73% more
likely to die in hospital after CABG. The excess risk of
in-hospital mortality associated with PVD was particularly
notable in patients with lower-extremity occlusive disease
(adjusted OR 2.03). The presence of cerebrovascular disease
had a small but nonsignificant effect on CABG-related
in-hospital deaths (adjusted OR 1.13). Excess mortality
rates in patients with PVD were due primarily to an
increased incidence of heart failure and dysrhythmias rather
than cerebrovascular accidents or peripheral arterial compli-
cations. The difference in mortality rate was also apparent at
long-term follow-up. Five-year mortality after CABG was
substantially higher in patients with PVD than in those
without PVD, with a crude hazard ratio of 2.77 and an
adjusted hazard ratio of 2.01 after multivariate adjustment
for comorbid conditions. Significantly elevated, adjusted
hazard ratios occurred in patients with overt cerebrovascular
disease, clinical and subclinical lower-extremity occlusive
disease, abdominal aortic aneurysm, and combined PVDs.
Asymptomatic carotid bruit or stenosis conferred a small
nonsignificant increased adjusted hazard ratio of 1.47. In
summary, the presence of clinical and subclinical PVD is a
strong predictor of increased in-hospital and long-term
mortality rate in patients undergoing CABG.
I. Poor LV Function
LV function is an important predictor of early and late
mortality after coronary artery surgery. LV dysfunction is
associated with an increased risk of perioperative and
long-term mortality in patients undergoing coronary bypass
surgery compared with patients with normal LV function.
Both low EF and clinical heart failure are predictive of
higher operative mortality rates with CABG (571). In 6630
patients who underwent isolated CABG surgery in the
CASS registry, the average operative mortality was 2.3%,
ranging from 1.9% in patients with an EF $0.50 to 6.7% in
patients with an EF ,0.19 (572). An operative mortality of
6.6% in patients with an EF ,0.35 in comparison with
2.6% in patients with an EF .0.50 was recently reported
(573). Compared with patients with an EF of 0.40 or
higher, patients whose EF was ,0.20 or between 0.20 and
0.39 had 3.4 and 1.5 times higher perioperative mortality
rates, respectively (17). Reports of perioperative mortality
rate varied widely, ranging from ’5% in excellent centers in
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patients of a younger age, with fewer symptoms, and having
no comorbid conditions, to .30% in patients who were
older, with severe ventricular dysfunction, and having sev-
eral comorbid conditions (571). A trend toward lower
operative mortality rates in recent years compared with
those in early years has been reported, perhaps due to better
myocardial protection techniques and perioperative man-
agement in the contemporary period.
Analysis of patients with an EF ,0.35 from the CASS
registry showed 5-year survival rates of 73%, 70%, and 62%
in patients with an EF from 0.31 to 0.35, 0.26 to 0.30, and
,0.25, respectively (574). A comparison between surgically
treated and medically treated groups revealed the greatest
surgical benefit in patients with an EF of 0.25 or less. The
medically treated patients had a 5-year survival rate of 43%
compared with 63% for those treated with coronary bypass
surgery. A comparison study of 5,824 patients who under-
went medical or surgical therapy for ischemic heart disease
in the Duke University Cardiovascular Database showed
that patients with the worst LV function (EF ,0.35) had
the greatest 10-year survival benefit from bypass surgery
(46% versus 27%). Patients with an EF of 0.35 to 0.50 had
a 10-year survival rate of 62% in the surgical group versus
50% in the medical group (90). Patients with severe LV
dysfunction have increased perioperative and long-term
mortality compared with patients with normal LV function.
However, the beneficial effects of myocardial revasculariza-
tion in patients with ischemic heart disease and severe LV
dysfunction are clearly evident when compared with medi-
cally treated patients in terms of symptom relief, exercise
tolerance, and long-term survival (90,571,575,576). Patient
selection is crucial for achieving the beneficial effects of
myocardial revascularization in this subset of patients and is
discussed in Section IX.
J. Transplantation Patients
Cardiac transplantation is an accepted treatment for
end-stage heart failure, with .30,000 cardiac transplanta-
tions performed worldwide to date (577). Allograft CAD is
the leading cause of death after the first year of transplan-
tation (578–580). This type of occlusive CAD is diffuse,
often rapidly progressive, and affects a substantial number of
heart transplant recipients. The incidence of angiographic
transplant vasculopathy is estimated at 40% to 45% at 3 to
5 years posttransplantation with a yearly attrition rate of
15% to 20% (581,582). Angina pectoris is rarely the
presenting symptom in patients with allograft CAD owing
to the lack of afferent autonomic innervation, although
partial reinnervation of the allograft can occur. Silent MI,
heart failure due to loss of allograft function, and sudden
cardiac death are the common signs of cardiac allograft
vasculopathy (581). Analysis of coronary angiograms of
affected cardiac allografts has revealed unique morphological
features consisting of diffuse, concentric narrowing in mid-
dle and distal vessels with distal vessel obliteration and a
paucity of calcium deposition (583). The underlying patho-
physiology of allograft vasculopathy is largely unknown, but
it is likely a common final pathway of a constellation of
immunologic and nonimmunologic injuries, namely chronic
rejection, cytomegalovirus infection, hyperlipidemia, and
older donor age (583–585). Treatment of hyperlipidemia
with pravastatin (586) or weekly low density lipoprotein
apheresis (587) has been reported to lower the incidence of
coronary vasculopathy or even lead to regression. Currently,
retransplantation is the only definitive therapy for advanced
allograft vasculopathy. Good results had been reported with
coronary angioplasty and directional coronary atherectomy
in selected patients with discrete and proximal coronary
lesions (588,589). In general, coronary bypass surgery is not
an option because of the diffuse type of coronary disease in
patients with cardiac allograft vasculopathy. Isolated cases of
successful coronary bypass grafting have been reported
(590,591). In a recent report of 5 patients who underwent
CABG for cardiac allograft vasculopathy, 3 patients died
during the perioperative period and 1 died at 50 days.
It is well known that ESRD is associated with an
increased risk of CAD (592). The safety and efficacy of
coronary bypass grafting were recently reported in 31 renal
transplant patients who underwent isolated coronary bypass
surgery (593). Perioperative mortality was 3.2%, and no
renal allograft function was impaired. Overall, 1- and 5-year
survival rates for patients undergoing open heart surgery
were 88% and 85%, respectively (593). The safety and
efficacy of CABG were also reported in a small series of 3
patients with transplanted livers, with no deaths or hepatic
decompensation and good improvement of cardiac symp-
toms (594).
K. CABG in Acute Coronary Syndromes
The acute coronary syndromes represent a continuum
from severe angina to acute MI. Various classifications are
based on the presence or absence of Q waves associated with
evidence for myocardial necrosis, the elevation or depression
of ST segments on the electrocardiogram, and clinical
definitions based on the pattern of angina. Historically, and
for the purposes of this document, a clinical definition
encompassing progressive, rest, and postinfarction angina
and Q-wave and non–Q wave MI will be used to examine
the effects of surgery.
The effectiveness of CABG for unstable angina was first
demonstrated in a randomized Veterans Administration
trial comparing medical therapy with CABG initiated in
1976 (595). Although there was no overall difference in
survival between medically and surgically treated patients,
an improvement in survival with CABG occurred in pa-
tients in the lowest tertile of EF (0.3 to 0.58) at 3, 5, and 8
years of follow-up (106), in those with 3-vessel disease
(596), and in those with LV dysfunction presenting with
electrocardiographic changes (597). At 5 years of follow-up,
surgically treated patients had less angina and improved
exercise tolerance and required fewer antianginal medica-
tions than did the medically treated patients (111). It is
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difficult to interpret the results of this study because surgical
and medical therapies have both evolved substantially,
including the routine use of modern techniques for myo-
cardial preservation, arterial bypass conduits, aspirin,
thrombolytics, and PTCA.
There have been no randomized trials specifically com-
paring CABG and PTCA in patients with unstable angina
and multivessel CAD. The BARI trial prespecified a com-
parison subgroup based on the severity of angina. In this
trial, 7% of patients had unstable angina or non-Q wave MI.
There was no difference in 5-year overall survival for these
patients treated with either CABG (88.8%) or PTCA
(86.1%, P 5 NS) (118). However, there was an increased
cardiac mortality in patients treated with PTCA (8.8%)
compared with CABG (4.9%), and this difference was
entirely due to a difference in outcomes in treated diabetic
patients (131).
In contrast, EAST included a large proportion (60%) of
randomized patients with Canadian Cardiovascular Society
Class IV angina, and there was no difference in mortality at
3 years (120). Similarly, 59% of enrollees in RITA had rest
angina, and this study demonstrated no significant differ-
ences in death or MI at 2.5 years of follow-up (127). There
was a particularly high incidence of unstable angina (83%)
in the small ERACI trial (132). These patients had mostly
complex lesions (50% type B2 and 13% type C), which are
associated with greater angioplasty complications (598).
However, in-hospital mortality was higher with CABG
(4.6% versus 1.5%), and 3-year survival and freedom from
Q-wave MI were similar for both forms of revascularization
(132).
No studies have addressed the important subset of pa-
tients with unstable angina after prior CABG. The culprit
lesion in these patients is often located in a vein graft, where
both angioplasty and reoperative CABG have less success
(393).
Several early studies performed before 1990 demonstrated
an increased surgical mortality ranging from 4.6% to 7.3%
in patients with unstable angina (395,599–601). More
recent studies have confirmed this finding (602,603). In the
series of Louagie et al (602), 474 patients admitted with
prolonged rest angina and requiring surgery during the same
hospitalization had an operative mortality of 6.8% and a
perioperative MI rate of 7.2%, and 19% required placement
of an IABP. A recent study examining early revasculariza-
tion versus conservative therapy for patients with non–Q
wave MI had a much higher 30-day surgical mortality (12%)
in patients undergoing early CABG compared with those
managed conservatively (5%) (398).
In patients with postinfarct angina, a higher mortality has
been observed, particularly with early operation after
Q-wave infarction (390,599,604). Braxton et al (606) com-
pared 116 patients operated on within 6 weeks of MI with
255 patients without prior MI. Mortality was highest (50%)
in 6 patients with Q-wave infarcts undergoing surgery ,48
hours after infarction versus 7.7% in 52 patients undergoing
surgery 3 to 42 days after infarction and versus 2% to 3%
when CABG was performed even later and in patients
without prior infarction. Factors associated with adverse
outcomes during CABG for unstable angina are listed in
Table 16.
The use of CABG for primary reperfusion during
Q-wave MI has largely been superseded by thrombolysis
and primary PTCA. Early coronary bypass for acute infarc-
tion may be appropriate in patients with residual ongoing
ischemia despite nonsurgical therapy, and if other condi-
tions warrant urgent surgery, including left main or 3-vessel
disease, associated valve disease, mechanical complications,
and anatomy unsuitable for other forms of therapy.
In conclusion, CABG offers a survival advantage com-
pared with medical therapy in patients with unstable angina
and LV dysfunction, particularly in those with 3-vessel
disease. Currently, there is no convincing survival advantage
for surgery over PTCA in patients with unstable angina
suitable for treatment with either technique. However, the
risk of CABG in patients with unstable angina, postinfarc-
tion angina, early after non-Q wave MI, and during acute
MI is increased severalfold relative to patients with stable
angina, although the risk is not necessarily higher than that
of medical therapy for these patients.
VI. IMPACT OF EVOLVING TECHNOLOGY
A. Less-Invasive CABG
Technical modifications of traditional CABG have been
developed in the last several years in an attempt to decrease
the morbidity of the operation, either by using limited
Table 16. Factors Associated With Adverse Outcome During
Coronary Artery Bypass Grafting for Unstable Angina
Factor
Relative Risk of
Mortality (Range)
Clinical
Recent MI: ,24 h (605),
,48 h (606), ,30 d (457)
2.1–18
Female (457,602,604,605) 1.4–1.7
Reoperation (457,602,604,605) 2.9–5.8
Age (457,458,604,607) 2.9–5.3*
IDDM (607) 8.3†
Angiographic/hemodynamic
No. of diseased vessels (602,604) . . .
LV dysfunction (457,458,604) 1.9–2.3 (EF 0.20–0.39)
5.9–10.7 (EF , 0.20)
Hypotension (458,605) 6.5–7.8
Surgical
Aortic cross-clamp time (602,607) 2.25‡
Urgent surgery (604,605) 1.8–1.9
Bypass time (607) . . .
IABP support (607) 4.1
MI indicates myocardial infarction; IDDM, insulin-dependent diabetes mellitus; LV,
left ventricular; IABP, intra-aortic balloon pump; and EF, ejection fraction.
*Age .70 years. †Relative risk for perioperative MI. ‡Relative risk major of
adverse outcome $100 vs ,100 minutes.
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incisions or by eliminating the use of CPB. These tech-
niques were greatly advanced by Bennett’s suggestion in
1994 at the International Symposium on Myocardial Pro-
tection in Chicago (608) that CABG could be performed
through a small left thoracotomy with the aid of a thoraco-
scope on a beating heart. Less-invasive CABG surgery can
be divided into 3 categories: 1) Off-bypass coronary artery
bypass is performed through a standard median sternotomy
and generally with a smaller skin incision. A local stabili-
zation device is used to immobilize the target vessels, and
anastomoses are performed without the use of CPB. 2)
Minimally invasive direct coronary artery bypass (MID-
CAB) is performed through a left anterior thoracotomy
without CPB, with or without thoracoscopic techniques. 3)
Port-access coronary artery bypass is performed with
femoral-femoral CPB and cardioplegic arrest with limited
incisions.
The potential benefits of off-pump CABG are the avoid-
ance of CPB and potentially a smaller skin incision and less
retraction of the sternum during median sternotomy. CPB
is associated with a 1% to 5% incidence of stroke and other
complications including myocardial stunning, pulmonary
edema, bleeding, renal insufficiency, and systemic thrombo-
embolism (609).
CABG surgery on a beating heart without CPB was first
reported by Kolessov in 1967, who was technically chal-
lenged by the motion of the heart, and access to the
posterior surface of the heart was not possible (10). The
technique was largely abandoned in the United States after
the advent of CPB. However, CABG on a beating heart
was still practiced in several countries, where much experi-
ence was accumulated (610,611). Off-pump coronary bypass
is performed on a beating heart by the reduction of cardiac
motion with a variety of pharmacological agents and me-
chanical devices. These include slowing the heart with
b-blockers and calcium channel blockers, creating a tempo-
rary cardiac arrest with adenosine (612), or vagal simulation
(613). Various techniques for elevation of the heart have
been developed, thereby allowing some access to the vessels
on the lateral side of the inferior surface of the heart in
addition to the vessels on the anterior surface. Because this
technique is performed through a full median sternotomy, it
would be considered slightly more invasive than the anterior
thoracotomy approach described in the next paragraph.
The term “MID-CAB” should be reserved for perfor-
mance of CABG without median sternotomy and without
the use of CPB. In general, this is performed through a left
anterior thoracotomy, which exposes the heart through the
fourth intercostal space with access to the LAD and
diagonal branches (and occasionally, anterior marginal ves-
sels). The right coronary artery may also be approached
through a right anterior thoracotomy in a similar manner.
At the Second Utrecht Minimally Invasive Coronary
Artery Bypass Grafting workshop, .3,000 performed cases
of CABG on a beating heart with 4,400 anastomoses were
reported (614). More than 1,000 cases were done with
minithoracotomy (ie, the MID-CAB procedure). The mean
number of anastomoses per patient ranged from 1.0 to 2.0
grafts. Forty-nine percent of these patients had single-vessel
disease, 28% had 2-vessel disease, and 13% had 3-vessel
disease. Hospital stay was reduced from an average of 8 days
for conventional CABG to 4 days. Patients returned to
work and social activities after 2 to 3 weeks.
Calafiore and colleagues (615) recently reported their
experience of 366 patients undergoing single-vessel left
IMA-to-LAD anastomosis via a small, left anterior thora-
cotomy. Half of the patients had single LAD disease and
the rest had LAD as a part of multivessel disease. The
30-day mortality rate was 0.8%, 23-month actuarial survival
rate was 98%, and event-free survival was 88% (91% in
patients with single-vessel disease versus 86% in those with
multivessel disease, P 5 0.006). Graft patency rate was 93%
by angiography or Doppler examination. Five percent and
2% of patients, respectively, required operative revision for
malfunctioning grafts during early (,30 days) and late (.30
days) periods. Forty percent of the patients were extubated
in the operating room or 1 hour postoperatively. Mean
intensive care unit and hospital stays were 4.2 and 53 hours,
respectively.
Although this and other early reports (614,616–618) of
clinical results are encouraging, they should be viewed with
caution. The number of anastomoses performed on a
beating heart is usually 1 and occasionally 2. The subset of
patients with single-vessel CAD who require coronary
revascularization is relatively small. Most clinical reports of
MID-CAB procedures have included patients with mul-
tivessel disease. Incomplete revascularization in patients
with multivessel occlusive CAD has been shown to be
associated with increased cardiac events and death
(117,619). Preliminary reports of MID-CAB experience
have demonstrated the benefits of rapid recovery, a shorter
hospital stay, less perioperative morbidity, a faster return to
routine activities, and cost reduction (620). Clearly, the
long-term efficacy of MID-CAB procedures remains to be
determined, particularly with regard to long-term graft
patency. The techniques and indication for the MID-CAB
procedure continue to evolve, and its ultimate role in the
surgical armamentarium of coronary artery revascularization
is being clarified.
The third emerging technique in less-invasive cardiac
surgery is the closed-chest, port-access, video-assisted
CABG operation developed at Stanford, Calif (621). CPB
and cardioplegia of a globally arrested heart are integral
parts of this technology. Vascular access for CPB is achieved
via the femoral artery and vein. A triple-lumen catheter with
an inflatable balloon at its distal end is used to achieve
endovascular aortic occlusion, cardioplegia delivery, and LV
decompression. With CPB and cardioplegic arrest, CABG
can be performed on a still and decompressed heart, through
several small ports and with the aid of a videoscope. In
comparison with the MID-CAB approach, the port-access
technique allows access to different areas of the heart, thus
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facilitating more complete revascularization, and the mo-
tionless heart allows for accurate anastomosis. The proposed
advantage of this approach compared with conventional
CABG is the avoidance of median sternotomy, with the
resultant diminished incisional pain and faster recovery. A
recent published report showed excellent perioperative
safety and graft patency in animal experiments with the
port-access technique in the performance of a left IMA-to-
LAD anastomosis (622). Clinical trials are currently ongo-
ing. The potential morbidity of the port-access technique
stems from the multiple port sites, limited thoracotomy, and
groin dissection for femoral-femoral bypass. The short- and
long-term safety, benefits, and efficacy of the minimally
invasive port-access approach must be compared with the
conventional operation in an appropriately controlled clin-
ical trial. As in any new technology, vigorous scientific
scrutiny must be applied before any conclusions can be
made.
B. Arterial and Alternate Conduits
The choice of graft conduits is crucially important in
CABG because short- and long-term graft patency is closely
associated with cardiac morbidity and mortality. The stan-
dard choice of graft conduits in the past 15 years has been
the in situ IMA and greater saphenous veins. In the early
1980s, the SVG was shown to be prone to progressive
intimal proliferation and atherosclerotic changes (623). In
1985, Barner et al (624) reported superior IMA graft
patency in comparison with SVGs in 1000 patients over a
12-year period. At 1 year, IMA grafts and SVGs had
comparable patency rates of 95% and 93%, respectively.
However, at 5 and 10 years, IMA grafts were shown to have
a superior patency rate of 88% and 83%, respectively,
compared with a patency rate of 74% and 41% in SVGs. In
addition, the use of a single IMA graft was associated with
a low perioperative complication rate. A large, long-term
follow-up study comparing patients receiving left IMA-to-
LAD and supplemental vein grafts with patients receiving
SVGs only demonstrated a significantly lower rate of
recurrent angina and MI, a lower incidence of reoperation
or PTCA, and higher actuarial 10-year survival among
patients with IMA grafts (625). The routine use of the left
IMA for LAD grafting with supplemental SVGs to other
coronary artery lesions is generally accepted as the standard
grafting method.
Circumstances may exist in which the autologous IMA
and/or greater saphenous vein is absent or unsuitable as a
result of intrinsic venous disease, prior myocardial revascu-
larization, varicose vein ligation, and previous peripheral
artery reconstruction. In these circumstances, alternative
coronary conduits must be used. Alternative conduits in-
clude autologous venous and arterial grafts, preserved non-
autologous venous and arterial grafts, and synthetic grafts.
When the greater SVG is not available, the lesser saphenous
vein and upper-extremity veins, mainly the cephalic and
basilic vein, can be used. Long-term patency of upper-
extremity vein conduits is poorer than that of the SVG. The
choices for autologous arterial conduits, in addition to the
left IMA, are the right IMA, radial artery, right gastroepi-
ploic artery, inferior epigastric artery, and very rarely, the
subscapular, intercostal, splenic, left gastric, and gastrodu-
odenal artery.
Barner in 1974 (626) first reported the results of the use
of bilateral IMAs as conduits for coronary revascularization.
Despite the short- and long-term superior patency rates for
IMA conduits in comparison with SVGs, early enthusiasm
was deterred by the high rate of postoperative complications
associated with the use of bilateral IMA grafts. Problems
included postoperative bleeding, prolonged ventilatory sup-
port, and sternal wound infection (627). Several subsequent
large series, however, have demonstrated the safety and
efficacy of the use of bilateral IMA grafts during both the
perioperative period and with long-term follow-up. The
only remaining caveat, however, is a higher rate of sternal
wound infection associated with bilateral IMA grafting
(628–630). By statistical analysis, patients who were obese,
diabetic, and required prolonged ventilatory support were
identified to have an increased risk of sternal wound
complications after bilateral IMA grafting. The long-term
clinical benefits of bilateral IMA grafting compared with
single IMA grafting include lower rates of recurrent angina
pectoris, MI, and need for reoperation and a trend toward
better survival (79,631,632). Use of the right IMA as a free
graft or sequential graft has been shown to have excellent
short- and long-term results (633,634).
The use of the radial artery as a conduit for coronary
bypass grafting was first reported by Carpentier et al (635)
in 1973. Its use was quickly abandoned when occlusion rates
up to 30% were reported (636,637). Interest in its use was
revived in 1989 when radial artery grafts were found to be
patent in patients who had undergone their coronary artery
surgery 13 to 18 years earlier. The radial artery is a thick
muscular artery with an average diameter of 2.5 mm and an
average length of 20 cm. It is prone to spasm when
mechanically stimulated, and perioperative calcium channel
blockers are often used to reduce this complication. The
technique of minimal manipulation and en bloc dissection
of the radial artery with its surrounding satellite veins and
fatty tissue is thought to account for the superior results in
recent experiences with radial artery grafting. Brodman et al
(638) reported a 95% 12-week patency rate in 175 patients
receiving 229 radial artery grafts (54 patients had bilateral
radial artery grafts). Perioperative MI and mortality rates
were similar to those of conventional bypass surgery. There
was no reported hand ischemia, wound hematoma, or
infection. A 2.6% incidence of transient forearm dysesthe-
sia, which resolved over 1 day to 4 weeks after surgery, was
reported. Acar et al (639) recently reported an 84% 5-year
radial artery graft patency rate in 100 consecutive patients
receiving the radial artery as a conduit for coronary revas-
cularization. In the same group of patients, the left IMA
graft patency rate was 90% at 5 years. Thus, the radial artery
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appears to be a safe and reliable arterial conduit for coronary
revascularization on the basis of these early clinical experi-
ences.
Use of the in situ right gastroepiploic artery as a conduit
for CABG was first reported in 1987 (640,641). This artery
can be harvested by extending the median sternotomy
incision toward the umbilicus and dissecting the artery
along the greater curvature of the stomach. A pedicle length
of 15 cm or more can be achieved by mobilizing the artery
to the origin of the gastroduodenal artery. It can be grafted
to the right or circumflex coronary artery by routing it in a
retrogastric fashion or to the LAD in an antegastric fashion.
Early graft patency ranged from 90% to 100% (642–644),
but long-term results have not been published. The inferior
epigastric artery free graft has been used for CABG since
1990 (645,646). This artery can be harvested by retracting
the rectus muscle via a paramedian incision. A length of 6 to
16 cm can be dissected from its origin from the external iliac
artery (647). Short-term patency rates of up to 98% have
been reported (648). Long-term results are not available.
Cryopreserved homologous SVGs and glutaraldehyde-
treated homologous umbilical veins grafts have been used
for clinical aortocoronary bypass surgery (649,650). Graft
patency was reported to be only 50% at 3 to 13 months.
These grafts should not be used unless other conduits are
unavailable. Similarly, the bovine IMA has been used, again
with an ’50% 1-year patency (651,652). Synthetic grafts
that have been used for aortocoronary bypass include Da-
cron grafts and polytetrafluoroethylene grafts. Only a few
successful cases of Dacron graft use have been reported, and
these were in patients in whom the graft was used as an
interposition between the ascending aorta and the proximal
end of a coronary artery with resultant high flow (653–655).
The patency of polytetrafluoroethylene grafts is also limited
and has been reported to be ’60% at 1 year (656,657).
C. Percutaneous Technology
Technological improvements have had a great impact on
PTCA and have included new medications and devices that
have reduced both the acute and long-term complications of
percutaneous coronary interventions. The most significant
medication advance has been the introduction of new platelet
inhibitors, which have reduced the incidence of MI and death
during angioplasty and related interventions (658).
In the area of devices, intracoronary stents have reduced
complications, including the need for emergency surgery, as
well as the need for repeated interventions due to restenosis
(659,660). New refinements in stent design and adjunctive
pharmacological therapy are further improving patient out-
comes after stenting. Directional coronary atherectomy has
also been shown to reduce restenosis compared with con-
ventional PTCA, but its role relative to stents is not yet clear
(661). Several new devices, such as transluminal extraction
catheter (InterVentional Technologies, Inc., San Diego,
CA) and Angioget thrombectomy catheter (Possis Medical,
Inc., Minneapolis, MN), that remove thrombus before
intervention either have been approved for use or are
undergoing investigation and may reduce complications in
some high-risk subsets of patients. Rotational atherectomy
or rotablation has expanded the types of lesions (eg, calcified
or long lesions) that can be treated without surgery (662).
Restenosis remains the greatest weakness of PTCA and is
being addressed by mechanical solutions such as stents and
directional atherectomy, which improve the intimal lumen
diameter, and by pharmacological interventions aimed at
preventing intimal hyperplasia. Promising approaches in-
cluded in this latter category are medications such as probucol
(663), gene therapy, and local radiation therapy (664).
After CABG surgery, failure of the SVG is a major cause
of recurrent cardiac ischemia. Angiographic studies have
shown that 16% to 31% of SVGs fail within 1 year
(665–668), and within 10 years, about half of all vein grafts
are totally occluded or have severe atherosclerotic disease
(77,669,670). It is estimated that vein graft failure is
responsible for recurrent angina at an annual rate of 4% to
9% in patients after aortocoronary artery bypass grafting
(671–673). In these patients, repeated CABG surgery is a
satisfactory option. However, in comparison with initial
bypass surgery, reoperation is technically more challenging
and is associated with higher perioperative morbidity and
mortality as well as less symptomatic relief (557,674,675).
As alternatives to repeated bypass surgery, various percuta-
neous techniques have been developed to treat stenotic vein
grafts. These techniques include conventional balloon an-
gioplasty and the use of newer interventional devices such as
coronary stents and directional coronary atherectomy.
In general, the results of angioplasty in SVGs are less
favorable than in native vessels, with less procedural success
and a higher rate of restenosis. Several factors influence the
clinical outcome of the procedure: age of the graft, location
of the stenosis within the graft, and the discrete (versus
diffuse) morphological features of the atherosclerotic
plaques (676–679). In a randomized comparison with
angioplasty, directional coronary atherectomy was associ-
ated with a higher initial success rate and fewer repeated
target-vessel interventions at 6 months but more periproce-
dural complications, most notably distal embolization and
non–Q wave MI (680,681). The transluminal extraction
catheter, another atherectomy device, may reduce the inci-
dence of distal embolization (682,683).
Intracoronary stents are now commonly used in the
management of SVG stenosis. A recent multicenter, pro-
spective, randomized trial compared the effects of stent
placement with those of balloon angioplasty on clinical and
angiographic outcomes in patients with obstructive disease
of SVGs (684). Compared with the balloon angioplasty
group, stenting of vein graft lesions resulted in a higher rate
of procedural efficacy (92% versus 69%) and a greater
increase in luminal diameter immediately after the proce-
dure (1.92 versus 1.21 mm) and at 6 months (0.85 versus
0.54 mm). The 6-month outcome in terms of freedom from
death, MI, repeated bypass surgery, or revascularization of
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the targeted vessel was significantly better in the stent group
(73% versus 58%). Although the difference in the rate of
restenosis between the stent and angioplasty groups did not
achieve statistical significance, it appears that stent place-
ment has certain advantages over conventional balloon
angioplasty in the initial and short-term angiographic and
clinical outcomes.
With the increasing use of MID-CAB for left IMA-to-
LAD grafting, a combined strategy of MID-CAB and
either balloon angioplasty or stent placement (“hybrid re-
vascularization”) to achieve complete revascularization in
patients with 2-vessel disease has been used in some centers
(685–688). Typically, 1 to 4 days after initial MID-CAB
for the left IMA-to-LAD grafting, PTCA is performed on
the second diseased vessel, which has included the right
coronary artery, the left circumflex artery, and the left main
coronary artery. The reverse order of performing PTCA
first with subsequent MID-CAB for the left IMA-to-LAD
revascularization has also been described (686). The hybrid
approach of MID-CAB and percutaneous intervention
provides complete revascularization through limited inci-
sions without CPB. It also provides a useful management
modality for isolated patients who are at high risk for either
procedure alone. This approach highlights the potential
complementary role of surgery and PTCA in the manage-
ment of CAD. However, long-term outcome data for
patients undergoing hybrid procedures are not yet available.
Thus, the theoretical benefits of combining procedures must
be matched by scientific proof of efficacy before this strategy
is likely to become commonplace.
D. Transmyocardial Revascularization
Intracavitary arterial blood in the LV is only millimeters
away from ischemic areas of myocardium. Indeed, commu-
nicating channels between the cavity and the myocardium
occur in reptilian hearts and in fetal hearts during the first 7
weeks of gestation until the coronary arterial system devel-
ops. This network of communicating channels between the
heart chambers and the coronary arteries, the myocardial
sinusoids, the arterial-luminal and venous-luminal connec-
tions, were described in a study by Wearn et al in 1933
(689). Early attempts to use these connections to supply the
ischemic myocardium included implantation of the left
IMA directly into the heart muscle (690) and direct-needle
acupuncture to the ischemic myocardium to create commu-
nicating channels (691,692). Sen and colleagues (691,692)
used direct acupuncture and found that these acupuncture
channels were protective from acute infarction after ligation
of the LAD. These channels appeared to be open and
endothelialized at 8 weeks but appeared to close within
several months due to fibrosis and scarring secondary to
local tissue injury. This technique was abandoned with the
arrival of aortocoronary artery bypass surgery in the late
1960s.
Use of the carbon dioxide laser for transmyocardial
revascularization was attempted in the early 1980s by
Mirhoseini and coworkers (693,694). A high-energy laser
beam was used to create channels from the epicardial to the
endocardial surface of an arrested or beating heart, thus
allowing oxygenated blood from the LV to perfuse the
ischemic myocardium. Brisk bleeding from the channels due
to ventricular perforation could be easily controlled with
light epicardial pressure. It was postulated that a high-
energy laser beam would minimize local tissue injury and
prevent premature fibrotic closure of the lased channels and
thus lead to improved channel patency (695). Long-term
channel patency on histological examination has been re-
ported in animal experiments and in sporadic clinical case
reports (695–697). The principal utility of transmyocardial
laser revascularization (TMLR) is directed toward patients
with severe angina pectoris refractory to medical therapy
and who are unsuitable for surgical revascularization,
PTCA, or heart transplantation. These patients often have
diffuse, small-vessel disease and are not appropriate candi-
dates for another PTCA or CABG. The use of TMLR for
the management of cardiac allograft vasculopathy has also
been reported (698,699).
The results of a multicenter trial with TMLR as the sole
therapy for 200 patients with refractory, end-stage CAD
and documented reversible ischemia was recently reported
by Horvath and colleagues (700). The perioperative mor-
tality rate was 9%. Postprocedure angina class according to
the Canadian angina classification was significantly de-
creased from their preoperative status at 3, 6, and 12 months
of follow-up. Hospital admissions for angina were decreased
from an average of 2.5 admissions in the year before
treatment to an average of 0.4 admissions in the year after
treatment. The number of perfusion defects in the treated
LV free wall was also significantly decreased as assessed by
radionuclide perfusion scan or positron emission tomo-
graphic scan performed after TMLR. A multicenter ran-
domized, prospective study comparing TMLR with contin-
ued medical management demonstrated improved event-
free survival in 160 patients with symptomatic, end-stage
CAD (701). In the TMLR group, 72% of patients im-
proved by at least two angina classes, while 69% of patients
in the medical therapy group had no change of angina class;
the remaining 31% experienced greater angina. Survival free
of death, unstable angina, or class IV angina at 6 months
was 73% for the TMLR group versus 12% in the medical
management group. Quality of life indexes also improved in
the TMLR group.
Early studies suggest that TMLR is a promising, new
surgical technique for alleviating angina symptoms and
improving quality of life in a small and select group of
patients for whom conventional revascularization is not an
option. However, the mechanisms for the demonstrated
clinical benefits of TMLR are poorly understood. Whether
or not lased channels remain patent for a long period of time
after TMLR is a subject of active investigation. Animal
experiments have shown that cardiac afferent nerve fibers are
destroyed during laser revascularization (702). This raises
1314 Eagle and Guyton et al. JACC Vol. 34, No. 4, 1999
ACC/AHA Guidelines for CABG Surgery October 1999:1262–347
the concern that angina relief may be due to denervation of
the heart rather than relief of ischemia. It has been hypoth-
esized that the benefit may be secondary to angiogenesis
induced by the laser injury. Clearly, further basic science and
clinical research is needed to clarify the mechanism of action
of TMLR. Nonetheless, TMLR is a possible therapeutic
option for a difficult subset of patients. The techniques of
TMLR are amenable to percutaneous methods, and indeed,
such systems are currently under investigation. In addition,
trials are under way wherein TMLR is combined with
bypass surgery; the premise is to improve coronary inflow to
areas adjacent to those on which TMLR has been per-
formed.
VII. INSTITUTIONAL AND OPERATOR COMPETENCE
A. Volume Considerations
Owing to the recent availability of hospital and
physician-specific mortality data and because of the per-
ceived economies of scale in consolidating complex medical
procedures into regional centers, considerable attention has
been directed to relating outcome after CABG to the
number of procedures performed. Before 1986, administra-
tive datasets were proposed as a means of risk adjustment to
compare outcomes between hospitals of high and low
volume (703,704). These studies found a relationship be-
tween mortality after CABG and the volume of procedures
performed annually. A cutoff at ’200 cases defined high-
and low-volume institutions. A relative risk of ’0.44 (1.29
to 0.65, 95% confidence interval) was found in high-volume
institutions. The ability of administrative datasets to accu-
rately stratify risk has since been questioned, particularly
because of their inability to distinguish preoperative comor-
bidity data from postprocedure complications data (705–
707).
Since 1986, in response to these criticisms, primary
cardiac surgical datasets have appeared with sufficient power
to address this question. Hannan et al (708) reported that in
New York State, after adjusting for case mix, the high-
volume institutions that performed .223 cases annually
experienced significantly lower mortality than did institu-
tions performing fewer than 223 cases annually, with a
relative risk of 0.74 (0.56 to 0.94, 95% confidence interval).
This same relationship was true for individual surgeon
volumes, with high-volume surgeons performing more and
low-volume surgeons performing fewer than 116 CABG
procedures annually. These cutoff points were determined
arbitrarily by being above or below the state median, based
on data from only 1 year.
The relationship between in-hospital mortality rate and
surgical volume was again explored in 1991, when the cutoff
for institutional volume was defined at 200 cases annually,
and the relative risk, while still significant, was reduced to
0.84 (0.66 to 1.07, 95% confidence interval) (709). This
report represented data collected over 3 years (1989 to
1992). In addition to showing the protective effect of
high-volume institutions, the study also showed consider-
able variation, particularly among the low-volume centers.
A further analysis of this patient population revealed that a
significant portion of the observed improvement found in
the overall risk-adjusted mortality rates in New York State
was a disproportionate improvement experienced by the
low-volume institutions compared with the high-volume
institutions. Hannan et al (709) postulated that this was due
in part to the outmigration of older, low-volume surgeons
and the inmigration of younger, better-trained surgeons. It
is also of interest that the relationship between individual
surgeon volume and outcome reported in 1989 and 1991
had disappeared.
The Department of Veterans Affairs Hospitals reported
on 24,394 patients operated on between 1987 and 1992
(710). While there appeared to be a significant relationship
between volume and mortality rate among the 43 hospitals
examined, when adjusted for case mix the relationship
disappeared. Again, low-volume hospitals had a higher
variation in mortality rates compared with the high-volume
institutions. This variation in outcome led the Department
of Veterans Affairs to routinely review low-volume institu-
tions (,100 cases annually).
A report of the STS National Cardiac Database reviewed
124,793 patients operated on by .1200 surgeons in .600
institutions. Only in institutions performing ,100 cases
annually (n 5 18) was the observed mortality rate of 5.0%
significantly higher than the expected rate of 3.0% (2.9% to
3.2%, 95% confidence interval) (711).
The question of whether high-volume institutions per-
formed significantly better than did moderate-volume insti-
tutions was addressed in a study from Canada. The Adult
Cardiac Care Network of Ontario suggested that concen-
trating CABG into high-volume, regional centers has
explained their low observed mortality rate and the lack of
variation between centers (712). This observation was not
confirmed in the STS report, as Clark (711) found no
protective relationship in high-volume institutions (.900
cases/y).
Criticism of these reports revolves primarily around the
adequacy of case-mix adjustment and the limitations of
observational studies. Sowden et al (713) performed a
meta-analysis of studies relating volume to outcome and
found that the stronger the relationship between volume
and outcome, the less case mix was accounted for. They
postulated that owing to the observational nature of these
studies, confounding accounted for most of the difference
between high and low volume, and as confounding was
reduced by improved risk stratification, the volume-
outcome relationship disappeared. Sowden et al (713) also
found that the volume-outcome relationship diminished
over time, suggesting that low-volume institutions had
“improved” faster than had high-volume institutions.
In summary, studies suggest that survival after CABG is
negatively affected when carried out in institutions that
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perform fewer than a threshold number of cases annually.
Similar conclusions have been drawn regarding individual
surgeon volumes. In states where reporting of outcomes is
an accepted practice (eg, New York State), the relationship
between low volumes at either an institutional or individual
level seems to have diminished over time. This observation
strengthens the argument for outcome tracking and sup-
ports a posture of close monitoring of institutions or
individuals that perform ,100 cases annually. It must be
remembered that these same studies also found a wide
variation in risk-adjusted mortality rates in low-volume
situations; ie, some institutions and practitioners main-
tained excellent outcomes despite relatively low volumes.
Therefore, credentialing policies based on conclusions
drawn from these data must be made with caution.
B. Report Cards and Quality Improvement
Mortality rates after CABG have declined since the 1987
release by the Health Care Financing Administration of
hospital-specific mortality data. The Northern New En-
gland Cardiovascular Disease Study Group reported a 24%
decline in regional mortality from 1987 to 1993 (13).
Hannan et al (714) reported that the actual mortality rate in
New York State declined from 3.52% in 1989 to 2.78% in
1992 while the risk-adjusted rate decreased from 4.17% to
2.45% during the same period The STS National Cardiac
Surgical Database reported that the risk-adjusted mortality
rate for CABG declined from 3.76% to 3.50% between
1990 and 1994 (16).
There are numerous potential explanations for this re-
duction in mortality after CABG. Some authors suggest
that the feedback of outcome data associated with either an
organized or implicit effort at quality improvement has been
principally responsible for this decline. O’Connor et al (13)
reported that a combination of regular feedback of mortality
data, associated with open discussion and visitation between
competing cardiac surgical programs in Maine, New
Hampshire, and Vermont, was directly responsible for the
24% reduction in mortality observed there. Hannan et al
(714) reported that the simple fact that outcomes were
tracked and reported back to institutions led implicitly to
improvement efforts that accounted for the New York State
decline in mortality rate. Grover et al (22) reported on a
program of data feedback and regular audit of programs by
members of the Audit Committee of the Veterans Affairs
Cardiac Surgery Consultants Committee that led to a
decrease in observed versus risk-adjusted mortality rates
within the Veterans Administration cardiac surgical system.
Omoigui et al (715), a group from the Cleveland Clinic,
suggested that the reduction in mortality noted in New
York State was caused by an outmigration of high-risk
patients due to the increased scrutiny provoked by public
release of mortality data. Despite this criticism, Hannan et
al (714) found no consistent bias against selecting high-risk
patients in the state of New York. Ghali et al (716)
suggested that the reduction seen in both northern New
England and New York State would have happened regard-
less of quality improvement efforts, as similar improvement
was found in Massachusetts where there was neither a
statewide, organized improvement effort nor dissemination
of mortality data. Peterson et al (717) examined Medicare
data on both the total amount of improvement and the
ultimate risk-adjusted mortality rate and found that New
York State and northern New England showed both the
lowest overall mortality rates as well as the greatest improve-
ments of any other state or region in the country. Peterson
et al concluded that reporting of outcomes, whether volun-
tary and anonymous (northern New England) or mandatory
and public (New York State), coupled with initiatives in
quality improvement are indeed effective in improving
mortality rates after CABG.
Although outcome tracking has resulted in fewer deaths
after CABG, many would suggest that public dissemination
of this information has fallen short in helping to inform
consumers. While the 1987 Health Care Financing Admin-
istration report of CABG mortality data received wide-
spread media attention, most newspapers focused on outlier
hospitals and thus provided little guidance to consumers
(718). When clinicians in Pennsylvania and New York State
were asked to assess how much the statewide reporting of
outcome data influenced their referral practices, surprisingly
few admitted that these efforts had any effect at all
(719,720). In California, data reflecting diagnosis-related
group mortality rates were distributed to hospitals and
criticized for being excessively complex, poorly displayed,
and not linked to process information that would allow
institutions to respond meaningfully to the data.
In conclusion, outcome reporting in the form of risk-
adjusted mortality rates after CABG has been effective in
reducing mortality rates nationwide. While distortion of
data (gaming) and outmigration of patients have been re-
ported, it is doubtful that these practices have had a meaningful
effect on this improvement. However, public release of hospital
and physician-specific mortality rates has not been shown to
drive this improvement and has failed to effectively guide
consumers or alter clinicians’ referral practices.
VIII. ECONOMIC ISSUES
A. Cost-Effectiveness of CABG
CABG represents a major investment for society, with an
initial hospital cost of ’$30,000 applied to .300,000
patients annually in the United States alone (’10 billion
dollars) (125). It is most appropriate to consider the cost of
CABG surgery compared with other medical treatment
modalities with regard to cost-effectiveness. Definitive data
for such a comparison are sparse, and multiple assumptions
must be made. The most reasonable system of analysis
appears to be an estimation of the dollars spent per
quality-adjusted life-year gained ($/QALY). In general, a
cost-effectiveness of $20,000 to $40,000/QALY is consis-
tent with other medical programs funded by society, such as
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hemodialysis and treatment of hypertension. A cost of
,$20,000/QALY would be considered particularly cost-
effective, while a cost .$60,000/QALY would be consid-
ered expensive (721).
A widely quoted analysis of the cost-effectiveness of
CABG surgery was compiled by Weinstein and Stason
(722) in 1982 utilizing data gathered from the then-
available randomized trials comparing medical therapy with
coronary artery bypass. The cost of coronary bypass is
relatively constant, whether it is conducted for left main
disease or for single-vessel disease. Cost-effectiveness is
excellent when the procedure is applied to patient subgroups
for whom the benefit in terms of survival or relief of
symptoms compared with medical therapy is great (as it
would be, for example, in a patient with severe angina and
triple-vessel disease). The cost-effectiveness of CABG be-
comes inordinately poor, however, when the benefit in
terms of survival is marginal and there are few symptoms in
the preoperative patient. These conclusions are depicted in
Figure 12, and examples are presented in Table 17. Cost-
effectiveness for coronary bypass in patients with left main
disease is exceptionally good at $9,000/QALY. It is simi-
larly quite attractive in patients with 3-vessel disease, at
$18,000/QALY. If one considers the cost-effectiveness of
coronary bypass in 2-vessel disease, Weinstein and Stason
found that the presence or absence of LAD disease was very
important. Because CABG surgery is particularly effective
in relieving angina, its cost-effectiveness, even in patients
with single-vessel disease, is not prohibitive if that patient
has severe angina. In the patient without angina or with
only mild angina, however, the cost of coronary bypass per
QALY was prohibitive in this analysis, exceeding $100,000
for patients with 2-vessel or 1-vessel disease.
It is not surprising that coronary bypass surgery is
cost-effective in exactly those groups of patients in whom
survival and/or symptomatic benefit is demonstrable. Most
important, within these subsets the cost-effectiveness of
coronary bypass compares favorably with other generally
accepted medical therapies.
Figure 12. Cost utility. VD 5 vessel disease; LMD 5 left main disease. Modified with permission from (721).
Table 17. Cost per Quality-Adjusted Life-Year ($/QALY) of
Revascularization Compared With Medical Therapy*
CABG for left main stenosis, with or without
angina
9,000
CABG for 3VD, with or without angina 18,000
CABG for 2VD with severe angina and LAD
stenosis
22,000
CABG for 2VD with severe angina, no LAD
disease
61,000
CABG for 2VD, no angina, with LAD
stenosis
27,000
CABG for 2VD no angina, no LAD disease 680,000
CABG for 1VD, severe angina 73,000
PTCA for 1VD, severe angina 9,000
PTCA for LAD stenosis, mild angina 92,000
CABG indicates coronary artery bypass graft; 1, 2, or 3VD, 1-, 2-, or 3-vessel disease;
LAD, left anterior descending coronary artery; and PTCA, percutaneous transluminal
coronary angioplasty.
*Adjusted to 1993 dollars from multiple sources in a review by Kupersmith et al
(721).
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B. Cost Comparison With Angioplasty
The cost-effectiveness of angioplasty is dependent on the
preangioplasty symptoms of the patient in the same way
that CABG surgery is so dependent, particularly in sub-
groups in whom revascularization cannot be shown to have
a survival benefit compared with medical therapy (ie, in
single-vessel disease). Because it relieves angina, angioplasty
for single-vessel-disease patients with severe angina is esti-
mated to have a cost-effectiveness of $9,000/QALY. In
patients with only mild angina, however, angioplasty in the
setting of LAD single-vessel disease is estimated to have a
poor cost-effectiveness of $92,000/QALY (723).
A direct comparison of the cost of angioplasty and
coronary bypass surgery for selected patients with multives-
sel disease (ie, those patients for whom either therapeutic
modality was considered appropriate) has been made in the
randomized trials of angioplasty versus CABG.
In general, the cost analyses of randomized trials have
revealed that the initial cost of angioplasty is ’50% to 65%
of the initial cost of bypass surgery. The incremental cost of
repeated procedures during the follow-up period has led to
a cumulative cost of angioplasty that approaches the cumu-
lative cost of bypass surgery at 3 years. The EAST found
that the 3-year inpatient cost of angioplasty was 94% of that
of bypass surgery (134). The RITA Trial, which included a
large number of patients with single-vessel disease, found
that the 2-year cumulative cost of angioplasty was 80% of
the cost of coronary bypass (135). The BARI trial con-
ducted a prospectively designed analysis of the comparative
cost of the 2 procedures from a subgroup of the participating
centers, comprising a total of 934 of the 1829 patients
enrolled (125). The mean initial hospital cost of angioplasty
was 65% of that of surgery, but after 5 years the cumulative
cost of initial surgical therapy was only $2,700 more than
the cost of initial angioplasty (an ’5% difference). Because
the surgical cohort had a higher overall 5-year survival, the
cost of this survival benefit could be calculated. It was found
to be $26,000/y of survival benefit for surgical therapy of 2-
and 3-vessel disease (in patients for whom either angioplasty
or surgery was considered appropriate initial therapy). As
considered in the previous section, this incremental cost for
double- and triple-vessel disease is within the range of costs
for generally accepted therapies. It is notable that this cost
of incremental benefit does not consider the benefit of
coronary bypass in terms of relief of angina during the
follow-up interval, which was demonstrated in each of these
3 trials (BARI, EAST, and RITA). If this factor were
included, the cost-effectiveness of CABG for incremental
benefit in these selected patients with multivessel disease
($/QALY) would be ,$26,000.
Previous considerations of both patient benefit and cost-
effectiveness have suggested that angioplasty is less effective
for patients with more advanced disease. Data gathered at
Duke University has shown that there is a significant cost
gradient for angioplasty as the extent of disease increases
(related to repeated procedures whose instance may be
reduced by stents), which is not apparent for coronary
bypass (Figure 13) (724).
C. Cost Reduction in Coronary Bypass
Estimates presented in the previous portion of this
section suggest that coronary bypass has been cost-effective
in the last 2 decades. Initiatives to decrease the length of
stay by using clinical pathways and standardized fast-track
protocols have reduced hospital costs. Indeed, the estimates
made by Weinstein and Stason are distinctly dated: im-
provements in outcomes and shortened lengths of hospital-
ization are likely to have considerably improved the cost-
effectiveness of CABG (and angioplasty) since 1982.
A major innovation has been the introduction of off-
bypass CABG, which has reduced the postprocedure length
of stay to between 2 and 3 days. In some centers, this has led
to a total 3-month cost for single-vessel coronary bypass
that is not significantly different from the total 3-month cost
for angioplasty of single-vessel disease (620). Considering
the favorable long-term patency of an IMA graft to the
LAD, the cost reductions possible with off-bypass CABG
may improve the relative cost-effectiveness of coronary
bypass compared with either medical therapy or percutane-
ous techniques, particularly for symptomatic, proximal
LAD disease.
IX. INDICATIONS
A. Introduction
1. Quality of Life. The CABG operation is indicated both
for the relief of symptoms and for the prolongation of life.
The 1991 Guidelines focused on survival relative to medical
therapy as the pivotal indication for operation. In addition
to extension of the length of life, this operation is an
important therapeutic tool for the relief of disabling symp-
toms.
The 1991 Guidelines state that “the evidence is complete
that the coronary artery bypass operation relieves angina in
most patients.” The results of the randomized trials of
CABG versus PTCA have confirmed and extended this
Figure 13. Percentage of 1-year costs for PTCA and CABG.
Reproduced with permission from (724).
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conclusion (725). Not only did CABG effectively relieve
angina in the symptomatic patients enrolled in the random-
ized trials, but also freedom from angina and from antian-
ginal medications was superior in the CABG cohorts
compared with PTCA cohorts.
The benefit realized from the use of CABG to relieve
disabling symptoms must be balanced against the risk of the
operation and tempered by the potential activity level of the
individual patient. This risk may be very low in selected
groups of patients. In a series of 1386 patients with single-
and double-vessel disease aged ,66 years, without CHF,
and an EF.0.35 from the early 1980s at Emory University,
a hospital mortality of 0.07% (1 patient) was reported. Not
only did these young, healthy patients have a very low risk,
but their potential for renewal of an active lifestyle was
exceptionally high. CABG in patients such as these for
relief of disabling angina after failure of medical therapy is
an attractive option, even if no survival benefit can be
predicted. If, on the other hand, one were to consider a
78-year-old patient with limiting arthritis and class II
angina, then the potential benefit of CABG will be consid-
erably less and the risk comparably greater. In this case, the
attractiveness of PTCA or continued medical therapy as the
appropriate therapy is enhanced.
Some caution must be expressed in the use of CABG for
relief of symptoms. CABG treats the manifestations of
CAD, not the disease process. As coronary disease
progresses, therefore, angina often returns. The hazard
function for return of angina is low for the first 5 years after
operation and then begins to rise, seemingly related to late
closure of bypass conduits. So long as the patient and the
practitioner understand that angina may return after 5 to 10
years, the application of CABG for the relief of angina
rather than for survival benefit is appropriate, particularly in
low-risk patients. If preoperative symptoms are disabling,
there is a high probability for a return to a fully functional
lifestyle and, as discussed in Section VIII, the procedure is
cost-effective as well.
2. Survival. The second important indication for CABG,
after relief of symptoms, is prolongation of life. The
randomized trials of CABG versus medical therapy have
defined patient subsets whose survival is enhanced. These
patients tend to be those with advanced coronary disease:
notably left main disease and triple-vessel disease (or
double-vessel disease including a proximal LAD stenosis)
combined with LV dysfunction. The survival benefit of
CABG was examined in detail in the 1991 Guidelines and
will be applied to specific patient subgroups in the following
sections.
B. Clinical Subsets
1. Asymptomatic or Mild Angina. For patients with no
symptoms or mild angina, the appropriateness of coronary
bypass surgical therapy is based on survival advantage
therapy compared with nonsurgical therapy. The relative
appropriateness of percutaneous versus surgical therapy is
discussed in Section III. To identify anatomic subsets in
which coronary bypass is beneficial, definition of “impor-
tant” coronary stenosis is necessary. For this and all subse-
quent sections, coronary stenosis will be defined as a 50% or
greater reduction of lumen diameter. This is the degree of
narrowing defined as important in the majority of random-
ized trials that have examined the relationship of coronary
anatomy and survival after CABG. It is important to note
that the level of angina in this category is not considered an
indication for surgery. Moderate or severe angina would
represent symptoms that many patients find unacceptable
despite adequate medical therapy. Contrariwise, in this
category, patients are either completely asymptomatic or
have acceptable symptoms such that bypass surgery for
symptom relief is not the issue.
The indication for bypass surgery in this category relates
to the extent of coronary disease, the demonstration of
objective signs or symptoms of this disease, and consider-
ation for the risk of nonmedical therapy, which may include
either bypass surgery or angioplasty. As stated in Section
III, C, the data on which these classifications are assigned
are based on 3 randomized controlled trials, several smaller
randomized trials, a subsequent meta-analysis of these data,
and several observational studies. The limitations of these
data are discussed in Section III, C and listed in Table 6.
Indications for CABG in Asymptomatic or Mild
Angina
Class I
1. Significant left main coronary artery stenosis.
2. Left main equivalent: significant (>70%) stenosis
of the proximal LAD and proximal left circumflex
artery.
3. Three-vessel disease. (Survival benefit is greater in
patients with abnormal LV function; eg, EF
<0.50.)
Class IIa
Proximal LAD stenosis with 1- or 2-vessel disease.*
Class IIb
One- or 2-vessel disease not involving the proximal
LAD.†
Class III
See text.
2. Stable Angina. For patients with stable angina, the
indication for CABG is based both on the likelihood of
improving survival and on the likelihood of relief of
lifestyle-limiting symptoms. Based on the 3 large, prospec-
tive, randomized trials comparing medical with surgical
*Becomes Class I if extensive ischemia documented by noninvasive study and/or
LVEF ,50%.
†If large area of viable myocardium and high-risk criteria or noninvasive testing,
becomes Class I.
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therapy and multiple observational studies, the patient
factors most influencing a decision to recommend CABG
include the presence of severe proximal multivessel coronary
disease, LV dysfunction, a strongly positive stress test, and
comorbid conditions such as PVD and diabetes. Additional
factors that are of critical importance relate to the perceived
immediate risk of bypass surgery and the long-term prog-
nosis, particularly whether the patient’s potential improve-
ment in longevity or quality of life due to a successful bypass
operation justifies the short-term risk.
Indications for CABG in Stable Angina
Class I
1. Significant left main coronary artery stenosis.
2. Left main equivalent: significant (>70%) stenosis
of the proximal LAD and proximal left circumflex
artery.
3. Three-vessel disease. (Survival benefit is greater
when LVEF <0.50.)
4. Two-vessel disease with significant proximal LAD
stenosis and either EF <0.50 or demonstrable
ischemia on noninvasive testing.
5. One- or 2-vessel CAD without significant proximal
LAD stenosis, but with a large area of viable
myocardium and high-risk criteria on noninvasive
testing.
6. Disabling angina despite maximal noninvasive
therapy, when surgery can be performed with ac-
ceptable risk. If angina is not typical, objective
evidence of ischemia should be obtained.
Class IIa
1. Proximal LAD stenosis with 1-vessel disease.*
2. One- or 2-vessel CAD without significant proximal
LAD stenosis, but with a moderate area of viable
myocardium and demonstrable ischemia on nonin-
vasive testing.
Class III
1. One- or 2-vessel disease not involving significant
proximal LAD stenosis, in patients who have mild
symptoms that are unlikely due to myocardial isch-
emia or who have not received an adequate trial of
medical therapy and
(A) Have only a small area of viable myocardium or
(B) Have no demonstrable ischemia on noninvasive
testing.
2. Borderline coronary stenoses (50% to 60% diameter
in locations other than the left main coronary
artery) and no demonstrable ischemia on noninva-
sive testing.
3. Insignificant coronary stenosis (<50% diameter re-
duction).
3. Unstable Angina/Non–Q Wave MI. Indications for
coronary bypass surgery in this category relate not only to
survival but also to the relief of symptoms. Thus, in general,
all of the survival indications listed for the asymptomatic
patient or the individual with stable angina apply. However,
timing of surgery becomes a critical consideration. Some
reports have suggested a high mortality after CABG in
patients with acute unstable angina or non–Q wave MI and
have shown that one of the independent predictors of
mortality after coronary bypass surgery is the stability of the
patient going to operation. Other investigators have not
found this association (Section V, K). In the patient in
whom stabilization with aggressive medical therapy may be
achieved, it is advisable to stabilize and reduce ongoing
ischemia before proceeding to bypass surgery.
Indications for CABG in Unstable Angina/Non–
Q Wave MI
Class I
1. Significant left main coronary artery stenosis.
2. Left main equivalent: significant (>70%) stenosis of
the proximal LAD and proximal left circumflex artery.
3. Ongoing ischemia not responsive to maximal non-
surgical therapy.
Class IIa
Proximal LAD stenosis with 1- or 2-vessel disease.*
Class IIb
One- or 2-vessel disease not involving the proximal
LAD.†
Class III
See text.
4. ST-Segment Elevation (Q-Wave) MI. Although early
coronary bypass surgery as a primary reperfusion strategy in
patients suffering from an ST-segment elevation infarction
has been reported, the widespread use of intravenous
thrombolytic therapy for this purpose and more recently,
primary angioplasty, has largely superseded early application
of bypass surgery. Studies have shown that eventual infarct
size and the subsequent risk of mortality and/or LV dys-
function are related to the time from the onset of symptoms
until coronary reperfusion. Although, on average, coronary
bypass surgery requires a longer time to establish coronary
reperfusion than either of the nonsurgical techniques, mod-
ification of the conditions of reperfusion that is possible
with surgical therapy may offer some benefit with regard to
eventual infarct size relative to percutaneous or thrombolytic
therapy. Despite this potential benefit of reperfusion mod-
ification, coronary bypass is rarely performed for this indi-
cation except in special circumstances. The decision to
perform surgery requires angiographic demonstration of
adequate target vessels in the region of infarction and
*Becomes Class I if extensive ischemia documented by noninvasive study and/or
LVEF ,50%.
†If large area of viable myocardium and high-risk criteria on noninvasive testing,
becomes Class I.
1320 Eagle and Guyton et al. JACC Vol. 34, No. 4, 1999
ACC/AHA Guidelines for CABG Surgery October 1999:1262–347
usually other regions as well. In most circumstances, early
coronary bypass for acute infarction is appropriate only in
patients with residual ongoing ischemia despite nonsur-
gical therapy, be it thrombolysis, angioplasty, or both. As
with angioplasty, the risks of bypass operation in patients
in the midst of an acute ST-segment elevation infarction
are substantially higher than are the risks in elective
candidates.
To determine the benefits and liabilities of treatment of
an acute MI with CABG requires accurately defining the
topic. The definition of acute MI is the resultant ischemic
muscle injury after reduction or interruption of the coronary
artery blood supply. The obvious weakness in this definition
is the variability of the tissue damage. This has been
addressed by subclassifying MIs into Q-wave and non–Q
wave-types. A Q-wave infarction has been defined as
ST-segment changes that progress to new Q waves in
addition to a creatine phosphokinase (CPK)-MB isoenzyme
elevation of .10 IU/L. Non–Q wave infarction is defined as
ST-segment and T-wave abnormalities that do not progress
to pathological Q waves but show abnormal elevations of
CPK-MB isoenzyme of .10 IU/L (606). The decision or
appropriateness to recommend surgical revascularization
in the face of an acute MI depends on the clinical
symptoms and the presence of persistent ischemia despite
maximum medical therapy. This is also the algorithm
that is used to decide to proceed with catheter-based
therapy. It appears that when there is a situation that is
not amenable to medical or catheter-based therapy and
persistent ischemia is present, CABG is indicated. This is
presuming that there is no overwhelming contraindica-
tion against operation.
There are specific conditions other than default that will
warrant CABG in the face of an acute MI: the presence of
left main stenosis, severe 3-vessel disease, associated valve
disease (whether secondary to the MI or unrelated), and
anatomy unsuitable for other forms of therapy. The litera-
ture is somewhat vague regarding the categories for surgical
intervention. Some of the reports address Q-wave versus
non–Q wave infarctions while others address the recency of
MI to operation (ie, ,6 hours, 6 hours to 2 days, 2 to 14
days, 2 to 6 weeks, and .6 weeks) or unstable angina
versus evolving MI, mechanical complications, acute
occlusions, and control patients. It is best to review these
separately and try to identify a common recommendation
and approach.
Braxton et al (606) studied the comparative effect of
operating on patients with a Q-wave MI and non–Q wave
MI versus a control group. Table 18 illustrates the mortality
and relative risks. Excluding the patients who require
emergency operation for mechanical complications of an
acute MI, the patients undergoing CABG within 48 hours
of the Q-wave MI will carry a significantly increased
operative mortality approaching 50%. The data imply that
for such patients, there is little to be gained by waiting .48
hours in most circumstances. The implication is also made
that symptomatic patients with a non–Q wave MI may
undergo surgical revascularization at any time with no
significant increase in mortality over elective patients (606).
This is substantiated in a recent article by Goodman et al
(603), wherein MI after thrombolytic therapy was evaluated
in relation to events with Q-wave versus non–Q wave MIs.
The non–Q wave MI was more likely to be nonanterior,
distally located, and have better global and regional LV
function. In the setting of thrombolysis after MI, patients
with a non–Q wave MI were more likely to have early,
complete, and sustained infarct-related artery patency and
better LV function. This identification of anatomic and
functional differences between Q-wave and non–Q wave
MIs should also translate into operative risk for these 2
patient cohorts and verifies the worse operative risk with
surgery in the early Q-wave period.
Creswell et al (601) retrospectively reviewed 2296 pa-
tients who underwent CABG after an acute MI. A gener-
alization that was made was that the operative mortality
decreased as the time between the acute MI and operation
increased. Patients who underwent operation ,6 hours had
an operative mortality of 8.4% and those who underwent
operation .6 hours, 4.3% (P 5 0.02) (Table 19). Addi-
tional findings were that despite the urgency of operation,
operative mortality was greater for those patients with a
preoperative MI than those without an MI. It is important
to note that when the independent risk factors of urgency of
operation, increased patient age, renal insufficiency, number
of previous MIs, and hypertension were adjusted for, the
Table 18. Coronary Artery Bypass Graft Surgery Mortality in Patients With Acute Myocardial
Infarction (MI)
Mortality % (n/N) Relative Risk
Q-Wave
MI
Non–Q-Wave
MI
Total
Mortality IABP Inotropes Perioperative
Group
,48 Hours 50 (3/6) 0 (0/1) 18 9.3 3.5 3.0
3–5 Days 0 (0/7) 16 (1/6) 3.3 14.6 1.5 1.2
6–42 Days 10 (4/45 1.9 (1/51) 2.2 5.99 1.8 1.4
IABP indicates intra-aortic balloon pump.
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time interval between MI and CABG was not a significant
predictor of death.
A third way to examine the impact of an MI on operative
mortality was reported by von Segesser et al (599). In this
series, 641 of 3,397 patients had stable or unstable angina,
respectively, and underwent CABG. These 641 patients
were divided into 5 groups. Group A patients had unstable
angina that involved the inclusion of 2 of 6 criteria including
impending infarction, electrocardiographic ST-segment
modifications, minimal increases in CPK values, prolonged
angina at rest, angina resistant to intravenous medication,
and postinfarction angina. Group B patients were sustaining
an evolving MI defined as either a new electrocardiographic
Q wave; electrocardiographic ST-segment modifications;
and CPK-MB values .8% of total CPK, CPK .3 times
normal; CPK-MB .10% of total CPK; or new LV dyski-
nesis on echocardiography or scintigraphy. Group C pa-
tients had mechanical complications of acute MI. Group D
patients had an acute coronary occlusion (emergency post-
PTCA or angiography), and Group E patients had stable
class IV angina (control).
In this series, acute CABG in patients with unstable
angina, evolving MI, and acute coronary occlusion demon-
strated results comparable to those of CABG in the elective
cohort. Late survival in these 3 cohorts was similar to that of
the group with stable angina. The worst late survival was in
those with mechanical complications, although it was ac-
ceptable. The conclusions of this investigation support acute
revascularizations in unstable angina and selected patients
after acute MI.
A review of other articles dealing with operation after
acute MI (38,456,600,726) suggests that unless patients are
in cardiogenic shock or have mechanical complications of
acute MI, early CABG can be performed with little of no
increase in risk of perioperative mortality.
Mechanical complications of acute MI include ventricular
septal defect, MR secondary to papillary muscle infarction
and/or rupture, and LV free-wall rupture (727–734). There
is general agreement that cardiogenic shock associated with
a mechanical complication of an MI warrants emergency
operation to correct the defect as a life-saving procedure.
Although there is less consensus as to the timing of
operation for patients with ventricular septal defect or MR
after acute MI with hemodynamic stability, most cardiac
surgical centers proceed promptly to surgery.
There does not appear to be clear documentation of the
best timing for stable patients with a mechanical complica-
tion. There has been the argument to delay operation to
allow the friable tissue to “mature” and hold sutures; this
invokes some Darwinian selection process and prompted
Norell et al (727) to approach all of these types of problems
acutely. Their results did not demonstrate a statistical
difference between acute and subacute operation. It must be
stated, however, that the numbers in many of these series
were small or included patient enrollment extending over
several decades while techniques, understanding of physiol-
ogy, and philosophy have advanced.
Indications for CABG in ST-Segment Elevation
(Q–Wave) MI
Class I
None.
Class IIa
Ongoing ischemia/infarction not responsive to maxi-
mal nonsurgical therapy.
Class IIb
1. Progressive LV pump failure with coronary stenosis
compromising viable myocardium outside the initial
infarct area.
2. Primary reperfusion in the early hours (<6 to 12
hours) of an evolving ST-segment elevation MI.
Class III
Primary reperfusion late (>12 hours) in an evolving
ST-segment elevation MI without ongoing ischemia.
5. Poor LV Function. As discussed in Section V, I,
increasing evidence suggests that chronic LV dysfunction
due to viable but hibernating myocardium in patients with
severe multivessel disease is relatively common. Further-
more, observational studies now support the notion that
coronary bypass surgery can result in stabilization and often
improvement in LV function in selected patients. Operation
on a patient with poor LV function is particularly appro-
priate if the patient has signs or symptoms of intermittent
ischemia and minimal or no CHF. On the other hand, if the
Table 19. Coronary Artery Bypass Graft Surgery Mortality After Acute Myocardial Infarction
(MI): Effect of Delaying Operation
Outcome <6 Hours 6–48 Hours 2–14 Days 2–6 Weeks >6 Weeks No MI
Op mort 9.1% 8.3% 5.2% 6.5% 2.9% 2.1%
Periop MI 9.1% 9.8% 2.8% 2.7% 4.0% 3.9%
Trans CVA 0.0% 3.0% 1.3% 0.4% 0.8% 0.8%
Perm CVA 9.1% 3.8% 2.9% 1.5% 2.3% 1.2%
AF 27.2% 40.9% 33.0% 39.1% 31.8% 30.7%
Op mort indicates operative mortality; Periop, perioperative; Trans, transient; CVA, cerebrovascular accident; Perm, permanent;
and AF, atrial fibrillation.
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patient has prominent signs and symptoms of CHF with
minimal angina, the decision to operate should be based on
objective evidence of hibernating myocardium (735). There
should be demonstration of substantial regions of myocar-
dial viability that would benefit from revascularization
(736). Such areas must be perfused by coronary arteries of
sufficient size and location to be reasonable targets for
bypass surgery (737).
The concept of operating on patients with poor LV
function for survival advantage comes from the randomized
trials that suggested that patients with left main, 3-vessel,
and 2-vessel disease and vessel disease involving the proxi-
mal LAD with concomitant LV dysfunction on average had
a greater survival advantage compared with those on medical
therapy. Although the randomized studies did not include
large numbers of patients with EFs ,0.30, subsequent
observational data suggest that these patients, although
having a higher immediate risk for bypass surgery, may achieve
a greater long-term gain in terms of survival advantage,
assuming that the concepts discussed above are applied (735–
737).
Indications for CABG in Patients With Poor LV
Function
Class I
1. Significant left main coronary artery stenosis.
2. Left main equivalent: significant (>70%) stenosis
of the proximal LAD and proximal left circumflex
artery.
3. Proximal LAD stenosis with 2- or 3-vessel disease.
Class IIa
Poor LV function, with significant viable noncontract-
ing revascularizable myocardium and without any of
the above anatomic patterns.
Class III
Poor LV function, without evidence of intermittent
ischemia and without evidence of significant revascu-
larizable viable myocardium.
6. Life-Threatening Ventricular Arrhythmias. The ben-
efits of CABG in patients with ventricular arrhythmias have
been studied in survivors of out-of-hospital cardiac arrest
and in patients with inducible ventricular tachycardia or
fibrillation under electrophysiological study. In general,
bypass surgery has been more effective in reducing episodes
of ventricular fibrillation than ventricular tachycardia, because
the mechanism of the latter arrhythmia usually involves reentry
with scarred endocardium rather than ischemia.
In survivors of cardiac arrest who have severe and oper-
able coronary disease, CABG surgery can suppress arrhyth-
mia induction, reduce subsequent cardiac arrest, and result
in a good long-term outcome (738–740). It is particularly
effective when an ischemic etiology for the arrhythmia can
be documented, for instance, with exercise (741). However,
because coronary revascularization may not alleviate all of
the factors that predispose to ventricular arrhythmias,
concomitant insertion of an implantable cardioverter-
defibrillator may be necessary (742). Similarly, continued
inducibility or clinical recurrence of ventricular tachycardia
after CABG usually requires defibrillator implantation.
Indications for CABG in Life-Threatening Ventricular
Arrhythmias
Class I
1. Left main coronary artery stenosis.
2. Three-vessel coronary disease.
Class IIa
1. Bypassable 1- or 2-vessel disease causing life-
threatening ventricular arrhythmias.‡
2. Proximal LAD disease with 1- or 2-vessel disease.‡
Class III
Ventricular tachycardia with scar and no evidence of
ischemia.
7. CABG After Failed PTCA. The decision to proceed
with emergency bypass surgery after a failed PTCA proce-
dure is a complex one. The interventional cardiologist and
consulting cardiac surgeon must together decide when the
procedure cannot be salvaged by percutaneous techniques,
often in the acute setting of ischemia or infarction. Impor-
tant considerations include the mechanisms of the failed
procedure, the potential to correct this situation surgically,
the extent of myocardium that is jeopardized, and the
overall clinical status of the patient. Threatened compared
with acute vessel closure poses a particularly challenging
situation, since the physicians must balance further attempts
at percutaneous salvage versus moving forward with surgery.
Factors that influence the outcome of surgery include
patient characteristics such as LV dysfunction, older age,
and previous MI (743,744), as well as anatomic factors such
as complex lesion characteristics, extent of multivessel dis-
ease, and the absence of collaterals (743–746). Finally,
outcome also depends on the total ischemic time and may be
adversely affected by a delay in transport to the operating
room (743,744,747,748). Bypass surgery is clearly the pro-
cedure of choice in the setting of hemodynamic compromise
or for retrieval of a foreign body, such as a fractured guide
wire or undeployed stent in a crucial anatomic position.
Emergency bypass for failed PTCA is understandably
associated with a higher rate of death and subsequent MI
compared with elective bypass surgery (743,749). It is
encouraging to observe the diminishing need for emergency
bypass surgery in this situation, owing in large measure to
the increasing use and availability of intracoronary stents
(659,750). Among patients who require emergency bypass
after a failed angioplasty in the current era, the rate of
complications remains substantial (751–753). This probably
‡Becomes Class I if arrhythmia is resuscitated sudden cardiac death or sustained
ventricular tachycardia.
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reflects the increased severity of CAD and other comorbidi-
ties in patients currently treated with PTCA. Therefore, a
coordinated approach and cooperative interaction between
the cardiologist, cardiac surgeon, and anesthesia team are
necessary to expedite resuscitation, transfer, and revascular-
ization of patients with failed PTCA.
Indications for CABG After Failed PTCA
Class I
1. Ongoing ischemia or threatened occlusion with
significant myocardium at risk.
2. Hemodynamic compromise.
Class IIa
1. Foreign body in crucial anatomic position.
2. Hemodynamic compromise in patients with im-
pairment of the coagulation system and without
previous sternotomy.
Class IIb
Hemodynamic compromise in patients with impair-
ment of the coagulation system and with previous
sternotomy.
Class III
1. Absence of ischemia.
2. Inability to revascularize due to target anatomy or
no-reflow state.
8. Patients With Previous CABG. Reoperation after
previous CABG can be successfully performed, but the risk
of hospital mortality is increased ’3-fold compared with
the primary operation. Moreover, reoperation is associated
with a diminished expectation for relief of symptoms and a
diminished expectation for prolongation of life compared
with the primary operation (see Sections IV, A2 and V, G).
For this reason, reoperation is generally reserved for relief of
disabling symptoms or for compelling evidence of poten-
tially life-threatening areas of myocardium at risk objec-
tively quantified by noninvasive studies. Because many of
these patients have had previous myocardial damage, con-
sideration of the consequences of infarction of an area of
myocardium demonstrated to be at risk must be weighed
against the cumulative effect of the current threatening
situation combined with prior damage.
The relative utility of percutaneous techniques in this
situation is increased, particularly if these techniques can be
applied to the native vessels. The application of percutane-
ous techniques to vein-graft stenosis is markedly inferior to
the results obtainable in the native vessels.
An increasingly common situation is the presence of a
functioning IMA graft to the LAD artery, with recurrent
ischemia in other regions of the heart. The potential loss of
this conduit consequent to a reoperation represents a major
negative factor in the long-term therapy of that patient and
is cause for additional caution in recommendation of a
reoperation.
Indications for CABG in Patients With Previous
CABG
Class I
Disabling angina despite maximal noninvasive ther-
apy. (If angina is not typical, then objective evidence of
ischemia should be obtained.)
Class IIa
Bypassable distal vessel(s) with a large area of threat-
ened myocardium by noninvasive studies.
Class IIb
Ischemia in the non-LAD distribution with a patent
IMA graft to the LAD supplying functioning myocar-
dium, without an aggressive attempt at medical man-
agement and/or percutaneous revascularization.
Class III
See text.
X. AREAS IN NEED OF FUTURE RESEARCH
The last 30 years of progress in CABG surgery have been
most impressive. Many challenges remain, however, as
analysis of current results reveals areas of patient selection
and perioperative management strategies that are poorly
defined by currently available data. Several patient subsets
particularly stand out as areas in need of further investiga-
tion. It appears that diabetic patients offer an unusual
challenge, since the results of coronary artery bypass in this
group of patients are distinctly inferior to the results in
nondiabetic patients. Perhaps more compulsive manage-
ment of perioperative and postoperative glucose levels will
improve this problem. There are current data suggesting
that coronary bypass may be superior to percutaneous
techniques in these patients, but stents were not used
extensively in the BARI trial. There is an absence of data on
minority patients with regard to CABG surgery, an impor-
tant area of future investigation. Appropriate management
of patients with acute coronary syndromes is an evolving
situation. Improvements in percutaneous techniques, in-
cluding the use of drugs that inhibit platelet function, has
dramatically altered management in this situation. At the
same time, CABG offers an opportunity for controlled
reperfusion and perhaps the best opportunity for resuscita-
tion of infarcting myocardium. The management of patients
with end-stage coronary disease, particularly patients who
have had multiple stenting procedures and/or multiple
coronary bypass procedures, is becoming an increasingly
difficult problem. The success of coronary bypass in younger
patients has led to the increasing consideration of CABG in
elderly and very elderly patients. These patients were sys-
tematically excluded from the randomized trials of coronary
bypass versus medical therapy and versus percutaneous
techniques. Data on optimal management of this increas-
ingly important and large patient subset are scarce.
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Many areas of perioperative management are also evolv-
ing and need refinement and evaluation. The use of multiple
arterial conduits appears to offer benefit, but the long-term
efficacy and benefit of radial artery grafts and second IMA
grafts are incompletely defined. Techniques for less-invasive
CABG are rapidly changing, and video-assisted technology
and robotic operative tools may lead to even more dramatic
changes in the near future. TMLR appears to offer clinical
benefit, but the mechanism of this benefit is very poorly
understood. This technique may be implementable via
percutaneous techniques. Gene therapy holds promise as a
technique for stimulation of the development of new vas-
culature in ischemic myocardium. Much of the morbidity
and mortality of coronary bypass is related to the use of
CPB. There are developing pharmacological and mechani-
cal methods for reducing the sequelae of CPB (drugs that
reduce coagulation and inflammatory complications, such as
aprotinin or aminocaproic acid, and leukocyte depletion to
diminish the early inflammatory response). The manage-
ment of patients with very poor LV function is also
evolving, as preoperative application of mechanical assis-
tance with an IABP appears to be useful. Operative tech-
niques such as ventricular remodeling (in the case of a
scarred myocardium or a grossly dilated LV) or mitral repair
in the case of chronic ischemic MR, are techniques that
warrant further study.
Modification of risk factors after CABG is perhaps the
most promising but also the most difficult area for future
improvement in long-term results. It remains discouraging
that attempts at smoking cessation have achieved only a
20% success rate. One would hope that the near certainty
of future problems with coronary disease would be a
strong motivational factor in this effort. Psychological
problems of anxiety and depression appear to be associ-
ated with, if not causally related to, CAD and its
progression. The pharmacological management of these
disorders is becoming increasingly effective. Progress in
the management of serum lipids, including reduction of
cholesterol and other lipid levels in patients with “aver-
age” levels, appears to offer promise in decreasing the
progression of coronary disease.
From the perspective of resource utilization by society,
cost analysis of medical therapy, percutaneous therapy, and
surgical therapy of coronary disease remains a current and
compellingly important area of research. Evolving tech-
niques will mean that these data and data analysis will need
to be repeatedly revisited in future years. As one attempts to
quantify the value of coronary bypass surgery, a recurrent
reevaluation of patient benefit is also obviously necessary.
Indeed, the future of coronary bypass depends on a quan-
titative demonstration of patient benefit and value to soci-
ety, as the various opportunities for delivery of sophisticated
medical care are increasingly competitive for the limited
resources available.
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